PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2464912-4	1988	An analysis of fluvoxamine minus placebo difference scores showed a significant correlation between memory functioning and CSF 5HIAA levels.	Fluvoxamine	15-26	colony stimulating factor 2	Homo sapiens	123-126
2464912-5	1988	Alcohol amnestic syndrome patients who had the highest blood levels of fluvoxamine demonstrated the largest changes in CSF 5HIAA and improvement in memory performance under fluvoxamine.	Fluvoxamine	71-82	colony stimulating factor 2	Homo sapiens	119-122
33602262-7	2021	RESULTS: All the SSRIs, including paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine, show a visible cytotoxicity within the range of applied doses, and a paradoxical effect on astrocytic inflammatory responses as manifested by the promotion of inducible nitric oxide synthase (iNOS) and/or nitric oxide (NO) and the inhibition of interleukin 6 (IL-6) and/or interleukin 1beta (IL-1beta).	Fluvoxamine	86-97	nitric oxide synthase 2	Homo sapiens	258-289
6134546-9	1983	the PRL-releasing effect of an additional acute fluvoxamine administration (same dose) was abolished after 4 days maintenance treatment.	Fluvoxamine	48-59	prolactin	Rattus norvegicus	4-7
6777458-8	1980	Psychometric tests demonstrated after 50 and 75 mg clovoxamine and 75 mg fluvoxamine an increase in attention, attention variability, concentration, CFF and after-effect in the Archimedean Spiral (indicating central activation), further an improvement in mood and affectivity as compared with placebo, while 125 mg clovoxamine and 75 mg imipramine produced an increase in reaction time, deterioration of mood and affect and psychomotor activity.	Fluvoxamine	73-84	host cell factor C1	Homo sapiens	149-152
33524820-0	2021	Multi-spectroscopic and molecular docking studies for binding interaction between fluvoxamine and human serum albumin.	Fluvoxamine	82-93	albumin	Homo sapiens	104-117
33524820-1	2021	In the present study, different spectroscopic techniques have been used to study the binding interaction between the antidepressant drug fluvoxamine and human serum albumin under simulated physiological conditions (pH 7.4).	Fluvoxamine	137-148	albumin	Homo sapiens	159-172
33524820-3	2021	The obtained results revealed that the formation of a complex between human serum albumin and fluvoxamine was responsible for quenching the native fluorescence of human serum albumin.	Fluvoxamine	94-105	albumin	Homo sapiens	76-89
33524820-3	2021	The obtained results revealed that the formation of a complex between human serum albumin and fluvoxamine was responsible for quenching the native fluorescence of human serum albumin.	Fluvoxamine	94-105	albumin	Homo sapiens	169-182
33524820-4	2021	The results indicated that the quenching mechanism between human serum albumin and fluvoxamine was static.	Fluvoxamine	83-94	albumin	Homo sapiens	65-78
33524820-7	2021	From the molecular docking results, it could be deduced that fluvoxamine was inserted into sub-domain II A (site I) of human serum albumin and led to a slight change in human serum albumin conformation.	Fluvoxamine	61-72	albumin	Homo sapiens	125-138
33524820-7	2021	From the molecular docking results, it could be deduced that fluvoxamine was inserted into sub-domain II A (site I) of human serum albumin and led to a slight change in human serum albumin conformation.	Fluvoxamine	61-72	albumin	Homo sapiens	175-188
34049262-0	2021	Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.	Fluvoxamine	120-131	solute carrier family 6 member 4	Homo sapiens	90-94
34049262-3	2021	To elucidate the role of halogen atoms in the binding of SSRIs to SERT, we designed a series of 22 fluoxetine and fluvoxamine analogs substituted with fluorine, chlorine, bromine, and iodine atoms, differently arranged on the phenyl ring.	Fluvoxamine	114-125	solute carrier family 6 member 4	Homo sapiens	66-70
33646885-5	2021	Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), reduced the BMP-4-stimulated OPG release, whereas a selective and specific norepinephrine reuptake inhibitor, reboxetine failed to affect the OPG release.	Fluvoxamine	0-11	bone morphogenetic protein 4	Mus musculus	74-79
33646885-5	2021	Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), reduced the BMP-4-stimulated OPG release, whereas a selective and specific norepinephrine reuptake inhibitor, reboxetine failed to affect the OPG release.	Fluvoxamine	0-11	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	91-94
33646885-10	2021	Both fluvoxamine and sertraline also inhibited the BMP-4-elicited phosphorylation of SMAD1/5/8.	Fluvoxamine	5-16	bone morphogenetic protein 4	Mus musculus	51-56
33646885-10	2021	Both fluvoxamine and sertraline also inhibited the BMP-4-elicited phosphorylation of SMAD1/5/8.	Fluvoxamine	5-16	SMAD family member 1	Mus musculus	85-94
33602262-7	2021	RESULTS: All the SSRIs, including paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine, show a visible cytotoxicity within the range of applied doses, and a paradoxical effect on astrocytic inflammatory responses as manifested by the promotion of inducible nitric oxide synthase (iNOS) and/or nitric oxide (NO) and the inhibition of interleukin 6 (IL-6) and/or interleukin 1beta (IL-1beta).	Fluvoxamine	86-97	nitric oxide synthase 2	Homo sapiens	291-295
33602262-7	2021	RESULTS: All the SSRIs, including paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine, show a visible cytotoxicity within the range of applied doses, and a paradoxical effect on astrocytic inflammatory responses as manifested by the promotion of inducible nitric oxide synthase (iNOS) and/or nitric oxide (NO) and the inhibition of interleukin 6 (IL-6) and/or interleukin 1beta (IL-1beta).	Fluvoxamine	86-97	interleukin 6	Homo sapiens	344-357
33602262-7	2021	RESULTS: All the SSRIs, including paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine, show a visible cytotoxicity within the range of applied doses, and a paradoxical effect on astrocytic inflammatory responses as manifested by the promotion of inducible nitric oxide synthase (iNOS) and/or nitric oxide (NO) and the inhibition of interleukin 6 (IL-6) and/or interleukin 1beta (IL-1beta).	Fluvoxamine	86-97	interleukin 6	Homo sapiens	359-363
33602262-7	2021	RESULTS: All the SSRIs, including paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine, show a visible cytotoxicity within the range of applied doses, and a paradoxical effect on astrocytic inflammatory responses as manifested by the promotion of inducible nitric oxide synthase (iNOS) and/or nitric oxide (NO) and the inhibition of interleukin 6 (IL-6) and/or interleukin 1beta (IL-1beta).	Fluvoxamine	86-97	interleukin 1 beta	Homo sapiens	372-389
33602262-7	2021	RESULTS: All the SSRIs, including paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine, show a visible cytotoxicity within the range of applied doses, and a paradoxical effect on astrocytic inflammatory responses as manifested by the promotion of inducible nitric oxide synthase (iNOS) and/or nitric oxide (NO) and the inhibition of interleukin 6 (IL-6) and/or interleukin 1beta (IL-1beta).	Fluvoxamine	86-97	interleukin 1 alpha	Homo sapiens	391-399
33897064-4	2021	Objective: The objective of this study was to investigate the effect of polymorphisms of the CYP3A4, CYP2C9, CYP3A5, ABCB1, CYP2C19, SCL6A4, and 5-HTR2A genes on the concentration/dose indicator of fluvoxamine and on the CYP3A expression level obtained by measuring the miR-27b plasma concentration levels in patients suffering from a recurrent depressive disorder.	Fluvoxamine	198-209	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-98
33140216-10	2021	Thus, we investigated the effect of fluvoxamine, a Sigma-1 receptor agonist, on Ito and ICa-L. Fluvoxamine enhanced Ito and altered its current kinetics, as shown by acceleration of activation and recovery from inactivation.	Fluvoxamine	95-106	sigma non-opioid intracellular receptor 1	Rattus norvegicus	51-67
33897064-3	2021	Previous research revealed that CYP2D6 is involved in the metabolism of fluvoxamine, the activity of which is highly dependent on the polymorphism of the gene encoding it.	Fluvoxamine	72-83	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
33834720-14	2021	The study shows the efficacy of APAH, fluvoxamine and milnacipran in the presence of CS.	Fluvoxamine	38-49	citrate synthase	Homo sapiens	85-87
33488945-8	2021	Fluvoxamine stimulation of Sig1R restored autophagic flux in cardiac fibroblasts, indicating that Sig1R appears to play a protective role in the activation of cardiac fibroblasts by inhibiting the IRE1 pathway and restoring autophagic flux.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	27-32
33488945-8	2021	Fluvoxamine stimulation of Sig1R restored autophagic flux in cardiac fibroblasts, indicating that Sig1R appears to play a protective role in the activation of cardiac fibroblasts by inhibiting the IRE1 pathway and restoring autophagic flux.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	98-103
31180700-0	2020	BDNF association study with obsessive-compulsive disorder, its clinical characteristics, and response to fluvoxamine-treatment in Iranian patients.	Fluvoxamine	105-116	brain derived neurotrophic factor	Homo sapiens	0-4
33302490-0	2020	A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine.	Fluvoxamine	135-146	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	83-89
33302490-0	2020	A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine.	Fluvoxamine	135-146	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	94-101
33002595-7	2020	Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE1-stimulated release of both OPG and IL-6.	Fluvoxamine	12-23	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	161-164
33002595-7	2020	Oppositely, fluvoxamine and sertraline, agents belonging to the class of selective serotonin reuptake inhibitor, upregulated the PGE1-stimulated release of both OPG and IL-6.	Fluvoxamine	12-23	interleukin 6	Mus musculus	169-173
33002595-10	2020	SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE1-stimulated release of OPG and IL-6.	Fluvoxamine	93-104	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	139-142
33002595-10	2020	SB203880, an inhibitor of p38 MAP kinase, suppressed the amplifying effects by duloxetine or fluvoxamine on the PGE1-stimulated release of OPG and IL-6.	Fluvoxamine	93-104	interleukin 6	Mus musculus	147-151
33158023-8	2020	Furthermore, FLV significantly enhanced the levels of glutathione (GSH) and peroxiredoxin 1 (PRDX1) and caused a significant reduction in 3-nitrotyrosine (3-NT) levels, the effects of which were abolished by co-treatment with BD1063.	Fluvoxamine	13-16	peroxiredoxin 1	Rattus norvegicus	76-91
33158023-8	2020	Furthermore, FLV significantly enhanced the levels of glutathione (GSH) and peroxiredoxin 1 (PRDX1) and caused a significant reduction in 3-nitrotyrosine (3-NT) levels, the effects of which were abolished by co-treatment with BD1063.	Fluvoxamine	13-16	peroxiredoxin 1	Rattus norvegicus	93-98
32629001-3	2020	The S1R agonist fluvoxamine was injected intraperitoneally from the second week to the last week for 21 days in total, and the effects were evaluated by patch clamp, western blot analysis, and Masson staining.	Fluvoxamine	16-27	sigma non-opioid intracellular receptor 1	Rattus norvegicus	4-7
32660197-8	2020	Furthermore, in comparison to Sig-1R-/- mice, fluvoxamine significantly increased serum levels of AST, ALT, MPO, and LDH in wildtype animals in a dose-dependent manner at 6 h after IRI.	Fluvoxamine	46-57	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	98-101
32660197-8	2020	Furthermore, in comparison to Sig-1R-/- mice, fluvoxamine significantly increased serum levels of AST, ALT, MPO, and LDH in wildtype animals in a dose-dependent manner at 6 h after IRI.	Fluvoxamine	46-57	glutamic pyruvic transaminase, soluble	Mus musculus	103-106
32660197-8	2020	Furthermore, in comparison to Sig-1R-/- mice, fluvoxamine significantly increased serum levels of AST, ALT, MPO, and LDH in wildtype animals in a dose-dependent manner at 6 h after IRI.	Fluvoxamine	46-57	myeloperoxidase	Mus musculus	108-111
31608449-8	2019	In the neurochemical tests, both thymol and fluvoxamine restored BDNF levels, improving the depressive condition.	Fluvoxamine	44-55	brain derived neurotrophic factor	Mus musculus	65-69
32802593-3	2020	Fluvoxamine inhibits many cytochrome P450 enzyme (CYP) including CYP2C9, which metabolizes azilsartan.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	65-71
31795773-6	2020	As CYP3A4 is an important metabolic pathway for all DOACs except dabigatran, it appears reasonable to recommend avoiding the co-prescription of fluoxetine and fluvoxamine (weak to moderate CYP3A4 inhibitors) and St John"s wort (CYP3A4 inducer).	Fluvoxamine	159-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	3-9
31172535-5	2019	Following a single oral dose of 3 mg, avadomide exposure when coadministered with the CYP1A2 inhibitor fluvoxamine was 154.81% and 107.59% of that when administered alone, for area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf ) and maximum observed plasma concentration (Cmax ), respectively.	Fluvoxamine	103-114	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	86-92
31810748-0	2020	The antidepressant-like effects of fluvoxamine in mice involve the mTOR signaling in the hippocampus and prefrontal cortex.	Fluvoxamine	35-46	mechanistic target of rapamycin kinase	Mus musculus	67-71
31810748-3	2020	Therefore, this study aims to evaluate whether mTOR underlies the antidepressant-like effects of fluvoxamine.	Fluvoxamine	97-108	mechanistic target of rapamycin kinase	Mus musculus	47-51
31810748-7	2020	It was found that fluvoxamine treatment fully reversed the effects of CUMS on the mTOR signaling in the hippocampus and PFC, and the usage of rapamycin significantly prevented the antidepressant-like effects of fluvoxamine in the CUMS model of depression.	Fluvoxamine	18-29	mechanistic target of rapamycin kinase	Mus musculus	82-86
31810748-8	2020	Taken together, the mTOR system is involved in the antidepressant mechanisms of fluvoxamine.	Fluvoxamine	80-91	mechanistic target of rapamycin kinase	Mus musculus	20-24
31493481-10	2019	SIGNIFICANCE: Our findings indicated that S1R inhibition contributed to atrial electrical remodeling, cardiac autonomic remodeling and atrial fibrosis, which could be attenuated by fluvoxamine, thus providing new insights into the relationship between the S1R and AF.	Fluvoxamine	181-192	sigma non-opioid intracellular receptor 1	Rattus norvegicus	42-45
31807102-13	2019	Conclusion: Fluvoxamine improved PSG parameters and ameliorated complaints of insomnia simultaneously during this 8-week study.	Fluvoxamine	12-23	pregnancy specific beta-1-glycoprotein 5	Homo sapiens	33-36
31493481-10	2019	SIGNIFICANCE: Our findings indicated that S1R inhibition contributed to atrial electrical remodeling, cardiac autonomic remodeling and atrial fibrosis, which could be attenuated by fluvoxamine, thus providing new insights into the relationship between the S1R and AF.	Fluvoxamine	181-192	sigma non-opioid intracellular receptor 1	Rattus norvegicus	256-259
30902656-2	2019	Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine.	Fluvoxamine	0-11	nerve growth factor	Rattus norvegicus	21-40
31182321-2	2019	Smoking induces CYP1A2 thereby increasing clozapine metabolism whereas fluvoxamine inhibits CYP1A2.	Fluvoxamine	71-82	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	92-98
30902656-2	2019	Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine.	Fluvoxamine	0-11	nerve growth factor	Rattus norvegicus	42-45
30902656-2	2019	Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	93-109
30902656-2	2019	Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine.	Fluvoxamine	211-222	nerve growth factor	Rattus norvegicus	21-40
30902656-2	2019	Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine.	Fluvoxamine	211-222	nerve growth factor	Rattus norvegicus	42-45
30902656-2	2019	Fluvoxamine enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via a sigma-1 receptor-mediated mechanism, which suggests that neurogenesis may be involved in the antidepressant action of fluvoxamine.	Fluvoxamine	211-222	sigma non-opioid intracellular receptor 1	Rattus norvegicus	93-109
29035919-2	2018	For compulsive-like nest-building behavior, dose-dependent attenuation of nesting by fluvoxamine was observed for the BIG1 compulsive-like strain during the first hour after administration.	Fluvoxamine	85-96	contactin 3	Mus musculus	118-122
30762305-0	2019	Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.	Fluvoxamine	112-123	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	49-55
30762305-1	2019	This study provides whole-body physiologically-based pharmacokinetic models of the strong index cytochrome P450 (CYP)1A2 inhibitor and moderate CYP3A4 inhibitor fluvoxamine and of the sensitive CYP1A2 substrate theophylline.	Fluvoxamine	161-172	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-150
30902567-8	2019	Conversely, while fluvoxamine reduced omeprazole metabolism in subjects carrying the CYP2C19*1 allele, it had no impact on omeprazole pharmacokinetics in subjects without this allele.	Fluvoxamine	18-29	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	85-92
30730837-0	2019	Selective serotonin reuptake inhibitor fluvoxamine ameliorates stress- and NSAID-induced peptic ulcer possibly by involving Hsp70.	Fluvoxamine	39-50	heat shock protein 1B	Mus musculus	124-129
30730837-3	2019	However, there is lack of evidence that fluvoxamine recruits Hsp70 to affect stress-induced gastric ulcer.	Fluvoxamine	40-51	heat shock protein 1B	Mus musculus	61-66
30730837-12	2019	Moreover, fluvoxamine further increased the expression of Hsp70 in the gastric tissue of stress- and indomethacin-treated mice.	Fluvoxamine	10-21	heat shock protein 1B	Mus musculus	58-63
30730837-14	2019	In addition, the present study suggests the possible involvement of Hsp70 in the amelioration of gastric ulcer by fluvoxamine.	Fluvoxamine	114-125	heat shock protein 1B	Mus musculus	68-73
30820426-0	2019	Evaluation of the Effect of Antidepressant Drug, Fluvoxamine, on Cyclooxygenase-2 Protein Expression in Lipopolysaccharide-stimulated Macrophages.	Fluvoxamine	49-60	prostaglandin-endoperoxide synthase 2	Homo sapiens	65-81
30820426-3	2019	In the line of the indicated study, we sought to evaluate the effect of fluvoxamine on the expression of some inflammatory mediators such as cyclooxygenase-2 (COX-2).	Fluvoxamine	72-83	prostaglandin-endoperoxide synthase 2	Homo sapiens	141-157
30820426-3	2019	In the line of the indicated study, we sought to evaluate the effect of fluvoxamine on the expression of some inflammatory mediators such as cyclooxygenase-2 (COX-2).	Fluvoxamine	72-83	prostaglandin-endoperoxide synthase 2	Homo sapiens	159-164
30820426-6	2019	Results: The expression of COX-2 significantly decreased by fluvoxamine in U937 macrophages.	Fluvoxamine	60-71	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-32
30543144-0	2019	Effects of fluvoxamine on nerve growth factor-induced neurite outgrowth inhibition by dexamethasone in PC12 cells.	Fluvoxamine	11-22	nerve growth factor	Rattus norvegicus	26-45
30543144-1	2019	In the present study, we examined the effects of fluvoxamine on nerve growth factor (NGF)-induced neurite outgrowth inhibition by dexamethasone (DEX) in PC12 cells.	Fluvoxamine	49-60	nerve growth factor	Rattus norvegicus	64-83
30543144-1	2019	In the present study, we examined the effects of fluvoxamine on nerve growth factor (NGF)-induced neurite outgrowth inhibition by dexamethasone (DEX) in PC12 cells.	Fluvoxamine	49-60	nerve growth factor	Rattus norvegicus	85-88
30543144-2	2019	Fluvoxamine increased NGF-induced neurite outgrowth.	Fluvoxamine	0-11	nerve growth factor	Rattus norvegicus	22-25
30543144-3	2019	Compared with co-treatment with NGF and fluvoxamine, p-Akt levels were higher than the values without fluvoxamine.	Fluvoxamine	40-51	AKT serine/threonine kinase 1	Rattus norvegicus	55-58
30543144-5	2019	Fluvoxamine concentration-dependently improved NGF-induced neurite outgrowth inhibition by DEX.	Fluvoxamine	0-11	nerve growth factor	Rattus norvegicus	47-50
30543144-6	2019	Fluvoxamine also improved the decrease in the NGF-induced p-Akt level caused by DEX.	Fluvoxamine	0-11	nerve growth factor	Rattus norvegicus	46-49
30543144-6	2019	Fluvoxamine also improved the decrease in the NGF-induced p-Akt level caused by DEX.	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	60-63
30543144-7	2019	Interestingly, the sigma-1 receptor antagonist NE-100 blocked the improvement effects of fluvoxamine on NGF-induced neurite outgrowth inhibition by DEX.	Fluvoxamine	89-100	sigma non-opioid intracellular receptor 1	Rattus norvegicus	19-35
30543144-7	2019	Interestingly, the sigma-1 receptor antagonist NE-100 blocked the improvement effects of fluvoxamine on NGF-induced neurite outgrowth inhibition by DEX.	Fluvoxamine	89-100	nerve growth factor	Rattus norvegicus	104-107
30543144-9	2019	These results indicate that the improvement effects of fluvoxamine on NGF-induced neurite outgrowth inhibition by DEX may be attributable to the phosphorylation of Akt and the sigma-1 receptor.	Fluvoxamine	55-66	nerve growth factor	Rattus norvegicus	70-73
30543144-9	2019	These results indicate that the improvement effects of fluvoxamine on NGF-induced neurite outgrowth inhibition by DEX may be attributable to the phosphorylation of Akt and the sigma-1 receptor.	Fluvoxamine	55-66	AKT serine/threonine kinase 1	Rattus norvegicus	164-167
30543144-9	2019	These results indicate that the improvement effects of fluvoxamine on NGF-induced neurite outgrowth inhibition by DEX may be attributable to the phosphorylation of Akt and the sigma-1 receptor.	Fluvoxamine	55-66	sigma non-opioid intracellular receptor 1	Rattus norvegicus	176-192
30728287-8	2019	These findings could have substantial clinical implications, as we further find that fluvoxamine, an antidepressant therapeutic with high affinity for S1R, protects mice from lethal septic shock and dampens the inflammatory response in human blood leukocytes.	Fluvoxamine	85-96	sigma non-opioid intracellular receptor 1	Mus musculus	151-154
29988737-0	2018	Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.	Fluvoxamine	70-81	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	11-17
29988737-2	2018	CYP2D6 is involved in the biotransformation of fluvoxamine.	Fluvoxamine	47-58	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
29988737-4	2018	Objective: The primary objective of our study was to investigate the effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder, in order to develop the algorithms of optimization of fluvoxamine therapy for reducing the risk of dose-dependent undesirable side effects and pharmacoresistance.	Fluvoxamine	139-150	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
29988737-4	2018	Objective: The primary objective of our study was to investigate the effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder, in order to develop the algorithms of optimization of fluvoxamine therapy for reducing the risk of dose-dependent undesirable side effects and pharmacoresistance.	Fluvoxamine	277-288	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
29988737-9	2018	Conclusion: This study demonstrated the lower efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorders with GA genotype in CYP2D6 1846G>A polymorphic marker.	Fluvoxamine	69-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	173-179
29785111-11	2018	Conclusion: HTR2A haplotypes are associated with OCD and its treatment response with a fluvoxamine in Iranian patients.	Fluvoxamine	87-98	5-hydroxytryptamine receptor 2A	Homo sapiens	12-17
29382554-12	2018	Western blot analysis revealed that the expression level of 5-HT2A receptor was specifically decreased in the prefrontal cortex of mice that had been administered yokukansan and fluvoxamine.	Fluvoxamine	178-189	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	60-75
28993551-11	2017	DDIs perpetrated by FLV and itraconazole were successfully predicted by use of the present method where two DDI predictors [perpetrator-specific inhibitory activities toward CYP isoforms (pAi, CYPs) and victim-specific fractional CYP-isoform contributions to the clearance (vfm, CYPs)] are determined successively as shown in the graphical abstract.	Fluvoxamine	20-23	serpin family E member 1	Homo sapiens	188-191
29155491-6	2018	The CYP3A4-selective inhibitor ketoconazole (2 muM) impaired CLZ N-oxide formation in all 14 of the livers used in inhibition studies (>=50% inhibition) while the CYP1A2-selective inhibitor fluvoxamine (10 muM) decreased norCLZ formation in nine.	Fluvoxamine	193-204	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
29155491-6	2018	The CYP3A4-selective inhibitor ketoconazole (2 muM) impaired CLZ N-oxide formation in all 14 of the livers used in inhibition studies (>=50% inhibition) while the CYP1A2-selective inhibitor fluvoxamine (10 muM) decreased norCLZ formation in nine.	Fluvoxamine	193-204	latexin	Homo sapiens	47-50
29155491-8	2018	Similarly, fluvoxamine (10 muM) readily inhibited CLZ oxidation in seven livers with high CYP1A2-mediated 7-ethoxyresorufin O-deethylation activity (at or above the median) and three livers with lower intrinsic CYP1A2 activity.	Fluvoxamine	11-22	latexin	Homo sapiens	27-30
29155491-8	2018	Similarly, fluvoxamine (10 muM) readily inhibited CLZ oxidation in seven livers with high CYP1A2-mediated 7-ethoxyresorufin O-deethylation activity (at or above the median) and three livers with lower intrinsic CYP1A2 activity.	Fluvoxamine	11-22	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	90-96
29155491-8	2018	Similarly, fluvoxamine (10 muM) readily inhibited CLZ oxidation in seven livers with high CYP1A2-mediated 7-ethoxyresorufin O-deethylation activity (at or above the median) and three livers with lower intrinsic CYP1A2 activity.	Fluvoxamine	11-22	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	211-217
29379174-2	2018	Here we report X-ray structures of engineered thermostable variants of the human serotonin transporter bound to the antidepressants sertraline, fluvoxamine, and paroxetine.	Fluvoxamine	144-155	solute carrier family 6 member 4	Homo sapiens	81-102
29101463-2	2018	This study was performed to investigate the potential drug-drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in patients with advanced solid tumors.	Fluvoxamine	115-126	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	98-104
28688742-8	2018	Clozapine-fluvoxamine combined treatment significantly attenuated the increments in body weight, insulin resistance, and levels of insulin, glucose, and triglycerides compared with clozapine monotherapy.	Fluvoxamine	10-21	insulin	Homo sapiens	97-104
28688742-8	2018	Clozapine-fluvoxamine combined treatment significantly attenuated the increments in body weight, insulin resistance, and levels of insulin, glucose, and triglycerides compared with clozapine monotherapy.	Fluvoxamine	10-21	insulin	Homo sapiens	131-138
29614681-4	2018	Fluvoxamine is a selective serotonin reuptake inhibitor and a potent SIGMAR1 agonist.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Mus musculus	69-76
28815595-6	2017	Escitalopram and fluvoxamine (100 nM to 1 muM) reversibly inhibited nAChR currents.	Fluvoxamine	17-28	latexin	Homo sapiens	42-45
28815595-6	2017	Escitalopram and fluvoxamine (100 nM to 1 muM) reversibly inhibited nAChR currents.	Fluvoxamine	17-28	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	68-73
28815595-8	2017	Block of nAChR currents by fluvoxamine and NE-100 was not additive suggesting a common site of action.	Fluvoxamine	27-38	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	9-14
28529139-2	2017	Some SSRIs such as fluvoxamine have agonistic activity towards for the sigma1 receptor, but it is not known whether the effect on the receptor plays a key role in the pharmacological effects.	Fluvoxamine	19-30	sigma non-opioid intracellular receptor 1	Mus musculus	71-86
28529139-4	2017	We also suggest that the anti-anhedonic effect of fluvoxamine is mediated by combined activation of the 5-HT1A and sigma1 receptors and it is associated with activation of prefrontal dopaminergic system.	Fluvoxamine	50-61	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	104-110
28243095-0	2017	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder.	Fluvoxamine	13-24	interleukin 6	Homo sapiens	35-48
28410959-2	2017	This study examined the role of brain derived neurotrophic factor (BDNF)-cAMP response element binding (CREB) protein signaling pathways, including protein kinase B (AKT), glycogen synthase kinase (GSK)-3beta and related molecules in the molecular response to haloperidol, fluvoxamine, combined haloperidol+fluvoxamine and clozapine treatments in rat frontal cortex, hippocampus and primary cortical neuronal cultures.	Fluvoxamine	273-284	brain-derived neurotrophic factor	Rattus norvegicus	67-71
28410959-2	2017	This study examined the role of brain derived neurotrophic factor (BDNF)-cAMP response element binding (CREB) protein signaling pathways, including protein kinase B (AKT), glycogen synthase kinase (GSK)-3beta and related molecules in the molecular response to haloperidol, fluvoxamine, combined haloperidol+fluvoxamine and clozapine treatments in rat frontal cortex, hippocampus and primary cortical neuronal cultures.	Fluvoxamine	273-284	cAMP responsive element binding protein 1	Rattus norvegicus	104-108
28410959-2	2017	This study examined the role of brain derived neurotrophic factor (BDNF)-cAMP response element binding (CREB) protein signaling pathways, including protein kinase B (AKT), glycogen synthase kinase (GSK)-3beta and related molecules in the molecular response to haloperidol, fluvoxamine, combined haloperidol+fluvoxamine and clozapine treatments in rat frontal cortex, hippocampus and primary cortical neuronal cultures.	Fluvoxamine	307-318	brain-derived neurotrophic factor	Rattus norvegicus	67-71
28410959-2	2017	This study examined the role of brain derived neurotrophic factor (BDNF)-cAMP response element binding (CREB) protein signaling pathways, including protein kinase B (AKT), glycogen synthase kinase (GSK)-3beta and related molecules in the molecular response to haloperidol, fluvoxamine, combined haloperidol+fluvoxamine and clozapine treatments in rat frontal cortex, hippocampus and primary cortical neuronal cultures.	Fluvoxamine	307-318	cAMP responsive element binding protein 1	Rattus norvegicus	104-108
28410959-3	2017	The effect of fluvoxamine augmentation on BDNF-CREB pathways in peripheral mononuclear cells (PMC s) of medicated schizophrenia patients was also studied.	Fluvoxamine	14-25	brain derived neurotrophic factor	Homo sapiens	42-46
28410959-3	2017	The effect of fluvoxamine augmentation on BDNF-CREB pathways in peripheral mononuclear cells (PMC s) of medicated schizophrenia patients was also studied.	Fluvoxamine	14-25	cAMP responsive element binding protein 1	Homo sapiens	47-51
28410959-4	2017	Chronic haloperidol (1mg/kg) +fluvoxamine (10mg/kg) treatment increased TrkB receptor and BDNF expression levels, and the phosphorylation of AKT/CREB/GSK-3beta, compared to the individual drugs in rat brain.	Fluvoxamine	30-41	brain-derived neurotrophic factor	Rattus norvegicus	90-94
28410959-4	2017	Chronic haloperidol (1mg/kg) +fluvoxamine (10mg/kg) treatment increased TrkB receptor and BDNF expression levels, and the phosphorylation of AKT/CREB/GSK-3beta, compared to the individual drugs in rat brain.	Fluvoxamine	30-41	AKT serine/threonine kinase 1	Rattus norvegicus	141-144
28410959-4	2017	Chronic haloperidol (1mg/kg) +fluvoxamine (10mg/kg) treatment increased TrkB receptor and BDNF expression levels, and the phosphorylation of AKT/CREB/GSK-3beta, compared to the individual drugs in rat brain.	Fluvoxamine	30-41	cAMP responsive element binding protein 1	Rattus norvegicus	145-149
28410959-4	2017	Chronic haloperidol (1mg/kg) +fluvoxamine (10mg/kg) treatment increased TrkB receptor and BDNF expression levels, and the phosphorylation of AKT/CREB/GSK-3beta, compared to the individual drugs in rat brain.	Fluvoxamine	30-41	glycogen synthase kinase 3 beta	Rattus norvegicus	150-159
28410959-6	2017	In primary neuronal cell cultures, pretreatment with a selective PI3K inhibitor abolished the haloperidol+fluvoxamine-induced phosphorylation of AKT and GSK-3beta, but did not affect the upregulation of CREB phosphorylation.	Fluvoxamine	106-117	AKT serine/threonine kinase 1	Rattus norvegicus	145-148
28410959-6	2017	In primary neuronal cell cultures, pretreatment with a selective PI3K inhibitor abolished the haloperidol+fluvoxamine-induced phosphorylation of AKT and GSK-3beta, but did not affect the upregulation of CREB phosphorylation.	Fluvoxamine	106-117	glycogen synthase kinase 3 beta	Rattus norvegicus	153-162
28410959-6	2017	In primary neuronal cell cultures, pretreatment with a selective PI3K inhibitor abolished the haloperidol+fluvoxamine-induced phosphorylation of AKT and GSK-3beta, but did not affect the upregulation of CREB phosphorylation.	Fluvoxamine	106-117	cAMP responsive element binding protein 1	Rattus norvegicus	203-207
28687730-3	2017	Nanomolar concentrations of fluvoxamine significantly increased cell viability and proliferation of neural stem cells (NSCs) through increasing mRNA expression of Notch1, Hes1 and Ki-67, and protein levels of NICD.	Fluvoxamine	28-39	notch receptor 1	Rattus norvegicus	163-169
28687730-3	2017	Nanomolar concentrations of fluvoxamine significantly increased cell viability and proliferation of neural stem cells (NSCs) through increasing mRNA expression of Notch1, Hes1 and Ki-67, and protein levels of NICD.	Fluvoxamine	28-39	hes family bHLH transcription factor 1	Rattus norvegicus	171-175
28687730-6	2017	Moreover, fluvoxamine treated EAE rats showed a decrease in IFN-gamma serum levels and an increase in IL-4, pro- and anti-inflammatory cytokines respectively, compared to untreated EAE rats.	Fluvoxamine	10-21	interferon gamma	Rattus norvegicus	60-69
28687730-6	2017	Moreover, fluvoxamine treated EAE rats showed a decrease in IFN-gamma serum levels and an increase in IL-4, pro- and anti-inflammatory cytokines respectively, compared to untreated EAE rats.	Fluvoxamine	10-21	interleukin 4	Rattus norvegicus	102-106
28687730-7	2017	Furthermore, immune cell infiltration and demyelination plaque significantly decreased in spinal cords of fluvoxamine-treated rats, which was accompanied by an increase in protein expression of MBP and GFAP positive cells and a decrease in lactate serum levels, a new biomarker of MS progression.	Fluvoxamine	106-117	myelin basic protein	Rattus norvegicus	194-197
28687730-7	2017	Furthermore, immune cell infiltration and demyelination plaque significantly decreased in spinal cords of fluvoxamine-treated rats, which was accompanied by an increase in protein expression of MBP and GFAP positive cells and a decrease in lactate serum levels, a new biomarker of MS progression.	Fluvoxamine	106-117	glial fibrillary acidic protein	Rattus norvegicus	202-206
28410959-7	2017	In the clinic, PMC s of treated patients showed upregulation of mRNA expression and protein levels of BDNF, CREB and AKT after addition of fluvoxamine.	Fluvoxamine	139-150	brain derived neurotrophic factor	Homo sapiens	102-106
28410959-7	2017	In the clinic, PMC s of treated patients showed upregulation of mRNA expression and protein levels of BDNF, CREB and AKT after addition of fluvoxamine.	Fluvoxamine	139-150	cAMP responsive element binding protein 1	Homo sapiens	108-112
28410959-7	2017	In the clinic, PMC s of treated patients showed upregulation of mRNA expression and protein levels of BDNF, CREB and AKT after addition of fluvoxamine.	Fluvoxamine	139-150	AKT serine/threonine kinase 1	Homo sapiens	117-120
28243095-3	2017	The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state.	Fluvoxamine	55-66	interleukin 6	Homo sapiens	77-90
28243095-3	2017	The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state.	Fluvoxamine	55-66	interleukin 6	Homo sapiens	92-96
28243095-11	2017	CONCLUSION: Effect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD.	Fluvoxamine	22-33	interleukin 6	Homo sapiens	37-41
27803785-3	2016	In this study, we aimed to evaluate the effect of fluvoxamine on the expression of some inflammatory genes like intercellular adhesion molecule (ICAM1), vascular cell adhesion molecule (VCAM1), cyclooxygenases2 (COX2), and inducible nitric oxide synthase (iNOS).	Fluvoxamine	50-61	intercellular adhesion molecule 1	Rattus norvegicus	145-150
27987210-8	2017	Picrotoxin-induced anhedonia was ameliorated by fluvoxamine and S-(+)-fluoxetine, selective serotonin reuptake inhibitors with high affinity for the sigma1 receptor.	Fluvoxamine	48-59	sigma non-opioid intracellular receptor 1	Mus musculus	149-164
27987210-9	2017	The effect of fluvoxamine was blocked by a 5-HT1A or a sigma1 receptor antagonist, and co-administration of the sigma1 receptor agonist (+)-SKF-10047 and the 5-HT1A receptor agonist osemozotan mimicked the effect of fluvoxamine.	Fluvoxamine	14-25	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	43-49
27987210-9	2017	The effect of fluvoxamine was blocked by a 5-HT1A or a sigma1 receptor antagonist, and co-administration of the sigma1 receptor agonist (+)-SKF-10047 and the 5-HT1A receptor agonist osemozotan mimicked the effect of fluvoxamine.	Fluvoxamine	14-25	sigma non-opioid intracellular receptor 1	Mus musculus	55-70
27402157-6	2017	Using this final PBPK model, it was predicted that weak CYP3A inhibitors (fluoxetine and fluvoxamine) are anticipated to have negligible DDI risk with palbociclib, whereas moderate CYP3A inhibitors (diltiazem and verapamil) may increase plasma palbociclib AUC by ~40%.	Fluvoxamine	89-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
27056295-4	2017	In rats, pretreatment with either dehydroepiandrosterone or fluvoxamine, a high-affinity sigma1-receptor agonist, improved survival, renal function and structure, and the inflammatory response after sublethal renal ischemia-reperfusion injury.	Fluvoxamine	60-71	sigma non-opioid intracellular receptor 1	Rattus norvegicus	89-104
27056295-5	2017	In human proximal tubular epithelial cells, stimulation by fluvoxamine or oxidative stress caused the sigma1-receptor to translocate from the endoplasmic reticulum to the cytosol and nucleus.	Fluvoxamine	59-70	sigma non-opioid intracellular receptor 1	Rattus norvegicus	102-117
27056295-6	2017	Fluvoxamine stimulation in these cells also activated nitric oxide production that was blocked by sigma1-receptor knockdown or Akt inhibition.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	98-113
27056295-6	2017	Fluvoxamine stimulation in these cells also activated nitric oxide production that was blocked by sigma1-receptor knockdown or Akt inhibition.	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	127-130
27056295-7	2017	Similarly, in the postischemic rat kidney, sigma1-receptor activation by fluvoxamine triggered the Akt-nitric oxide synthase signaling pathway, resulting in time- and isoform-specific endothelial and neuronal nitric oxide synthase activation and nitric oxide production.	Fluvoxamine	73-84	sigma non-opioid intracellular receptor 1	Rattus norvegicus	43-58
27056295-7	2017	Similarly, in the postischemic rat kidney, sigma1-receptor activation by fluvoxamine triggered the Akt-nitric oxide synthase signaling pathway, resulting in time- and isoform-specific endothelial and neuronal nitric oxide synthase activation and nitric oxide production.	Fluvoxamine	73-84	AKT serine/threonine kinase 1	Rattus norvegicus	99-102
27056295-8	2017	Concurrently, intravital two-photon imaging revealed prompt peritubular vasodilation after fluvoxamine treatment, which was blocked by the sigma1-receptor antagonist or various nitric oxide synthase blockers.	Fluvoxamine	91-102	sigma non-opioid intracellular receptor 1	Rattus norvegicus	139-154
27821711-6	2017	Using this information, a clinical study using the CYP1A2 inhibitor fluvoxamine was performed, resulting in an AUCi/AUC ratio of 1.60, confirming the role of CYP1A2 and indicating a balanced DDI risk profile.	Fluvoxamine	68-79	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	51-57
27821711-6	2017	Using this information, a clinical study using the CYP1A2 inhibitor fluvoxamine was performed, resulting in an AUCi/AUC ratio of 1.60, confirming the role of CYP1A2 and indicating a balanced DDI risk profile.	Fluvoxamine	68-79	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	158-164
28361099-9	2017	Further, using a pharmacogenomics genotyping panel, we discovered that the patient had the CYP2D6 nonfunctioning variant genotype *4/*4 that results in very low metabolic activity on a number of psychotropic drugs, including fluvoxamine which he was prescribed.	Fluvoxamine	225-236	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	91-97
28315270-5	2017	Several clinical studies showed that sigma-1 receptor agonists such as fluvoxamine and ifenprodil could have beneficial effects in patients with neuropsychiatric disorders.	Fluvoxamine	71-82	sigma non-opioid intracellular receptor 1	Rattus norvegicus	37-53
27569183-3	2017	In this study we looked at how Fluvoxamine treatment regulates depressive-like signs, motor impairments and the expression of IL-1beta, IL-6, TNF-alpha, TGF-beta and IL-10 cytokines in the striatum of a stressed Parkinsonian rat model.	Fluvoxamine	31-42	interleukin 1 beta	Rattus norvegicus	126-134
27569183-3	2017	In this study we looked at how Fluvoxamine treatment regulates depressive-like signs, motor impairments and the expression of IL-1beta, IL-6, TNF-alpha, TGF-beta and IL-10 cytokines in the striatum of a stressed Parkinsonian rat model.	Fluvoxamine	31-42	interleukin 6	Rattus norvegicus	136-140
27569183-3	2017	In this study we looked at how Fluvoxamine treatment regulates depressive-like signs, motor impairments and the expression of IL-1beta, IL-6, TNF-alpha, TGF-beta and IL-10 cytokines in the striatum of a stressed Parkinsonian rat model.	Fluvoxamine	31-42	tumor necrosis factor	Rattus norvegicus	142-151
27569183-3	2017	In this study we looked at how Fluvoxamine treatment regulates depressive-like signs, motor impairments and the expression of IL-1beta, IL-6, TNF-alpha, TGF-beta and IL-10 cytokines in the striatum of a stressed Parkinsonian rat model.	Fluvoxamine	31-42	transforming growth factor, beta 1	Rattus norvegicus	153-161
27569183-3	2017	In this study we looked at how Fluvoxamine treatment regulates depressive-like signs, motor impairments and the expression of IL-1beta, IL-6, TNF-alpha, TGF-beta and IL-10 cytokines in the striatum of a stressed Parkinsonian rat model.	Fluvoxamine	31-42	interleukin 10	Rattus norvegicus	166-171
27569183-9	2017	Lipid peroxidation, mRNA levels of IL-1beta, IL-6 and TNF-alpha were down-regulated while IL-10 and TGF-beta levels were up-regulated in the lesioned striatum of Fluvoxamine treated rats.	Fluvoxamine	162-173	interleukin 1 beta	Rattus norvegicus	35-43
27569183-9	2017	Lipid peroxidation, mRNA levels of IL-1beta, IL-6 and TNF-alpha were down-regulated while IL-10 and TGF-beta levels were up-regulated in the lesioned striatum of Fluvoxamine treated rats.	Fluvoxamine	162-173	interleukin 6	Rattus norvegicus	45-49
27569183-9	2017	Lipid peroxidation, mRNA levels of IL-1beta, IL-6 and TNF-alpha were down-regulated while IL-10 and TGF-beta levels were up-regulated in the lesioned striatum of Fluvoxamine treated rats.	Fluvoxamine	162-173	tumor necrosis factor	Rattus norvegicus	54-63
27569183-9	2017	Lipid peroxidation, mRNA levels of IL-1beta, IL-6 and TNF-alpha were down-regulated while IL-10 and TGF-beta levels were up-regulated in the lesioned striatum of Fluvoxamine treated rats.	Fluvoxamine	162-173	interleukin 10	Rattus norvegicus	90-95
27569183-9	2017	Lipid peroxidation, mRNA levels of IL-1beta, IL-6 and TNF-alpha were down-regulated while IL-10 and TGF-beta levels were up-regulated in the lesioned striatum of Fluvoxamine treated rats.	Fluvoxamine	162-173	transforming growth factor, beta 1	Rattus norvegicus	100-108
27803785-3	2016	In this study, we aimed to evaluate the effect of fluvoxamine on the expression of some inflammatory genes like intercellular adhesion molecule (ICAM1), vascular cell adhesion molecule (VCAM1), cyclooxygenases2 (COX2), and inducible nitric oxide synthase (iNOS).	Fluvoxamine	50-61	vascular cell adhesion molecule 1	Rattus norvegicus	186-191
27803785-3	2016	In this study, we aimed to evaluate the effect of fluvoxamine on the expression of some inflammatory genes like intercellular adhesion molecule (ICAM1), vascular cell adhesion molecule (VCAM1), cyclooxygenases2 (COX2), and inducible nitric oxide synthase (iNOS).	Fluvoxamine	50-61	nitric oxide synthase 2	Rattus norvegicus	223-254
27803785-3	2016	In this study, we aimed to evaluate the effect of fluvoxamine on the expression of some inflammatory genes like intercellular adhesion molecule (ICAM1), vascular cell adhesion molecule (VCAM1), cyclooxygenases2 (COX2), and inducible nitric oxide synthase (iNOS).	Fluvoxamine	50-61	nitric oxide synthase 2	Rattus norvegicus	256-260
27803785-7	2016	RESULTS: The expression of ICAM1, VCAM1, COX2, and iNOS was significantly decreased by fluvoxamine in endothelial cells, macrophages, and in rat carrageenan-induced paw edema.	Fluvoxamine	87-98	intercellular adhesion molecule 1	Rattus norvegicus	27-32
27803785-7	2016	RESULTS: The expression of ICAM1, VCAM1, COX2, and iNOS was significantly decreased by fluvoxamine in endothelial cells, macrophages, and in rat carrageenan-induced paw edema.	Fluvoxamine	87-98	vascular cell adhesion molecule 1	Rattus norvegicus	34-39
27803785-7	2016	RESULTS: The expression of ICAM1, VCAM1, COX2, and iNOS was significantly decreased by fluvoxamine in endothelial cells, macrophages, and in rat carrageenan-induced paw edema.	Fluvoxamine	87-98	nitric oxide synthase 2	Rattus norvegicus	51-55
26809458-3	2016	OBJECTIVES: We studied the dose-dependent efficacy of S1R agonist fluvoxamine (FLU) in the prevention of DM-induced depression and investigated the significance of the S1R-BDNF pathway.	Fluvoxamine	66-77	sigma non-opioid intracellular receptor 1	Rattus norvegicus	54-57
27002781-1	2016	BACKGROUND: The aim of this study was to determine the impact of fluvoxamine, an inhibitor of Cytochrome P450 (CYP) 2C19 (CYP2C19), on the pharmacokinetics of escitalopram, a substrate of CYP2C19.	Fluvoxamine	65-76	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	94-120
27002781-1	2016	BACKGROUND: The aim of this study was to determine the impact of fluvoxamine, an inhibitor of Cytochrome P450 (CYP) 2C19 (CYP2C19), on the pharmacokinetics of escitalopram, a substrate of CYP2C19.	Fluvoxamine	65-76	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	122-129
27002781-1	2016	BACKGROUND: The aim of this study was to determine the impact of fluvoxamine, an inhibitor of Cytochrome P450 (CYP) 2C19 (CYP2C19), on the pharmacokinetics of escitalopram, a substrate of CYP2C19.	Fluvoxamine	65-76	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	188-195
27339616-1	2016	RATIONALE: We previously reported that the fluvoxamine-induced increase in prefrontal dopamine levels is enhanced by adrenalectomy/castration (which results in circulating neurosteroid deficiency), via combined activation of serotonin1A (5-HT1A) and sigma1 receptors.	Fluvoxamine	43-54	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	238-244
26809458-3	2016	OBJECTIVES: We studied the dose-dependent efficacy of S1R agonist fluvoxamine (FLU) in the prevention of DM-induced depression and investigated the significance of the S1R-BDNF pathway.	Fluvoxamine	79-82	sigma non-opioid intracellular receptor 1	Rattus norvegicus	54-57
26809458-10	2016	S1R and BDNF protein levels were decreased in DM, while FLU induced SIR-BDNF production.	Fluvoxamine	56-59	brain-derived neurotrophic factor	Rattus norvegicus	72-76
26764533-4	2016	Antidepressants with distinct mechanisms of action, such as clomipramine, duloxetine and fluvoxamine, also increased BDNF mRNA expression in astrocytic and microglial cultures.	Fluvoxamine	89-100	brain-derived neurotrophic factor	Rattus norvegicus	117-121
26845564-0	2016	The ubiquitination of serotonin transporter in lymphoblasts derived from fluvoxamine-resistant depression patients.	Fluvoxamine	73-84	solute carrier family 6 member 4	Homo sapiens	22-43
26845564-7	2016	In our study, we have used lymphoblasts derived from the peripheral blood lymphocytes to quantitatively examine SERT protein expression and ubiquitination in fluvoxamine-responsive and fluvoxamine-resistant MDD patients.	Fluvoxamine	158-169	solute carrier family 6 member 4	Homo sapiens	112-116
26845564-8	2016	We found that the protein levels of SERT were higher in the fluvoxamine-resistant MDD patients.	Fluvoxamine	60-71	solute carrier family 6 member 4	Homo sapiens	36-40
26845564-9	2016	Ubiquitinated protein levels of SERT were lower in the fluvoxamine-resistant MDD patients.	Fluvoxamine	55-66	solute carrier family 6 member 4	Homo sapiens	32-36
26845564-11	2016	In sum, these findings suggest that the downregulation of the ubiquitination of SERT protein induces insufficient degradation of SERT by proteasome, which resulted in the upregulation of SERT protein in fluvoxamine-resistant MDD patients.	Fluvoxamine	203-214	solute carrier family 6 member 4	Homo sapiens	80-84
26845564-11	2016	In sum, these findings suggest that the downregulation of the ubiquitination of SERT protein induces insufficient degradation of SERT by proteasome, which resulted in the upregulation of SERT protein in fluvoxamine-resistant MDD patients.	Fluvoxamine	203-214	solute carrier family 6 member 4	Homo sapiens	129-133
26845564-11	2016	In sum, these findings suggest that the downregulation of the ubiquitination of SERT protein induces insufficient degradation of SERT by proteasome, which resulted in the upregulation of SERT protein in fluvoxamine-resistant MDD patients.	Fluvoxamine	203-214	solute carrier family 6 member 4	Homo sapiens	129-133
26988603-6	2016	Fluvoxamine inhibited serum-induced ruffle formation, cell migration, and invasion of human GBM and glioma stem cells in vitro by suppressing both FAK and Akt/mammalian target of rapamycin signaling.	Fluvoxamine	0-11	protein tyrosine kinase 2	Homo sapiens	147-150
26988603-6	2016	Fluvoxamine inhibited serum-induced ruffle formation, cell migration, and invasion of human GBM and glioma stem cells in vitro by suppressing both FAK and Akt/mammalian target of rapamycin signaling.	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Homo sapiens	155-158
26988603-6	2016	Fluvoxamine inhibited serum-induced ruffle formation, cell migration, and invasion of human GBM and glioma stem cells in vitro by suppressing both FAK and Akt/mammalian target of rapamycin signaling.	Fluvoxamine	0-11	mechanistic target of rapamycin kinase	Homo sapiens	159-188
26886336-1	2016	Fluvoxamine-perpetrated drug-drug interactions (DDIs) of victims metabolized by multiple cytochrome P450 isoforms (CYP1A2, CYP2C19, and CYP3A4) were simulated using 2 compartment-based tube modeling, assuming a multiple inhibition-constant (Ki) model, as well as a previously reported single Ki model.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	115-121
26886336-1	2016	Fluvoxamine-perpetrated drug-drug interactions (DDIs) of victims metabolized by multiple cytochrome P450 isoforms (CYP1A2, CYP2C19, and CYP3A4) were simulated using 2 compartment-based tube modeling, assuming a multiple inhibition-constant (Ki) model, as well as a previously reported single Ki model.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	123-130
26886336-1	2016	Fluvoxamine-perpetrated drug-drug interactions (DDIs) of victims metabolized by multiple cytochrome P450 isoforms (CYP1A2, CYP2C19, and CYP3A4) were simulated using 2 compartment-based tube modeling, assuming a multiple inhibition-constant (Ki) model, as well as a previously reported single Ki model.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	136-142
26626327-2	2016	Fluvoxamine is a potent CYP1A2 inhibitor and may increase the ratio of clozapine to its primary metabolite N-desmethylclozapine (NDMC).	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	24-30
26712326-4	2016	The results confirmed that the selective 5-HT1A antagonist WAY-100635 (0.05 mg/kg) partially blocked the fluvoxamine-quetiapine synergistic effect (maximum DA increase dropped from 325% to 214%).	Fluvoxamine	105-116	5-hydroxytryptamine receptor 1A	Homo sapiens	41-47
25316382-9	2015	Taken together, Sig-1R stimulation by SA4503 or fluvoxamine treatment increased hippocampal neurogenesis, which is closely associated with amelioration of depressive-like behaviors in CaMKIV null mice.	Fluvoxamine	48-59	sigma non-opioid intracellular receptor 1	Mus musculus	16-22
30620511-5	2016	Flu-voxamine inhibits CYPlA2 and CYP2C9 activity, and paroxetine inhibits CYP2D6 activity.	Fluvoxamine	0-12	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	33-39
30620511-7	2016	Fluvoxamine and paroxetine inhibit not only CYP but also P-glycoprotein.	Fluvoxamine	0-11	peptidylprolyl isomerase G	Homo sapiens	44-47
25316382-3	2015	Here, we demonstrate that chronic stimulation of Sig-1R by treatment with the agonist SA4503 or the SSRI fluvoxamine for 14 days improves depressive-like behaviors in CaMKIV null mice.	Fluvoxamine	105-116	sigma non-opioid intracellular receptor 1	Mus musculus	49-55
25316382-9	2015	Taken together, Sig-1R stimulation by SA4503 or fluvoxamine treatment increased hippocampal neurogenesis, which is closely associated with amelioration of depressive-like behaviors in CaMKIV null mice.	Fluvoxamine	48-59	calcium/calmodulin-dependent protein kinase IV	Mus musculus	184-190
25316382-3	2015	Here, we demonstrate that chronic stimulation of Sig-1R by treatment with the agonist SA4503 or the SSRI fluvoxamine for 14 days improves depressive-like behaviors in CaMKIV null mice.	Fluvoxamine	105-116	calcium/calmodulin-dependent protein kinase IV	Mus musculus	167-173
26099559-1	2015	Co-administration of fluvoxamine (FLV) (perpetrator) and ramelteon (victim, high-clearance CYP1A2 substrate) reportedly showed a 130-fold increase in the area under blood-ramelteon-levels curve (AUCR), which is unpredictable by any method assuming the traditional well-stirred hepatic extraction (Eh ) model.	Fluvoxamine	21-32	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	91-97
26415980-7	2015	Our results indicate that fluvoxamine suppresses beta-casein expression in MCF-12A cells via inhibition of STAT5 phosphorylation caused by induction of ER stress.	Fluvoxamine	26-37	signal transducer and activator of transcription 5A	Homo sapiens	107-112
26099559-1	2015	Co-administration of fluvoxamine (FLV) (perpetrator) and ramelteon (victim, high-clearance CYP1A2 substrate) reportedly showed a 130-fold increase in the area under blood-ramelteon-levels curve (AUCR), which is unpredictable by any method assuming the traditional well-stirred hepatic extraction (Eh ) model.	Fluvoxamine	34-37	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	91-97
25719307-5	2015	Fluoxetine and norfluoxetine are also potent inhibitors of CYP2D6, and fluvoxamine is a potent inhibitor of both CYP1A2 and CYP2C19.	Fluvoxamine	71-82	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	113-119
29124205-5	2015	We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R).	Fluvoxamine	26-37	sigma non-opioid intracellular receptor 1	Homo sapiens	82-98
29124205-5	2015	We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R).	Fluvoxamine	26-37	sigma non-opioid intracellular receptor 1	Homo sapiens	100-106
29124205-5	2015	We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R).	Fluvoxamine	39-42	sigma non-opioid intracellular receptor 1	Homo sapiens	82-98
29124205-5	2015	We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R).	Fluvoxamine	39-42	sigma non-opioid intracellular receptor 1	Homo sapiens	100-106
25719307-5	2015	Fluoxetine and norfluoxetine are also potent inhibitors of CYP2D6, and fluvoxamine is a potent inhibitor of both CYP1A2 and CYP2C19.	Fluvoxamine	71-82	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	124-131
25590967-0	2015	Fluvoxamine alleviates seizure activity and downregulates hippocampal GAP-43 expression in pentylenetetrazole-kindled mice: role of 5-HT3 receptors.	Fluvoxamine	0-11	growth associated protein 43	Mus musculus	70-76
25590967-10	2015	Repeated administration of fluvoxamine (20 mg/kg) in PTZ-kindled mice suppressed seizure scores, protected against hippocampal neuronal loss, and downregulated GAP-43 expression, without producing any signs of the 5-HT syndrome in healthy rats.	Fluvoxamine	27-38	growth associated protein 43	Mus musculus	160-166
25756551-2	2015	Recent evidence from animal and clinical studies that adding fluvoxamine to antipsychotics alters the expression of transcripts encoding for the GABA-A receptor and BDNF led us to postulate that fluvoxamine augmentation may improve memory in schizophrenia.	Fluvoxamine	61-72	brain derived neurotrophic factor	Homo sapiens	165-169
25756551-2	2015	Recent evidence from animal and clinical studies that adding fluvoxamine to antipsychotics alters the expression of transcripts encoding for the GABA-A receptor and BDNF led us to postulate that fluvoxamine augmentation may improve memory in schizophrenia.	Fluvoxamine	195-206	brain derived neurotrophic factor	Homo sapiens	165-169
25689244-16	2015	CONCLUSION: Fluvoxamine attenuated the laboratory response to clopidogrel, possibly through inhibition of CYP2C19, whereas citalopram did not affect this response.	Fluvoxamine	12-23	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	106-113
25159194-6	2015	Co-administration of pomalidomide with fluvoxamine (CYP1A2 inhibitor) in the presence of ketoconazole approximately doubled pomalidomide exposure.	Fluvoxamine	39-50	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	52-58
25727963-0	2015	Role of the 5-HT1A autoreceptor in the enhancement of fluvoxamine-induced increases in prefrontal dopamine release by adrenalectomy/castration in mice.	Fluvoxamine	54-65	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	12-18
25727963-1	2015	We have found that fluvoxamine-induced increases in prefrontal dopamine release are enhanced by adrenalectomy/castration and 5-HT1A receptors are involved in the enhancement.	Fluvoxamine	19-30	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	125-131
24676049-5	2014	RESULTS: The activities of citrate synthase, malate dehydrogenase, and complexes I, II-III, and IV were decreased after prolonged administration of fluvoxamine in rats.	Fluvoxamine	148-159	citrate synthase	Rattus norvegicus	27-43
25704012-3	2015	Preclinical studies showed that some selective serotonin reuptake inhibitors (SSRIs; fluvoxamine, fluoxetine, excitalopram), donepezil, and ifenprodil act as sigma-1 receptor agonists.	Fluvoxamine	85-96	sigma non-opioid intracellular receptor 1	Mus musculus	158-174
25704012-5	2015	A study using positron emission tomography have demonstrated that an oral administration of fluvoxamine or donepezil could bind to sigma-1 receptor in the healthy human brain, suggesting that sigma-1 receptor might be involved in the therapeutic mechanisms of these drugs.	Fluvoxamine	92-103	sigma non-opioid intracellular receptor 1	Mus musculus	131-147
25704012-5	2015	A study using positron emission tomography have demonstrated that an oral administration of fluvoxamine or donepezil could bind to sigma-1 receptor in the healthy human brain, suggesting that sigma-1 receptor might be involved in the therapeutic mechanisms of these drugs.	Fluvoxamine	92-103	sigma non-opioid intracellular receptor 1	Mus musculus	192-208
25704012-6	2015	Moreover, case reports suggest that sigma-1 receptor agonists, including fluvoxamine, and ifenprodil, may be effective in the treatment of cognitive impairment in schizophrenia, delirium in elderly people, and flashbacks in post-traumatic stress disorder.	Fluvoxamine	73-84	sigma non-opioid intracellular receptor 1	Mus musculus	36-52
26514046-6	2015	Some antidepressants, such as paroxetine and fluvoxamine, are strong inhibitors of the CYP system.	Fluvoxamine	45-56	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-90
24814141-0	2014	Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression.	Fluvoxamine	108-119	catechol-O-methyltransferase	Homo sapiens	26-54
24814141-1	2014	We investigated the association between remission of depressive symptoms in fluvoxamine treatment and catechol-O-methyltransferase (COMT) gene.	Fluvoxamine	76-87	catechol-O-methyltransferase	Homo sapiens	102-130
24814141-1	2014	We investigated the association between remission of depressive symptoms in fluvoxamine treatment and catechol-O-methyltransferase (COMT) gene.	Fluvoxamine	76-87	catechol-O-methyltransferase	Homo sapiens	132-136
24846087-3	2014	Here we present the case of a 29-year-old female patient with disorganized schizophrenia who exhibited OCS due to fluvoxamine-induced elevation of CLZ serum levels via inhibition of CYP 1A2 und 2C19.	Fluvoxamine	114-125	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	182-189
24709917-2	2014	Fluvoxamine, one of the currently known antidepressants, is a sigma-1 receptor agonist; its effectiveness in treating acute cerebral ischemia has not been reported.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	62-78
24709917-8	2014	Moreover, NE-100, a selective sigma-1 receptor antagonist, completely blocked the neuroprotective effect of fluvoxamine.	Fluvoxamine	108-119	sigma non-opioid intracellular receptor 1	Rattus norvegicus	30-46
24709917-9	2014	The present findings suggest that the sigma-1 receptor agonist fluvoxamine reduces infarct volume and ameliorates neurological impairment even on postischemic treatment.	Fluvoxamine	63-74	sigma non-opioid intracellular receptor 1	Rattus norvegicus	38-54
25089150-1	2014	BACKGROUND: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.	Fluvoxamine	140-151	brain derived neurotrophic factor	Homo sapiens	82-115
25089150-1	2014	BACKGROUND: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.	Fluvoxamine	140-151	brain derived neurotrophic factor	Homo sapiens	61-65
24793403-7	2014	Two notable drug-drug interactions are evident: asenapine (an inhibitor of CYP2D6) can increase plasma levels of paroxetine, and fluvoxamine (a CYP1A2 inhibitor) can increase plasma levels of asenapine.	Fluvoxamine	129-140	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	144-150
24423185-8	2014	Estradiol"s or PPT"s inhibition of the fluvoxamine-induced slowing of 5-HT clearance mediated by ERalpha, was blocked after inhibition of either MAPK/ERK1/2 or PI3K/Akt signaling pathways.	Fluvoxamine	39-50	tachykinin, precursor 1	Rattus norvegicus	15-18
24423185-8	2014	Estradiol"s or PPT"s inhibition of the fluvoxamine-induced slowing of 5-HT clearance mediated by ERalpha, was blocked after inhibition of either MAPK/ERK1/2 or PI3K/Akt signaling pathways.	Fluvoxamine	39-50	estrogen receptor 1	Rattus norvegicus	97-104
24423185-8	2014	Estradiol"s or PPT"s inhibition of the fluvoxamine-induced slowing of 5-HT clearance mediated by ERalpha, was blocked after inhibition of either MAPK/ERK1/2 or PI3K/Akt signaling pathways.	Fluvoxamine	39-50	mitogen activated protein kinase 3	Rattus norvegicus	145-149
24423185-8	2014	Estradiol"s or PPT"s inhibition of the fluvoxamine-induced slowing of 5-HT clearance mediated by ERalpha, was blocked after inhibition of either MAPK/ERK1/2 or PI3K/Akt signaling pathways.	Fluvoxamine	39-50	mitogen activated protein kinase 3	Rattus norvegicus	150-156
25032855-0	2014	Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Mus musculus	50-66
25032855-3	2014	Fluvoxamine (Flv) is a selective serotonin reuptake inhibitor (SSRI) with a high affinity for Sig-1R.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Mus musculus	94-100
25032855-3	2014	Fluvoxamine (Flv) is a selective serotonin reuptake inhibitor (SSRI) with a high affinity for Sig-1R.	Fluvoxamine	13-16	sigma non-opioid intracellular receptor 1	Mus musculus	94-100
24855828-5	2014	Both ticlopidine and fluvoxamine were competitive inhibitors of CYP2C19.	Fluvoxamine	21-32	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	64-71
24421401-7	2014	Effects of the SSRI fluvoxamine and 5-HT(1A)R agonist 8-OH-DPAT were also potentiated in RGS6(+/-) mice.	Fluvoxamine	20-31	regulator of G-protein signaling 6	Mus musculus	89-93
24582626-0	2014	Fluvoxamine moderates reduced voluntary activity following chronic dexamethasone infusion in mice via recovery of BDNF signal cascades.	Fluvoxamine	0-11	brain derived neurotrophic factor	Mus musculus	114-118
24582626-10	2014	However, marked expression of the XBP1 gene was observed in cDEX-mice treated with Flu compared with mice given saline and untreated cDEX-mice.	Fluvoxamine	83-86	X-box binding protein 1	Mus musculus	34-38
24582626-11	2014	Expression of 5-HT2A and Sigma-1 receptors decreased after cDEX infusion compared with the saline group, and these decreases normalized to control levels upon Flu treatment.	Fluvoxamine	159-162	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	14-20
24582626-12	2014	Our results indicate that the Flu moderates reductions in voluntary activity following chronic dexamethasone infusions in mice via recovery of BDNF signal cascades.	Fluvoxamine	30-33	brain derived neurotrophic factor	Mus musculus	143-147
24508523-5	2014	The order of potency for drugs at the sigma-1 receptor chaperone was as follows: fluvoxamine>sertraline>fluoxetine>escitalopram>citalopram>paroxetine>duoxetine.	Fluvoxamine	81-92	sigma non-opioid intracellular receptor 1	Rattus norvegicus	38-54
24508523-7	2014	Furthermore, fluvoxamine, fluoxetine, escitalopram, and mirtazapine significantly potentiated NGF-induced neurite outgrowth in cell assays, and the effects of all these drugs, excluding mirtazapine, were antagonized by NE-100, a selective antagonist of the sigma-1 receptor chaperone.	Fluvoxamine	13-24	sigma non-opioid intracellular receptor 1	Rattus norvegicus	257-273
24508523-10	2014	These findings suggest that activation at the sigma-1 receptor chaperone may be involved in the action of some SSRIs, such as fluvoxamine, fluoxetine and escitalopram.	Fluvoxamine	126-137	sigma non-opioid intracellular receptor 1	Rattus norvegicus	46-62
24396420-8	2014	These results suggest that sigma1 receptors mediate fluvoxamine-elicited changes in the expression levels of mTOR, Camk2gamma and GSK-3beta in N2a cells, which indicates that sigma1 receptors are likely to be involved in the pharmacological effects of fluvoxamine.	Fluvoxamine	52-63	mechanistic target of rapamycin kinase	Mus musculus	109-113
24396420-8	2014	These results suggest that sigma1 receptors mediate fluvoxamine-elicited changes in the expression levels of mTOR, Camk2gamma and GSK-3beta in N2a cells, which indicates that sigma1 receptors are likely to be involved in the pharmacological effects of fluvoxamine.	Fluvoxamine	52-63	glycogen synthase kinase 3 beta	Mus musculus	130-139
24396420-0	2014	Effects of BD1047, a sigma1 receptor antagonist, on the expression of mTOR, Camk2gamma and GSK-3beta in fluvoxamine-treated N2a cells.	Fluvoxamine	104-115	sigma non-opioid intracellular receptor 1	Mus musculus	21-36
24396420-0	2014	Effects of BD1047, a sigma1 receptor antagonist, on the expression of mTOR, Camk2gamma and GSK-3beta in fluvoxamine-treated N2a cells.	Fluvoxamine	104-115	mechanistic target of rapamycin kinase	Mus musculus	70-74
24396420-8	2014	These results suggest that sigma1 receptors mediate fluvoxamine-elicited changes in the expression levels of mTOR, Camk2gamma and GSK-3beta in N2a cells, which indicates that sigma1 receptors are likely to be involved in the pharmacological effects of fluvoxamine.	Fluvoxamine	252-263	mechanistic target of rapamycin kinase	Mus musculus	109-113
24396420-0	2014	Effects of BD1047, a sigma1 receptor antagonist, on the expression of mTOR, Camk2gamma and GSK-3beta in fluvoxamine-treated N2a cells.	Fluvoxamine	104-115	glycogen synthase kinase 3 beta	Mus musculus	91-100
24373833-9	2014	These mechanisms likely underlie in part the anti-hypertrophic and cardioprotective action of the sigma1R agonists including fluvoxamine.	Fluvoxamine	125-136	sigma non-opioid intracellular receptor 1	Rattus norvegicus	98-105
24396420-3	2014	The present study aimed to observe the effects of fluvoxamine on the expression levels of mammalian target of rapamycin (mTOR), Ca2+/calmodulin-dependent protein kinase 2gamma (Camk2gamma) and glycogen synthase kinase-3beta (GSK-3beta) in fluvoxamine-treated N2a cells and attempted to elucidate whether sigma1 receptors mediate the pharmacological effects of fluvoxamine.	Fluvoxamine	50-61	mechanistic target of rapamycin kinase	Homo sapiens	90-119
24396420-3	2014	The present study aimed to observe the effects of fluvoxamine on the expression levels of mammalian target of rapamycin (mTOR), Ca2+/calmodulin-dependent protein kinase 2gamma (Camk2gamma) and glycogen synthase kinase-3beta (GSK-3beta) in fluvoxamine-treated N2a cells and attempted to elucidate whether sigma1 receptors mediate the pharmacological effects of fluvoxamine.	Fluvoxamine	50-61	mechanistic target of rapamycin kinase	Homo sapiens	121-125
24396420-3	2014	The present study aimed to observe the effects of fluvoxamine on the expression levels of mammalian target of rapamycin (mTOR), Ca2+/calmodulin-dependent protein kinase 2gamma (Camk2gamma) and glycogen synthase kinase-3beta (GSK-3beta) in fluvoxamine-treated N2a cells and attempted to elucidate whether sigma1 receptors mediate the pharmacological effects of fluvoxamine.	Fluvoxamine	50-61	glycogen synthase kinase 3 beta	Homo sapiens	193-223
24396420-3	2014	The present study aimed to observe the effects of fluvoxamine on the expression levels of mammalian target of rapamycin (mTOR), Ca2+/calmodulin-dependent protein kinase 2gamma (Camk2gamma) and glycogen synthase kinase-3beta (GSK-3beta) in fluvoxamine-treated N2a cells and attempted to elucidate whether sigma1 receptors mediate the pharmacological effects of fluvoxamine.	Fluvoxamine	50-61	glycogen synthase kinase 3 beta	Homo sapiens	225-234
24373833-0	2014	Fluvoxamine rescues mitochondrial Ca2+ transport and ATP production through sigma(1)-receptor in hypertrophic cardiomyocytes.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	76-93
24373833-1	2014	AIMS: We previously reported that fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma1-receptor (sigma1R), ameliorates cardiac hypertrophy and dysfunction via sigma1R stimulation.	Fluvoxamine	34-45	sigma non-opioid intracellular receptor 1	Rattus norvegicus	115-130
24373833-1	2014	AIMS: We previously reported that fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma1-receptor (sigma1R), ameliorates cardiac hypertrophy and dysfunction via sigma1R stimulation.	Fluvoxamine	34-45	sigma non-opioid intracellular receptor 1	Rattus norvegicus	132-139
24373833-1	2014	AIMS: We previously reported that fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma1-receptor (sigma1R), ameliorates cardiac hypertrophy and dysfunction via sigma1R stimulation.	Fluvoxamine	34-45	sigma non-opioid intracellular receptor 1	Rattus norvegicus	194-201
24373833-5	2014	Interestingly, sigma1R stimulation with fluvoxamine rescued impaired mitochondrial Ca(2+) mobilization and ATP production, an effect abolished by treatment of cells with the sigma1R antagonist, NE-100.	Fluvoxamine	40-51	sigma non-opioid intracellular receptor 1	Rattus norvegicus	15-22
24373833-5	2014	Interestingly, sigma1R stimulation with fluvoxamine rescued impaired mitochondrial Ca(2+) mobilization and ATP production, an effect abolished by treatment of cells with the sigma1R antagonist, NE-100.	Fluvoxamine	40-51	sigma non-opioid intracellular receptor 1	Rattus norvegicus	174-181
24373833-8	2014	SIGNIFICANCE: These results suggest that sigma1R stimulation with fluvoxamine promotes SR-mitochondrial Ca(2+) transport and mitochondrial ATP production, whereas sigma1R stimulation suppresses intracellular Ca(2+) overload through IP3Rs and RyRs.	Fluvoxamine	66-77	sigma non-opioid intracellular receptor 1	Rattus norvegicus	41-48
23716885-7	2013	CONCLUSIONS: There would be an accumulation of aripiprazole when coadministered with fluvoxamine, a known inhibitor of CYP3A4, leading to hepatic damage and reduction in aripiprazole when administered along with carbamazepine.	Fluvoxamine	85-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-125
25252797-4	2014	Fluvoxamine (10 - 100 muM) concentration-dependently suppressed both monosynaptic A-fiber- and C-fiber-mediated EPSCs, which were attenuated by the selective 5-HT1A receptor antagonist WAY100635.	Fluvoxamine	0-11	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	158-164
25252797-8	2014	These results suggest that fluvoxamine reduces excitatory synaptic transmission from primary afferent fibers via presynaptic mechanisms involving 5-HT1A and/or 5-HT3 receptors, which may contribute to its analgesic effects.	Fluvoxamine	27-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	146-152
23896940-4	2013	Here, the effects of diclofenac, different antidepressants (sertraline, venlafaxine, and fluvoxamine), and vitamin B6 (pyridoxine) on IL-10 and tumor necrosis factor-alpha (TNF-alpha) change with and without immune challenges with lipopolysaccharide (LPS) were investigated in in vitro culture of astrocytes from 2-day-old Swiss-Albino mice.	Fluvoxamine	89-100	interleukin 10	Mus musculus	134-139
23896940-4	2013	Here, the effects of diclofenac, different antidepressants (sertraline, venlafaxine, and fluvoxamine), and vitamin B6 (pyridoxine) on IL-10 and tumor necrosis factor-alpha (TNF-alpha) change with and without immune challenges with lipopolysaccharide (LPS) were investigated in in vitro culture of astrocytes from 2-day-old Swiss-Albino mice.	Fluvoxamine	89-100	tumor necrosis factor	Mus musculus	144-171
23851260-4	2013	Systemic administration of fluvoxamine, a selective 5-HT reuptake inhibitor with agonistic activity towards the sigma1 receptor, increased prefrontal dopamine (DA) levels, and adrenalectomy/castration potentiated this fluvoxamine-induced increase in DA.	Fluvoxamine	27-38	sigma non-opioid intracellular receptor 1	Mus musculus	112-127
23851260-4	2013	Systemic administration of fluvoxamine, a selective 5-HT reuptake inhibitor with agonistic activity towards the sigma1 receptor, increased prefrontal dopamine (DA) levels, and adrenalectomy/castration potentiated this fluvoxamine-induced increase in DA.	Fluvoxamine	218-229	sigma non-opioid intracellular receptor 1	Mus musculus	112-127
23728612-0	2013	Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers.	Fluvoxamine	70-81	histamine receptor H1	Homo sapiens	0-21
25358426-0	2014	Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.	Fluvoxamine	96-107	cyclin D1	Homo sapiens	0-4
25358426-0	2014	Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.	Fluvoxamine	96-107	nuclear receptor subfamily 3 group C member 1	Homo sapiens	25-48
25358426-2	2014	The purpose of this study was to investigate whether Bcl1 polymorphisms of GRs are associated with the antidepressant effect of milnacipran, a serotonin noradrenaline reuptake inhibitor (SNRI), and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), in Japanese patients with depression.	Fluvoxamine	198-209	cyclin D1	Homo sapiens	53-57
25358426-7	2014	However, when milnacipran- and fluvoxamine-treated subjects were analyzed independently, patients with G allele in Bcl1 polymorphism had a significantly better response to fluvoxamine than those with C/C genotype.	Fluvoxamine	31-42	cyclin D1	Homo sapiens	115-119
25358426-7	2014	However, when milnacipran- and fluvoxamine-treated subjects were analyzed independently, patients with G allele in Bcl1 polymorphism had a significantly better response to fluvoxamine than those with C/C genotype.	Fluvoxamine	172-183	cyclin D1	Homo sapiens	115-119
25069239-7	2013	Some SSRIs (fluoxetine and fluvoxamine), which have sigma-1 receptor agonistic activity, inhibited the development of methamphetamine-induced behavioral sensitization.	Fluvoxamine	27-38	sigma non-opioid intracellular receptor 1	Mus musculus	52-68
25069239-10	2013	These results suggest that sigma-1 receptor agonistic activity might be involved in the attenuating effects of fluoxetine and fluvoxamine on methamphetamine-induced behavioral sensitization and rewarding effects.	Fluvoxamine	126-137	sigma non-opioid intracellular receptor 1	Mus musculus	27-43
23044468-8	2013	Moreover, sigma-1 receptor agonists, including the endogenous neurosteroid dehydroepiandosterone (DHEA) and the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, show potent cardioprotective and antidepressive effects in rodents, via sigma-1 receptor stimulation.	Fluvoxamine	158-169	sigma non-opioid intracellular receptor 1	Mus musculus	10-26
23288236-0	2013	5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.	Fluvoxamine	65-76	solute carrier family 6 member 4	Homo sapiens	0-8
23001793-5	2013	Ketoconazole (inhibitor of CYP3A4/5) inhibited metabolism of (-)-THP or (+)-THP at same degree, whereas the inhibition of fluvoxamine (inhibitor of CYP1A2) on metabolism of (+)-THP was greater than that of (-)-THP; moreover, the metabolic rate of (+)-THP was 5.3-fold of (-)-THP in recombinant human CYP1A2.	Fluvoxamine	122-133	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	148-154
23001793-5	2013	Ketoconazole (inhibitor of CYP3A4/5) inhibited metabolism of (-)-THP or (+)-THP at same degree, whereas the inhibition of fluvoxamine (inhibitor of CYP1A2) on metabolism of (+)-THP was greater than that of (-)-THP; moreover, the metabolic rate of (+)-THP was 5.3-fold of (-)-THP in recombinant human CYP1A2.	Fluvoxamine	122-133	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	300-306
23428811-6	2013	Our findings suggest that SSRIs such as fluvoxamine protect against PO- and TAC-induced cardiac dysfunction by upregulating sigma-1 receptor expression and stimulating sigma-1 receptor-mediated Akt-eNOS signaling.	Fluvoxamine	40-51	sigma non-opioid intracellular receptor 1	Rattus norvegicus	124-140
23428811-6	2013	Our findings suggest that SSRIs such as fluvoxamine protect against PO- and TAC-induced cardiac dysfunction by upregulating sigma-1 receptor expression and stimulating sigma-1 receptor-mediated Akt-eNOS signaling.	Fluvoxamine	40-51	sigma non-opioid intracellular receptor 1	Rattus norvegicus	168-184
23044468-8	2013	Moreover, sigma-1 receptor agonists, including the endogenous neurosteroid dehydroepiandosterone (DHEA) and the selective serotonin reuptake inhibitor (SSRI) fluvoxamine, show potent cardioprotective and antidepressive effects in rodents, via sigma-1 receptor stimulation.	Fluvoxamine	158-169	sigma non-opioid intracellular receptor 1	Mus musculus	243-259
23408363-5	2013	RESULTS: Addition of 25 or 50 mg fluvoxamine induces a mean rise of plasma concentrations of clozapine with a factor 2-3, probably even higher with the addition of 100 mg.	Fluvoxamine	33-44	transcription termination factor 2	Homo sapiens	110-120
21989809-3	2012	Previously, we have reported that acute haloperidol (HALO)-fluvoxamine (FLU) in vivo and in vitro treatment regulated GABA-Abeta2/3 receptor subunits, and protein kinase C (PKC) and mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) signaling pathways.	Fluvoxamine	72-75	protein kinase C, gamma	Rattus norvegicus	173-176
23041149-0	2012	Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine.	Fluvoxamine	73-84	sigma non-opioid intracellular receptor 1	Mus musculus	19-34
23041149-1	2012	We studied the involvement of the sigma(1) receptor in the antidepressant-like effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine in DBA/2 mice using the forced swimming test.	Fluvoxamine	140-151	sigma non-opioid intracellular receptor 1	Mus musculus	34-51
23041149-6	2012	These results suggested that the sigma(1) receptor was associated with fluvoxamine-induced antidepressant-like effects but not with paroxetine-induced antidepressant-like effects.	Fluvoxamine	71-82	sigma non-opioid intracellular receptor 1	Mus musculus	33-50
22859721-0	2012	In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.	Fluvoxamine	131-142	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	39-46
22859721-5	2012	One of the identified tight binders, the widely used antidepressant fluvoxamine, was cocrystallized with CYP46A1.	Fluvoxamine	68-79	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	105-112
22859721-7	2012	The NH(2)-containing arm of the Y-shaped fluvoxamine coordinates the CYP46A1 heme iron, whereas the methoxy-containing arm points away from the heme group and has multiple hydrophobic interactions with aliphatic amino acid residues.	Fluvoxamine	41-52	cytochrome P450 family 46 subfamily A member 1	Homo sapiens	69-76
22225849-2	2012	Previously, we reported that acute systemic treatment with estradiol or progesterone blocked the ability of the selective serotonin reuptake inhibitor, fluvoxamine, to inhibit serotonin transporter function in ovariectomized rats.	Fluvoxamine	152-163	solute carrier family 6 member 4	Rattus norvegicus	176-197
22225849-9	2012	The AD-like effect of estradiol involved ER beta and G-protein coupled receptor 30, whereas its blockade of fluvoxamine"s effects was ER alpha-mediated.	Fluvoxamine	108-119	estrogen receptor 1	Rattus norvegicus	134-142
22297159-2	2012	In particular, some selective serotonin (5-HT) reuptake inhibitors, such as citalopram and fluvoxamine, seem to exert part of their antidepressant effects through oxytocin (OT) release.	Fluvoxamine	91-102	oxytocin/neurophysin I prepropeptide	Homo sapiens	163-171
22297159-2	2012	In particular, some selective serotonin (5-HT) reuptake inhibitors, such as citalopram and fluvoxamine, seem to exert part of their antidepressant effects through oxytocin (OT) release.	Fluvoxamine	91-102	oxytocin/neurophysin I prepropeptide	Homo sapiens	173-175
21989809-3	2012	Previously, we have reported that acute haloperidol (HALO)-fluvoxamine (FLU) in vivo and in vitro treatment regulated GABA-Abeta2/3 receptor subunits, and protein kinase C (PKC) and mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) signaling pathways.	Fluvoxamine	72-75	mitogen activated protein kinase 1	Rattus norvegicus	254-257
21989809-6	2012	HALO and FLU each given alone increased PKC phosphorylation levels (29 +- 15% and 40 +- 11.8%, vs. control, respectively) and did not affect ERK2 phosphorylation, while HALO-FLU combined treatment did not alter PKC phosphorylation levels and significantly decreased ERK2 phosphorylation levels (58 +- 4.4% vs. control).	Fluvoxamine	9-12	protein kinase C, gamma	Rattus norvegicus	40-43
22649406-0	2012	Fluvoxamine attenuated endoplasmic reticulum stress-induced leptin resistance.	Fluvoxamine	0-11	leptin	Homo sapiens	60-66
24900029-11	2012	CONCLUSION: Anesthesia, body temperature, and fluvoxamine affect the result of [(18)F]FP-CIT PET in mice by altering striatal and bone uptakes.	Fluvoxamine	46-57	citron	Mus musculus	89-92
22649406-3	2012	In the present study, we found that fluvoxamine, a selective serotonin reuptake inhibitor used for depression, can attenuate ER stress-induced "leptin resistance," i.e., insensitivity to the anti-obesity hormone leptin.	Fluvoxamine	36-47	leptin	Homo sapiens	144-150
22649406-3	2012	In the present study, we found that fluvoxamine, a selective serotonin reuptake inhibitor used for depression, can attenuate ER stress-induced "leptin resistance," i.e., insensitivity to the anti-obesity hormone leptin.	Fluvoxamine	36-47	leptin	Homo sapiens	212-218
22649406-6	2012	ER stress caused an impairment of leptin-induced STAT3 phosphorylation which was reversed by fluvoxamine.	Fluvoxamine	93-104	leptin	Homo sapiens	34-40
22649406-6	2012	ER stress caused an impairment of leptin-induced STAT3 phosphorylation which was reversed by fluvoxamine.	Fluvoxamine	93-104	signal transducer and activator of transcription 3	Homo sapiens	49-54
22649406-7	2012	Fluvoxamine would be a novel leptin-sensitizing drug, which targets ER stress.	Fluvoxamine	0-11	leptin	Homo sapiens	29-35
22288409-5	2012	Among SSRIs, fluvoxamine, a potent sigma-1 receptor agonist, has the highest affinity at sigma-1 receptors.	Fluvoxamine	13-24	sigma non-opioid intracellular receptor 1	Rattus norvegicus	35-51
22288409-7	2012	Furthermore, phencyclidine (PCP)-induced cognitive impairment, associated with animal models of schizophrenia is significantly improved by sub-chronic administration of sigma-1 receptor agonists such as fluvoxamine, SA4503 (cutamesine) and donepezil.	Fluvoxamine	203-214	sigma non-opioid intracellular receptor 1	Rattus norvegicus	169-185
22288409-9	2012	A positron emission tomography (PET) study using the specific sigma-1 receptor ligand [11C]SA4503 demonstrates that fluvoxamine and donepezil bind to sigma-1 receptors in the healthy human brain.	Fluvoxamine	116-127	sigma non-opioid intracellular receptor 1	Rattus norvegicus	62-78
22288409-10	2012	In clinical studies, some sigma-1 receptor agonists, including fluvoxamine, donepezil and neurosteroids, improve cognitive impairment and clinical symptoms in neuropsychiatric diseases.	Fluvoxamine	63-74	sigma non-opioid intracellular receptor 1	Rattus norvegicus	26-42
22467103-3	2012	Fluvoxamine (50 mg/kg/day) alone significantly elevated the serum level of adiponectin, but no significant difference was found between other drug-treated groups and the control group.	Fluvoxamine	0-11	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	75-86
21739267-5	2012	Coadministration of fluvoxamine, a less potent CYP3A4 inhibitor, decreased the CL/F of aripiprazole by 39% in CYP2D6 EMs and 40% in IMs, indicating the same inhibitory effect on CYP enzymes, regardless of the CYP2D6 genotype.	Fluvoxamine	20-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
21739267-5	2012	Coadministration of fluvoxamine, a less potent CYP3A4 inhibitor, decreased the CL/F of aripiprazole by 39% in CYP2D6 EMs and 40% in IMs, indicating the same inhibitory effect on CYP enzymes, regardless of the CYP2D6 genotype.	Fluvoxamine	20-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	110-116
21739267-5	2012	Coadministration of fluvoxamine, a less potent CYP3A4 inhibitor, decreased the CL/F of aripiprazole by 39% in CYP2D6 EMs and 40% in IMs, indicating the same inhibitory effect on CYP enzymes, regardless of the CYP2D6 genotype.	Fluvoxamine	20-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	209-215
21739267-6	2012	Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration.	Fluvoxamine	262-273	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
21739267-6	2012	Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration.	Fluvoxamine	262-273	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
21739267-6	2012	Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration.	Fluvoxamine	262-273	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
21739267-6	2012	Percent contribution of CYP2D6 to total CL/F (CYP2D6 plus CYP3A4) of aripiprazole estimated as a reduced percentage of CL/F by CYP enzyme inhibition was 62% for CYP2D6 EMs and 24% for IMs in paroxetine coadministration, and 40% for CYP2D6 EMs and 18% for IMs in fluvoxamine coadministration.	Fluvoxamine	262-273	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
21979923-2	2011	Enzymes involved in duloxetine metabolism are cytochrome P450 isoenzymes (CYP) CYP1A2 and to a lesser extent CYP2D6 whereas the selective serotonin reuptake inhibitor Fluvoxamine is known to be a potent inhibitor of CYP1A2.	Fluvoxamine	167-178	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	216-222
22293694-7	2012	By contrast, fluvoxamine administration significantly attenuated TAC-induced myocardial hypertrophy concomitant with recovery of Sig-1R expression in LV.	Fluvoxamine	13-24	sigma non-opioid intracellular receptor 1	Mus musculus	129-135
22293694-9	2012	The fluvoxamine cardioprotective effect was nullified by treatment with a Sig-1R antagonist, NE-100 (1 mg/kg).	Fluvoxamine	4-15	sigma non-opioid intracellular receptor 1	Mus musculus	74-80
22293694-11	2012	Fluvoxamine treatment significantly restored TAC-induced impaired Akt and eNOS phosphorylation in LV.	Fluvoxamine	0-11	thymoma viral proto-oncogene 1	Mus musculus	66-69
22293694-12	2012	Our findings suggest that fluvoxamine protects heart against TAC-induced cardiac dysfunction via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in mice.	Fluvoxamine	26-37	sigma non-opioid intracellular receptor 1	Mus musculus	113-119
22293694-12	2012	Our findings suggest that fluvoxamine protects heart against TAC-induced cardiac dysfunction via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in mice.	Fluvoxamine	26-37	sigma non-opioid intracellular receptor 1	Mus musculus	139-145
22293694-12	2012	Our findings suggest that fluvoxamine protects heart against TAC-induced cardiac dysfunction via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in mice.	Fluvoxamine	26-37	thymoma viral proto-oncogene 1	Mus musculus	155-158
22293694-13	2012	This is the first report of a potential role of Sig-1R stimulation by fluvoxamine in preventing cardiac hypertrophy and myocardial injury in TAC mice.	Fluvoxamine	70-81	sigma non-opioid intracellular receptor 1	Mus musculus	48-54
21979923-7	2011	Our findings indicate that duloxetine plasma levels can be enhanced by a potent CYP1A2 inhibition by FLX and that DLX, even in higher plasma levels, seems to be well tolerated.	Fluvoxamine	101-104	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	80-86
21487652-3	2011	RESULTS: Fluvoxamine-induced increases in the extracellular levels of dopamine (DA), but not of 5-HT and noradrenaline, were significantly higher in adrenalectomized/castrated than in sham-operated mice, and this effect was blocked by BD1047, a selective sigma(1) receptor antagonist.	Fluvoxamine	9-20	sigma non-opioid intracellular receptor 1	Mus musculus	255-272
21487652-5	2011	Moreover, fluvoxamine increased c-Fos expression, a marker of neuronal activity, in the prefrontal cortex of adrenalectomized/castrated mice, and this effect was blocked by BD1047.	Fluvoxamine	10-21	FBJ osteosarcoma oncogene	Mus musculus	32-37
21487652-0	2011	Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and sigma(1) receptor activation.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Mus musculus	136-153
21487652-7	2011	CONCLUSIONS: These findings suggest that fluvoxamine enhances prefrontal dopaminergic neurotransmission via both 5-HT reuptake inhibition and sigma(1) receptor activation under the circulating neuroactive steroid-deficient conditions.	Fluvoxamine	41-52	sigma non-opioid intracellular receptor 1	Mus musculus	142-159
21487652-1	2011	RATIONALE: Fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor (SSRI) and an agonist for the sigma(1) receptors, increases extracellular monoamines in the prefrontal cortex, but it is not known whether the sigma(1) receptor is involved in the neurochemical effect of fluvoxamine.	Fluvoxamine	11-22	sigma non-opioid intracellular receptor 1	Mus musculus	102-119
20547595-0	2011	CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.	Fluvoxamine	38-49	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
24250395-10	2011	Our results suggest that IP administration of fluvoxamine produces a noticeable anti-inflammatory effect in the carrageenan-induced paw edema in rats and at least, a part of this effect is mediated through glucocorticoid receptor.	Fluvoxamine	46-57	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	206-229
20547595-6	2011	We investigated the joint effect of smoking (an inducer of CYP1A2) and CYP2D6 genotype on interindividual variability in fluvoxamine steady-state concentration.	Fluvoxamine	121-132	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	71-77
20547595-8	2011	While CYP2D6 genotype significantly influenced fluvoxamine concentration in all four dose groups (p < 0.05), the percentage variance explained (R2) by CYP2D6 decreased as the dose of fluvoxamine increased.	Fluvoxamine	47-58	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	6-12
20547595-8	2011	While CYP2D6 genotype significantly influenced fluvoxamine concentration in all four dose groups (p < 0.05), the percentage variance explained (R2) by CYP2D6 decreased as the dose of fluvoxamine increased.	Fluvoxamine	186-197	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	154-160
20547595-10	2011	Together, CYP2D6 genotype and smoking status explained 23% of the variance in fluvoxamine concentration but only at the low 50 mg/d dose group.	Fluvoxamine	78-89	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	10-16
20547595-11	2011	These findings contribute to evidence-based and personalized choice of fluvoxamine dose using smoking status and CYP2D6 genetic variation.	Fluvoxamine	71-82	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	113-119
21326811-0	2011	Neonatal exposure to fluoxetine and fluvoxamine alteres spine density in mouse hippocampal CA1 pyramidal neurons.	Fluvoxamine	36-47	carbonic anhydrase 1	Mus musculus	91-94
21371073-2	2011	The serotonin transporter (SERT) handles serotonin (5-hydroxytryptamine (5-HT)) and is blocked by the antidepressant SERT inhibitors fluoxetine and fluvoxamine.	Fluvoxamine	148-159	solute carrier family 6 member 4	Rattus norvegicus	4-25
21371073-2	2011	The serotonin transporter (SERT) handles serotonin (5-hydroxytryptamine (5-HT)) and is blocked by the antidepressant SERT inhibitors fluoxetine and fluvoxamine.	Fluvoxamine	148-159	solute carrier family 6 member 4	Rattus norvegicus	27-31
21371073-2	2011	The serotonin transporter (SERT) handles serotonin (5-hydroxytryptamine (5-HT)) and is blocked by the antidepressant SERT inhibitors fluoxetine and fluvoxamine.	Fluvoxamine	148-159	solute carrier family 6 member 4	Rattus norvegicus	117-121
21371073-10	2011	In in vitro experiments, SERT affected the contractility of aortas from female rats, as evidenced by an eightfold increase in potency of 5-HT in fluvoxamine (1 mumol/L)-incubated WT aortas compared with control.	Fluvoxamine	145-156	solute carrier family 6 member 4	Rattus norvegicus	25-29
21044620-0	2011	Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding.	Fluvoxamine	34-45	sigma non-opioid intracellular receptor 1	Rattus norvegicus	0-16
21044620-0	2011	Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding.	Fluvoxamine	34-45	AKT serine/threonine kinase 1	Rattus norvegicus	56-59
21044620-0	2011	Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding.	Fluvoxamine	34-45	nitric oxide synthase 3	Rattus norvegicus	60-64
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Fluvoxamine	0-19	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	176-182
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Fluvoxamine	0-19	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	184-190
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Fluvoxamine	0-19	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	192-198
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Fluvoxamine	0-19	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	200-207
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Fluvoxamine	0-19	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	211-217
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Fluvoxamine	0-19	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	221-227
21277363-4	2011	Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively.	Fluvoxamine	0-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	232-238
21044620-5	2011	Fluvoxamine administration significantly attenuated pressure overload-induced vascular injury with concomitant increase in receptor expression and subsequent decrease in IP3 receptor expression.	Fluvoxamine	0-11	inositol 1,4,5-trisphosphate receptor, type 3	Rattus norvegicus	170-182
21044620-6	2011	Fluvoxamine treatment also significantly restored pressure overload-induced impaired Akt phosphorylation and stimulated eNOS protein expression as well as Akt-mediated eNOS phosphorylation (Ser1177).	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	85-88
21044620-6	2011	Fluvoxamine treatment also significantly restored pressure overload-induced impaired Akt phosphorylation and stimulated eNOS protein expression as well as Akt-mediated eNOS phosphorylation (Ser1177).	Fluvoxamine	0-11	nitric oxide synthase 3	Rattus norvegicus	120-124
21044620-6	2011	Fluvoxamine treatment also significantly restored pressure overload-induced impaired Akt phosphorylation and stimulated eNOS protein expression as well as Akt-mediated eNOS phosphorylation (Ser1177).	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	155-158
21044620-7	2011	Fluvoxamine"s vasculoprotective effect was nullified by co-administration of a sigma-1 receptor antagonist.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	79-95
22506441-3	2011	We report a case of gynecomastia and galactorrhea in an adolescent male while on a combination of risperidone and fluvoxamine, although the serum prolactin was within normal range.	Fluvoxamine	114-125	prolactin	Homo sapiens	146-155
21427517-10	2011	The behavioral effects induced by mixed sigma(1)-receptor/SSRI antidepressants, like fluvoxamine or sertraline, may therefore involve a non-selective action at both targets.	Fluvoxamine	85-96	sigma non-opioid intracellular receptor 1	Mus musculus	40-57
20619611-0	2010	Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine.	Fluvoxamine	98-109	catechol-O-methyltransferase	Homo sapiens	10-38
20802134-0	2010	Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice.	Fluvoxamine	33-44	sigma non-opioid intracellular receptor 1	Mus musculus	0-15
20802134-3	2010	Here, we investigated the role of sigma(1)-receptor (sigma(1)R) stimulation with fluvoxamine on myocardial hypertrophy and cardiac functional recovery.	Fluvoxamine	81-92	sigma non-opioid intracellular receptor 1	Mus musculus	53-62
20802134-7	2010	In contrast, fluvoxamine administration significantly attenuated TAC-induced myocardial hypertrophy concomitant with recovery of sigma(1)R expression in the LV.	Fluvoxamine	13-24	sigma non-opioid intracellular receptor 1	Mus musculus	129-138
20802134-9	2010	The fluvoxamine cardioprotective effect was nullified by treatment with a sigma(1)R antagonist [NE-100 (1 mg/kg)].	Fluvoxamine	4-15	sigma non-opioid intracellular receptor 1	Mus musculus	74-83
20802134-11	2010	Fluvoxamine treatment significantly restored TAC-induced impaired Akt and endothelial nitric oxide synthase (eNOS) phosphorylation in the LV.	Fluvoxamine	0-11	thymoma viral proto-oncogene 1	Mus musculus	66-69
20802134-11	2010	Fluvoxamine treatment significantly restored TAC-induced impaired Akt and endothelial nitric oxide synthase (eNOS) phosphorylation in the LV.	Fluvoxamine	0-11	nitric oxide synthase 3, endothelial cell	Mus musculus	74-107
20802134-12	2010	Our findings suggest that fluvoxamine protects against TAC-induced cardiac dysfunction via upregulated sigma(1)R expression and stimulation of sigma(1)R-mediated Akt-eNOS signaling in mice.	Fluvoxamine	26-37	sigma non-opioid intracellular receptor 1	Mus musculus	103-112
20802134-12	2010	Our findings suggest that fluvoxamine protects against TAC-induced cardiac dysfunction via upregulated sigma(1)R expression and stimulation of sigma(1)R-mediated Akt-eNOS signaling in mice.	Fluvoxamine	26-37	sigma non-opioid intracellular receptor 1	Mus musculus	143-152
20802134-12	2010	Our findings suggest that fluvoxamine protects against TAC-induced cardiac dysfunction via upregulated sigma(1)R expression and stimulation of sigma(1)R-mediated Akt-eNOS signaling in mice.	Fluvoxamine	26-37	thymoma viral proto-oncogene 1	Mus musculus	162-165
20802134-13	2010	This is the first report of a potential role for sigma(1)R stimulation by fluvoxamine in attenuating cardiac hypertrophy and restoring contractility in TAC mice.	Fluvoxamine	74-85	sigma non-opioid intracellular receptor 1	Mus musculus	49-58
21273663-3	2010	The kinetic analysis of chlorpromazine metabolism carried out in the absence or presence of antidepressants showed that fluvoxamine potently inhibited chlorpromazine 5-sulfoxidation (K(i) = 2.8 muM), mono-N-demethylation (K(i) = 1.4 muM) and di-N-demethylation (K(i) = 1.1 muM) via a competitive mechanism at therapeutic antidepressant concentrations.	Fluvoxamine	120-131	latexin	Homo sapiens	194-197
21273663-3	2010	The kinetic analysis of chlorpromazine metabolism carried out in the absence or presence of antidepressants showed that fluvoxamine potently inhibited chlorpromazine 5-sulfoxidation (K(i) = 2.8 muM), mono-N-demethylation (K(i) = 1.4 muM) and di-N-demethylation (K(i) = 1.1 muM) via a competitive mechanism at therapeutic antidepressant concentrations.	Fluvoxamine	120-131	latexin	Homo sapiens	233-236
21273663-3	2010	The kinetic analysis of chlorpromazine metabolism carried out in the absence or presence of antidepressants showed that fluvoxamine potently inhibited chlorpromazine 5-sulfoxidation (K(i) = 2.8 muM), mono-N-demethylation (K(i) = 1.4 muM) and di-N-demethylation (K(i) = 1.1 muM) via a competitive mechanism at therapeutic antidepressant concentrations.	Fluvoxamine	120-131	latexin	Homo sapiens	233-236
20722474-0	2010	Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions.	Fluvoxamine	32-43	sigma non-opioid intracellular receptor 1	Rattus norvegicus	10-26
20722474-5	2010	The fluvoxamine administration significantly attenuated PO-induced myocardial hypertrophy with concomitant increase in the expression of Sig-1R in LV.	Fluvoxamine	4-15	sigma non-opioid intracellular receptor 1	Rattus norvegicus	137-143
20722474-8	2010	Fluvoxamine treatment significantly restored PO-induced impaired eNOS and Akt activity in the LV.	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	74-77
20722474-1	2010	OBJECTIVE: We here investigated the effect of sigma-1 receptor (Sig-1R) stimulation with fluvoxamine on myocardial hypertrophy, cardiac functional recovery and defined mechanisms underlying its cardioprotective action.	Fluvoxamine	89-100	sigma non-opioid intracellular receptor 1	Rattus norvegicus	46-62
20722474-10	2010	Fluvoxamine treatment protects PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in ovariectomized rats.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	77-83
20722474-10	2010	Fluvoxamine treatment protects PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in ovariectomized rats.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	103-109
20722474-1	2010	OBJECTIVE: We here investigated the effect of sigma-1 receptor (Sig-1R) stimulation with fluvoxamine on myocardial hypertrophy, cardiac functional recovery and defined mechanisms underlying its cardioprotective action.	Fluvoxamine	89-100	sigma non-opioid intracellular receptor 1	Rattus norvegicus	64-70
20722474-10	2010	Fluvoxamine treatment protects PO-induced cardiac injury via upregulation of Sig-1R and stimulation of Sig-1R-mediated Akt-eNOS signaling in ovariectomized rats.	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	119-122
20435083-3	2010	All three activities were substantially inhibited (>or=75%) by the CYP1 inhibitor alpha-naphthoflavone, whereas only MROD and CECOD were substantially inhibited by the CYP1A2-preferential inhibitor fluvoxamine.	Fluvoxamine	201-212	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	70-74
20435083-3	2010	All three activities were substantially inhibited (>or=75%) by the CYP1 inhibitor alpha-naphthoflavone, whereas only MROD and CECOD were substantially inhibited by the CYP1A2-preferential inhibitor fluvoxamine.	Fluvoxamine	201-212	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	171-177
19004511-3	2010	METHODS: We assessed the effect of SSRIs, (citalopram, fluvoxamine and fluoxetine), on TNF-alpha-induced expression of VCAM-1 and ICAM-1 in human aorta endothelial cells and adhesiveness to U937 monocytes.	Fluvoxamine	55-66	tumor necrosis factor	Homo sapiens	87-96
20846463-6	2010	One micromolar of paroxetine, fluvoxamine or sertraline increased cPLA2a expression during chronic treatment; citalopram had a similar effect at 0.1-0.5 muM; these are therapeutically relevant concentrations.	Fluvoxamine	30-41	phospholipase A2, group V	Mus musculus	66-71
20491280-9	2010	The authors investigated whether 5-HTTLPR was associated with the antidepressant response to fluvoxamine, a selective serotonin reuptake inhibitor.	Fluvoxamine	93-104	solute carrier family 6 member 4	Homo sapiens	33-41
19958758-0	2010	Involvement of the 5-HT(1A) receptor in the anti-immobility effects of fluvoxamine in the forced swimming test and mouse strain differences in 5-HT(1A) receptor binding.	Fluvoxamine	71-82	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	19-36
19958758-4	2010	The anti-immobility effects of fluvoxamine in DBA/2 mice were inhibited by the 5-HT(1A) receptor antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide (WAY 100635).	Fluvoxamine	31-42	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	79-96
19958758-6	2010	These results suggest that fluvoxamine-induced antidepressant-like effects in DBA/2 mice are mediated by the 5-HT(1A) receptor.	Fluvoxamine	27-38	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	109-126
19958758-10	2010	These results suggest that, although the anti-immobility effects of fluvoxamine in DBA/2 mice are mediated by the 5-HT(1A) receptor, strain differences in 5-HT(1A) receptor binding are not related to variation in immobility time and responses to fluvoxamine.	Fluvoxamine	68-79	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	114-131
19004511-3	2010	METHODS: We assessed the effect of SSRIs, (citalopram, fluvoxamine and fluoxetine), on TNF-alpha-induced expression of VCAM-1 and ICAM-1 in human aorta endothelial cells and adhesiveness to U937 monocytes.	Fluvoxamine	55-66	vascular cell adhesion molecule 1	Homo sapiens	119-125
19004511-3	2010	METHODS: We assessed the effect of SSRIs, (citalopram, fluvoxamine and fluoxetine), on TNF-alpha-induced expression of VCAM-1 and ICAM-1 in human aorta endothelial cells and adhesiveness to U937 monocytes.	Fluvoxamine	55-66	intercellular adhesion molecule 1	Homo sapiens	130-136
19004511-10	2010	ICAM-1 expression was decreased in the presence of fluvoxamine and fluoxetine at concentrations from 10(-7) M to 10(-4) M (p<0.05) and in the presence of citalopram at concentrations from 10(-7) M to 10(-5) M (p<0.05).	Fluvoxamine	51-62	intercellular adhesion molecule 1	Homo sapiens	0-6
20007294-7	2010	The minor caffeine-fluvoxamine interaction (1.78-fold) was slightly higher than predicted values based on determination of a moderate f(m) value for CYP1A1, although CYP1A2 may also be involved in caffeine metabolism.	Fluvoxamine	19-30	Cytochrome P450 1A1	Canis lupus familiaris	149-155
20007294-7	2010	The minor caffeine-fluvoxamine interaction (1.78-fold) was slightly higher than predicted values based on determination of a moderate f(m) value for CYP1A1, although CYP1A2 may also be involved in caffeine metabolism.	Fluvoxamine	19-30	cytochrome P450 family 1 subfamily A member 2	Canis lupus familiaris	166-172
19760522-6	2010	In addition, we performed an association analysis between TSNAX and the efficacy of fluvoxamine treatment in 120 Japanese patients with MDD.	Fluvoxamine	84-95	translin associated factor X	Homo sapiens	58-63
20128812-6	2010	Further, the selective 5-HT reuptake inhibitor fluvoxamine increased WAY 100635 induced head twitches in SERT +/+ and +/- mice.	Fluvoxamine	47-58	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	105-109
19995565-13	2010	SIGNIFICANCE: This study demonstrates that fluvoxamine treatment rapidly increased phosphorylation of Akt-1.	Fluvoxamine	43-54	AKT serine/threonine kinase 1	Rattus norvegicus	102-107
19995565-0	2010	Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells.	Fluvoxamine	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	118-123
19995565-7	2010	Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.	Fluvoxamine	26-37	AKT serine/threonine kinase 1	Rattus norvegicus	54-59
19995565-7	2010	Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.	Fluvoxamine	26-37	AKT serine/threonine kinase 1	Rattus norvegicus	93-98
19995565-7	2010	Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.	Fluvoxamine	26-37	sigma non-opioid intracellular receptor 1	Rattus norvegicus	103-119
19995565-7	2010	Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.	Fluvoxamine	39-42	AKT serine/threonine kinase 1	Rattus norvegicus	54-59
19995565-7	2010	Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.	Fluvoxamine	39-42	AKT serine/threonine kinase 1	Rattus norvegicus	93-98
19995565-7	2010	Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.	Fluvoxamine	39-42	sigma non-opioid intracellular receptor 1	Rattus norvegicus	103-119
19843060-5	2009	RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions.	Fluvoxamine	63-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-23
19875396-1	2010	A patient with an SCN5A p.W822X nonsense mutation, localized in the transmembrane region DII-S4 of the Na(v)1.5 sodium channel and leading to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day.	Fluvoxamine	246-257	sodium voltage-gated channel alpha subunit 5	Homo sapiens	18-23
19875396-1	2010	A patient with an SCN5A p.W822X nonsense mutation, localized in the transmembrane region DII-S4 of the Na(v)1.5 sodium channel and leading to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day.	Fluvoxamine	246-257	immunoglobulin lambda variable 2-18	Homo sapiens	103-111
19875396-1	2010	A patient with an SCN5A p.W822X nonsense mutation, localized in the transmembrane region DII-S4 of the Na(v)1.5 sodium channel and leading to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day.	Fluvoxamine	259-268	sodium voltage-gated channel alpha subunit 5	Homo sapiens	18-23
19875396-1	2010	A patient with an SCN5A p.W822X nonsense mutation, localized in the transmembrane region DII-S4 of the Na(v)1.5 sodium channel and leading to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day.	Fluvoxamine	259-268	immunoglobulin lambda variable 2-18	Homo sapiens	103-111
20118554-0	2010	Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.	Fluvoxamine	65-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	33-52
20118554-7	2010	Among non-smoker patients, the C/D ratios of fluvoxamine in those with one and two mutated alleles of CYP2D6 were 1.6- and 1.4-fold higher, respectively, than those with no mutated alleles, though the differences among those three genotype groups were not significant.	Fluvoxamine	45-56	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
20016223-0	2010	Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.	Fluvoxamine	128-139	nitric oxide synthase 1	Homo sapiens	69-92
20016223-0	2010	Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.	Fluvoxamine	128-139	nitric oxide synthase 1	Homo sapiens	99-103
20016223-6	2010	In addition, we performed an association analysis between NOS1 and the efficacy of fluvoxamine treatment in 117 MDD patients.	Fluvoxamine	83-94	nitric oxide synthase 1	Homo sapiens	58-62
21179660-7	2010	In addition, responders to fluvoxamine, paroxetine, milnacipran, and sertraline all increased serum BDNF levels.	Fluvoxamine	27-38	brain derived neurotrophic factor	Homo sapiens	100-104
19679463-3	2009	Anti-cancer effects of a selective sigma-1 agonist, 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), in glioblastoma were shown previously, leading to the present work where the effects on glioblastoma cells of 17 agonists or antagonists of sigma-1 receptors were studied, including currently marketed drugs fluvoxamine, dextromethorphan, donepezil, memantine and haloperidol.	Fluvoxamine	311-322	translocator protein	Homo sapiens	98-101
19928541-5	2009	GAF scales for depressive symptoms including the "waiting-for-instruction" behavior improved in 7 of these 9 cases with fluvoxamine.	Fluvoxamine	120-131	fibroblast growth factor 9	Homo sapiens	0-3
19843060-5	2009	RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions.	Fluvoxamine	63-74	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	28-34
20021354-7	2009	Moreover, a recent study using the specific sigma-1 receptor ligand [(11)C] SA4503 and positron emission tomography (PET) have demonstrated that an oral administration of fluvoxamine, but not paroxetine, could bind to sigma-1 receptors in the healthy human brain, in a dose-dependent manner.	Fluvoxamine	171-182	sigma non-opioid intracellular receptor 1	Rattus norvegicus	44-60
19386277-8	2009	In addition, we performed an association analysis of GRM2 and GRM3 and the efficacy of fluvoxamine treatment in 117 Japanese patients with MDD.	Fluvoxamine	87-98	glutamate metabotropic receptor 2	Homo sapiens	53-57
19386277-0	2009	Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population.	Fluvoxamine	111-122	glutamate metabotropic receptor 2	Homo sapiens	72-76
20021354-5	2009	In a cell culture system, we demonstrated that fluvoxamine, but not sertraline or paroxetine, significantly potentiated nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and that the effect of fluvoxamine on NGF-induced neurite outgrowth was significantly antagonized by treatment with the selective sigma-1 receptor antagonist NE-100.	Fluvoxamine	47-58	nerve growth factor	Rattus norvegicus	120-139
20021354-5	2009	In a cell culture system, we demonstrated that fluvoxamine, but not sertraline or paroxetine, significantly potentiated nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and that the effect of fluvoxamine on NGF-induced neurite outgrowth was significantly antagonized by treatment with the selective sigma-1 receptor antagonist NE-100.	Fluvoxamine	47-58	nerve growth factor	Rattus norvegicus	141-144
20021354-5	2009	In a cell culture system, we demonstrated that fluvoxamine, but not sertraline or paroxetine, significantly potentiated nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and that the effect of fluvoxamine on NGF-induced neurite outgrowth was significantly antagonized by treatment with the selective sigma-1 receptor antagonist NE-100.	Fluvoxamine	47-58	nerve growth factor	Rattus norvegicus	225-228
20021354-5	2009	In a cell culture system, we demonstrated that fluvoxamine, but not sertraline or paroxetine, significantly potentiated nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and that the effect of fluvoxamine on NGF-induced neurite outgrowth was significantly antagonized by treatment with the selective sigma-1 receptor antagonist NE-100.	Fluvoxamine	47-58	sigma non-opioid intracellular receptor 1	Rattus norvegicus	317-333
19593168-4	2009	In patients comedicated with fluvoxamine, a strong CYP1A2 inhibitor, clozapine and norclozapine concentrations correlate with CYP3A activity (r = 0.44, P = 0.075; r = 0.63, P = 0.007, respectively).	Fluvoxamine	29-40	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	51-57
19593168-4	2009	In patients comedicated with fluvoxamine, a strong CYP1A2 inhibitor, clozapine and norclozapine concentrations correlate with CYP3A activity (r = 0.44, P = 0.075; r = 0.63, P = 0.007, respectively).	Fluvoxamine	29-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-131
19225771-0	2009	Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.	Fluvoxamine	60-71	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	22-28
19386277-0	2009	Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population.	Fluvoxamine	111-122	glutamate metabotropic receptor 3	Homo sapiens	81-85
19386277-6	2009	Therefore, we studied the association between Group II mGluR genes (GRM2 and GRM3) and mood disorders and the efficacy of fluvoxamine treatment in Japanese MDD patients.	Fluvoxamine	122-133	glutamate metabotropic receptor 2	Homo sapiens	68-72
19386277-6	2009	Therefore, we studied the association between Group II mGluR genes (GRM2 and GRM3) and mood disorders and the efficacy of fluvoxamine treatment in Japanese MDD patients.	Fluvoxamine	122-133	glutamate metabotropic receptor 3	Homo sapiens	77-81
19225771-1	2009	PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4.	Fluvoxamine	9-20	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	45-70
19225771-1	2009	PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4.	Fluvoxamine	9-20	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	75-81
19225771-1	2009	PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4.	Fluvoxamine	9-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
19225771-1	2009	PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4.	Fluvoxamine	22-25	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	45-70
19225771-1	2009	PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4.	Fluvoxamine	22-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	75-81
19225771-1	2009	PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4.	Fluvoxamine	22-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
18976545-0	2009	Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene.	Fluvoxamine	0-11	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	38-53
19457229-16	2009	In addition, fluvoxamine and ranitidine decreased the levels of the oxidant parameters, myeloperoxidase and malondialdeyhyde, in the stomach tissues of the rats when compared to indomethacin group.	Fluvoxamine	13-24	myeloperoxidase	Rattus norvegicus	88-103
18976545-0	2009	Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene.	Fluvoxamine	0-11	pro-opiomelanocortin-alpha	Mus musculus	96-110
18976545-2	2009	We previously reported that fluvoxamine, a selective serotonin reuptake inhibitor, together with pharmacological inactivation of 5-HT2C receptors exert feeding suppression through activation of 5-HT1B receptors in mice.	Fluvoxamine	28-39	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	194-200
18976545-3	2009	Here, we report that fluvoxamine exerted anorexic effects in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene (2CREnd mice), whereas fluvoxamine had no effect on food intake in age-matched wild-type mice and 5-HT2C receptor mutant mice, which are associated with decreases in hypothalamic proopiomelanocortin (POMC) expression.	Fluvoxamine	21-32	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	61-76
18976545-3	2009	Here, we report that fluvoxamine exerted anorexic effects in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene (2CREnd mice), whereas fluvoxamine had no effect on food intake in age-matched wild-type mice and 5-HT2C receptor mutant mice, which are associated with decreases in hypothalamic proopiomelanocortin (POMC) expression.	Fluvoxamine	21-32	pro-opiomelanocortin-alpha	Mus musculus	119-133
18976545-5	2009	These results suggest that fluvoxamine-induced feeding suppression requires a perturbation of 5-HT2C receptor and beta-endorphin signalling plus functional hypothalamic POMC activity, whereas mCPP-induced feeding suppression does not always require functional 5-HT2C receptor, beta-endorphin, and POMC activity in mice.	Fluvoxamine	27-38	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	94-109
18976545-5	2009	These results suggest that fluvoxamine-induced feeding suppression requires a perturbation of 5-HT2C receptor and beta-endorphin signalling plus functional hypothalamic POMC activity, whereas mCPP-induced feeding suppression does not always require functional 5-HT2C receptor, beta-endorphin, and POMC activity in mice.	Fluvoxamine	27-38	pro-opiomelanocortin-alpha	Mus musculus	114-128
18976545-5	2009	These results suggest that fluvoxamine-induced feeding suppression requires a perturbation of 5-HT2C receptor and beta-endorphin signalling plus functional hypothalamic POMC activity, whereas mCPP-induced feeding suppression does not always require functional 5-HT2C receptor, beta-endorphin, and POMC activity in mice.	Fluvoxamine	27-38	pro-opiomelanocortin-alpha	Mus musculus	169-173
18976545-5	2009	These results suggest that fluvoxamine-induced feeding suppression requires a perturbation of 5-HT2C receptor and beta-endorphin signalling plus functional hypothalamic POMC activity, whereas mCPP-induced feeding suppression does not always require functional 5-HT2C receptor, beta-endorphin, and POMC activity in mice.	Fluvoxamine	27-38	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	260-275
18976545-5	2009	These results suggest that fluvoxamine-induced feeding suppression requires a perturbation of 5-HT2C receptor and beta-endorphin signalling plus functional hypothalamic POMC activity, whereas mCPP-induced feeding suppression does not always require functional 5-HT2C receptor, beta-endorphin, and POMC activity in mice.	Fluvoxamine	27-38	pro-opiomelanocortin-alpha	Mus musculus	277-291
18976545-5	2009	These results suggest that fluvoxamine-induced feeding suppression requires a perturbation of 5-HT2C receptor and beta-endorphin signalling plus functional hypothalamic POMC activity, whereas mCPP-induced feeding suppression does not always require functional 5-HT2C receptor, beta-endorphin, and POMC activity in mice.	Fluvoxamine	27-38	pro-opiomelanocortin-alpha	Mus musculus	297-301
18949539-0	2009	Spectrofluorimetric determination of fluvoxamine in dosage forms and plasma via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.	Fluvoxamine	37-48	OXA1L mitochondrial inner membrane protein	Homo sapiens	124-129
19571598-4	2009	Therefore, we examined the association between the orphan nuclear receptor Rev-erbalpha gene (NR1D1) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder.	Fluvoxamine	121-132	nuclear receptor subfamily 1 group D member 1	Homo sapiens	94-99
18322468-0	2009	Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine.	Fluvoxamine	77-88	solute carrier family 6 member 4	Rattus norvegicus	52-73
18322468-4	2009	Local application of the SSRI, fluvoxamine, directly into the CA3 area of hippocampus increased significantly 5-HT clearance time parameters in male rats and female rats in estrus or diestrus, but not in proestrus.	Fluvoxamine	31-42	carbonic anhydrase 3	Rattus norvegicus	62-65
19347611-0	2009	CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients.	Fluvoxamine	34-45	clock circadian regulator	Homo sapiens	0-5
19347611-3	2009	Therefore, we examined the association between CLOCK and the efficacy of fluvoxamine treatment in 121 patients with Japanese major depressive disorder (MDD).	Fluvoxamine	73-84	clock circadian regulator	Homo sapiens	47-52
19347611-11	2009	Our results indicate that CLOCK genotype may be a predictor of fluvoxamine treatment response in Japanese MDD.	Fluvoxamine	63-74	clock circadian regulator	Homo sapiens	26-31
18493251-1	2008	BACKGROUND AND PURPOSE: The pharmacokinetic-pharmacodynamic (PK-PD) correlation of fluvoxamine 5-HT transporter (SERT) occupancy was determined in rat frontal cortex ex vivo.	Fluvoxamine	83-94	solute carrier family 6 member 4	Rattus norvegicus	113-117
18817806-0	2009	Intracerebroventricular fluvoxamine administration inhibited pain behavior but increased Fos expression in affective pain pathways.	Fluvoxamine	24-35	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	89-92
18817806-3	2009	A 5-HT1 receptor antagonist (WAY-100635) and a 5-HT2 receptor antagonist (ketanserin), injected i.c.v., induced hyperalgesia and inhibited fluvoxamine"s anti-nociceptive effects.	Fluvoxamine	139-150	5-hydroxytryptamine receptor 2A	Homo sapiens	47-61
18817806-7	2009	Moreover, fluvoxamine alone increased Fos in the BL and PFC.	Fluvoxamine	10-21	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	38-41
18817806-9	2009	The results indicated that 5-HT2 receptor activities participate minimally in Fos induction by fluvoxamine in the PFC and BL.	Fluvoxamine	95-106	5-hydroxytryptamine receptor 2A	Homo sapiens	27-41
18817806-9	2009	The results indicated that 5-HT2 receptor activities participate minimally in Fos induction by fluvoxamine in the PFC and BL.	Fluvoxamine	95-106	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	78-81
18817806-10	2009	In contrast, WAY-100635 affected the Fos expression produced by fluvoxamine.	Fluvoxamine	64-75	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	37-40
18817806-11	2009	In the portion of the brain with affectional pain pathways, 5-HT1 receptor activities induced anti-nociceptive effects and decreased Fos expression with fluvoxamine, while 5-HT2 receptor activation affected to anti-nociceptive effects but did not induce Fos expression.	Fluvoxamine	153-164	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	133-136
18655223-5	2008	The calibration line for fluvoxamine showed good linearity in the range of 5-5000 ng/mL (r > 0.999) with the limit of quantification of 5 ng/mL (RSD = 6.51%).	Fluvoxamine	25-36	calcium binding protein, spermatid associated 1	Rattus norvegicus	148-155
18978520-0	2008	Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.	Fluvoxamine	65-76	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	29-35
18978520-3	2008	This study investigated the dose-dependent effect of CYP2D6-variant alleles on the steady-state fluvoxamine concentration.	Fluvoxamine	96-107	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	53-59
18978520-9	2008	The present study suggests that the effect of the CYP2D6 genotype on fluvoxamine metabolism is greater at lower doses of fluvoxamine.	Fluvoxamine	69-80	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	50-56
18978520-9	2008	The present study suggests that the effect of the CYP2D6 genotype on fluvoxamine metabolism is greater at lower doses of fluvoxamine.	Fluvoxamine	121-132	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	50-56
18596927-8	2008	Fluvoxamine (but not sertraline or paroxetine) and the sigma-1 receptor agonists SA4503, PPBP, and DHEA-sulfate significantly potentiated NGF-induced neurite outgrowth in PC12 cells in a concentration-dependent manner.	Fluvoxamine	0-11	nerve growth factor	Rattus norvegicus	138-141
18596927-9	2008	The potentiation by fluvoxamine and the three sigma-1 receptor agonists was blocked by co-administration of the selective sigma-1 receptor antagonist NE-100, suggesting that sigma-1 receptors play a role in blocking the enhancement of NGF-induced neurite outgrowth.	Fluvoxamine	20-31	sigma non-opioid intracellular receptor 1	Rattus norvegicus	122-138
18596927-9	2008	The potentiation by fluvoxamine and the three sigma-1 receptor agonists was blocked by co-administration of the selective sigma-1 receptor antagonist NE-100, suggesting that sigma-1 receptors play a role in blocking the enhancement of NGF-induced neurite outgrowth.	Fluvoxamine	20-31	nerve growth factor	Rattus norvegicus	235-238
18596927-12	2008	CONCLUSION: These findings suggest that stimulation of sigma-1 receptors and subsequent interaction with IP(3) receptors, PLC-gamma, PI3K, p38MAPK, JNK, and the Ras/Raf/MAPK signaling pathways are involved in the mechanisms of action of sigma-1 receptor agonists such as fluvoxamine and SA4503.	Fluvoxamine	271-282	sigma non-opioid intracellular receptor 1	Rattus norvegicus	55-71
18609433-2	2009	Fluvoxamine, a SSRI, is mainly metabolized by cytochrome P450 (CYP) 2D6 and 1A2.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-79
19043208-7	2008	Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls.	Fluvoxamine	0-11	neuropeptide Y	Rattus norvegicus	52-66
19043208-7	2008	Fluvoxamine-treated rats showed significantly lower neuropeptide Y (NPY) immunostaining levels in the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH) than untreated controls.	Fluvoxamine	0-11	neuropeptide Y	Rattus norvegicus	68-71
19043208-8	2008	Hypophagic and weight-inhibiting effects of fluvoxamine might be mediated via decreased NPY in PVN and DMH.	Fluvoxamine	44-55	neuropeptide Y	Rattus norvegicus	88-91
18655786-13	2008	Furthermore, differences in 5-HT transporter binding may cause variations in responses to fluvoxamine.	Fluvoxamine	90-101	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	28-44
18816299-3	2008	In vitro, fluvoxamine, tolfenamic acid, mefenamic acid and rofecoxib potently inhibited CYP1A2 [the 50% inhibitory concentration (IC(50)) < 10 microM].	Fluvoxamine	10-21	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	88-94
18596927-3	2008	The SSRI fluvoxamine, with sigma-1 receptor agonism, is shown to potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC 12 cells.	Fluvoxamine	9-20	sigma non-opioid intracellular receptor 1	Rattus norvegicus	27-43
18596927-3	2008	The SSRI fluvoxamine, with sigma-1 receptor agonism, is shown to potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC 12 cells.	Fluvoxamine	9-20	nerve growth factor	Rattus norvegicus	76-95
18596927-3	2008	The SSRI fluvoxamine, with sigma-1 receptor agonism, is shown to potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC 12 cells.	Fluvoxamine	9-20	nerve growth factor	Rattus norvegicus	97-100
18596927-5	2008	In this study, we examined the roles of cellular signaling pathways in the potentiation of NGF-induced neurite outgrowth by fluvoxamine and sigma-1 receptor agonists.	Fluvoxamine	124-135	nerve growth factor	Rattus norvegicus	91-94
18691982-11	2008	Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, and nefazodone is a substantial inhibitor of CYP3A4.	Fluvoxamine	59-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	51-57
18691982-11	2008	Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, and nefazodone is a substantial inhibitor of CYP3A4.	Fluvoxamine	59-70	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95
18691982-11	2008	Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, and nefazodone is a substantial inhibitor of CYP3A4.	Fluvoxamine	59-70	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	100-107
16959056-0	2007	Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors.	Fluvoxamine	0-11	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	136-142
18482738-5	2008	Sertraline, fluoxetine, fluvoxamine, citalopram and paroxetine all significantly shortened the period of Period1-bioluminescence rhythms in rat-1 fibroblasts.	Fluvoxamine	24-35	period circadian regulator 1	Rattus norvegicus	105-112
18690879-2	2008	Recent human studies have shown that the magnitude of inhibitory interactions caused by the reversible CYP1A2 inhibitor fluvoxamine decreases as liver function worsens, and virtually vanishes in patients with more advanced hepatocellular insufficiency.	Fluvoxamine	120-131	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	103-109
17709099-5	2007	The structure-activity relationship readily distinguished the pro-apoptotic and growth inhibitory effect of SSRIs from their eponymous action (blockage of the serotonin transporter): acetylation of the SSRIs fluvoxamine and paroxetine abrogated the ability of these compounds to inhibit 5HT-uptake, but did not impair their cytotoxic action.	Fluvoxamine	208-219	solute carrier family 6 member 4	Homo sapiens	159-180
18438654-7	2008	CONCLUSION: Co-administration of the CYP1A2 inhibitor fluvoxamine with ramosetron resulted in an interaction.	Fluvoxamine	54-65	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-43
17920044-8	2007	Other SSRIs, sertraline and fluvoxamine, also inhibited Kir4.1 channel currents whereas the tetracyclic (mianserin) or the 5-HT1A receptor-related (buspirone) antidepressants did not.	Fluvoxamine	28-39	potassium inwardly rectifying channel subfamily J member 10	Homo sapiens	56-62
16959056-2	2007	Here, we report that fluvoxamine (3-30 mg/kg), a selective serotonin reuptake inhibitor (SSRI), in the presence of SB 242084 (1-2 mg/kg), a selective 5-HT2C receptor antagonist, exerts appetite-suppressing effects while fluvoxamine or SB 242084 alone has no effect.	Fluvoxamine	21-32	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	150-165
16959056-5	2007	These results suggest that fluvoxamine and inactivation of 5-HT2C receptors exert feeding suppression through activation of 5-HT1B receptors, and that 5-HT1B receptors up-regulate hypothalamic POMC and CART gene expression and down-regulate hypothalamic orexin gene expression in mice.	Fluvoxamine	27-38	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	124-130
16959056-5	2007	These results suggest that fluvoxamine and inactivation of 5-HT2C receptors exert feeding suppression through activation of 5-HT1B receptors, and that 5-HT1B receptors up-regulate hypothalamic POMC and CART gene expression and down-regulate hypothalamic orexin gene expression in mice.	Fluvoxamine	27-38	hypocretin	Mus musculus	254-260
17823102-5	2007	The primary pharmacokinetic interactions with smoking occur with drugs that are CYP1A2 substrates, such as caffeine, clozapine, fluvoxamine, olanzapine, tacrine, and theophylline.	Fluvoxamine	128-139	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	80-86
17662512-7	2007	The mRNA expression of chemokine receptors, IL8RA and CCR1, and of RGS7 was significantly down-regulated following fluvoxamine augmentation.	Fluvoxamine	115-126	C-X-C motif chemokine receptor 1	Homo sapiens	44-49
17662512-7	2007	The mRNA expression of chemokine receptors, IL8RA and CCR1, and of RGS7 was significantly down-regulated following fluvoxamine augmentation.	Fluvoxamine	115-126	C-C motif chemokine receptor 1	Homo sapiens	54-58
17662512-7	2007	The mRNA expression of chemokine receptors, IL8RA and CCR1, and of RGS7 was significantly down-regulated following fluvoxamine augmentation.	Fluvoxamine	115-126	regulator of G protein signaling 7	Homo sapiens	67-71
17092970-0	2007	The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.	Fluvoxamine	118-129	brain derived neurotrophic factor	Homo sapiens	30-63
17092970-2	2007	The purpose of the present study was to investigate whether the G196A polymorphism of the brain-derived neurotrophic factor (BDNF) gene is associated with the antidepressant effect of milnacipran, a serotonin norepinephrine reuptake inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor.	Fluvoxamine	248-259	brain derived neurotrophic factor	Homo sapiens	90-123
17092970-2	2007	The purpose of the present study was to investigate whether the G196A polymorphism of the brain-derived neurotrophic factor (BDNF) gene is associated with the antidepressant effect of milnacipran, a serotonin norepinephrine reuptake inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor.	Fluvoxamine	248-259	brain derived neurotrophic factor	Homo sapiens	125-129
17092970-7	2007	In all subjects receiving milnacipran or fluvoxamine, the G/A genotype of the BDNF G196A polymorphism was associated with a significantly better therapeutic effect in the MADRS scores during this study.	Fluvoxamine	41-52	brain derived neurotrophic factor	Homo sapiens	78-82
17092970-9	2007	These results suggest that the BDNF G196A polymorphism in part determines the antidepressant effect of both milnacipran and fluvoxamine.	Fluvoxamine	124-135	brain derived neurotrophic factor	Homo sapiens	31-35
17318509-9	2007	Furthermore, when 5-HTnergic neuronal function was examined using antibodies against tryptophan hydroxylase (TPH) following the behavioral tests, fluvoxamine significantly reversed the loss of TPH-positive cells produced by OBX in the dorsal raphe.	Fluvoxamine	146-157	tryptophan hydroxylase 1	Rattus norvegicus	85-107
17431033-9	2007	Fluvoxamine, an inhibitor of CYP2C19, inhibited timolol metabolism to a lesser extent, confirming its minor contribution.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	29-36
17481608-5	2007	Pretreatment with the selective serotonin reuptake inhibitor fluvoxamine, the relatively selective noradrenaline reuptake inhibitor reboxetine, or the non-selective monoaminergic reuptake inhibitor imipramine, significantly inhibited IL-6 and NO production in a dose-dependent manner.	Fluvoxamine	61-72	interleukin 6	Mus musculus	234-238
17504220-6	2007	Interactions mediated by potent CYP1A2 inhibitors (such as fluvoxamine) or inducers (like cigarette smoke) appear to be consistent, predictable and usually clinically significant.	Fluvoxamine	59-70	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	32-38
17516189-4	2007	The likely cause of the prolonged delirium was the interaction of promethazine and fluvoxamine through the inhibition of the CYP2D6 enzyme.	Fluvoxamine	83-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	125-131
17254018-10	2007	The selective 5-HT reuptake inhibitor fluvoxamine (50 and 100 pmol) significantly decreased 5-HT clearance in BDNF+/+ mice, but not in BDNF+/- mice.	Fluvoxamine	38-49	brain derived neurotrophic factor	Mus musculus	110-114
17318509-9	2007	Furthermore, when 5-HTnergic neuronal function was examined using antibodies against tryptophan hydroxylase (TPH) following the behavioral tests, fluvoxamine significantly reversed the loss of TPH-positive cells produced by OBX in the dorsal raphe.	Fluvoxamine	146-157	tryptophan hydroxylase 1	Rattus norvegicus	109-112
17318509-9	2007	Furthermore, when 5-HTnergic neuronal function was examined using antibodies against tryptophan hydroxylase (TPH) following the behavioral tests, fluvoxamine significantly reversed the loss of TPH-positive cells produced by OBX in the dorsal raphe.	Fluvoxamine	146-157	tryptophan hydroxylase 1	Rattus norvegicus	193-196
17318509-10	2007	CONCLUSION: We demonstrated that chronic treatment with milnacipran or fluvoxamine was effective to improve both the hyperemotional behavior and the loss of TPH-positive cells seen in OBX rats.	Fluvoxamine	71-82	tryptophan hydroxylase 1	Rattus norvegicus	157-160
17417072-0	2007	Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients.	Fluvoxamine	109-120	ATP binding cassette subfamily B member 1	Homo sapiens	54-59
17307149-2	2007	In order to gain insights for developing personalized drugs, the 3D (dimensional) structure of CYP2C19 has been developed based on the crystal structure of CYP2C9 (PDB code 1R90), and its structure-activity relationship with the ligands of CEC, Fluvoxamine, Lescol, and Ticlopidine investigated through the structure-activity relationship approach.	Fluvoxamine	245-256	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	95-102
17307149-2	2007	In order to gain insights for developing personalized drugs, the 3D (dimensional) structure of CYP2C19 has been developed based on the crystal structure of CYP2C9 (PDB code 1R90), and its structure-activity relationship with the ligands of CEC, Fluvoxamine, Lescol, and Ticlopidine investigated through the structure-activity relationship approach.	Fluvoxamine	245-256	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	156-162
17417072-1	2007	UNLABELLED: This study investigated effects of the 3435 C>T genotype of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1, MDR1) gene on the steady-state plasma concentration of fluvoxamine (FLV).	Fluvoxamine	203-214	ATP binding cassette subfamily B member 1	Homo sapiens	79-139
17417072-1	2007	UNLABELLED: This study investigated effects of the 3435 C>T genotype of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1, MDR1) gene on the steady-state plasma concentration of fluvoxamine (FLV).	Fluvoxamine	203-214	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
17417072-1	2007	UNLABELLED: This study investigated effects of the 3435 C>T genotype of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1, MDR1) gene on the steady-state plasma concentration of fluvoxamine (FLV).	Fluvoxamine	203-214	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
17417072-1	2007	UNLABELLED: This study investigated effects of the 3435 C>T genotype of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1, MDR1) gene on the steady-state plasma concentration of fluvoxamine (FLV).	Fluvoxamine	216-219	ATP binding cassette subfamily B member 1	Homo sapiens	79-139
17417072-1	2007	UNLABELLED: This study investigated effects of the 3435 C>T genotype of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1, MDR1) gene on the steady-state plasma concentration of fluvoxamine (FLV).	Fluvoxamine	216-219	ATP binding cassette subfamily B member 1	Homo sapiens	141-146
17417072-1	2007	UNLABELLED: This study investigated effects of the 3435 C>T genotype of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1, MDR1) gene on the steady-state plasma concentration of fluvoxamine (FLV).	Fluvoxamine	216-219	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
16495935-4	2007	Furthermore, the effect of fluvoxamine on PCP-induced cognitive deficits was antagonized by co-administration of the selective sigma-1 receptor antagonist NE-100 (1 mg/kg/day).	Fluvoxamine	27-38	sigma non-opioid intracellular receptor 1	Mus musculus	127-143
16495935-9	2007	Therefore, sigma-1 receptor agonists such as fluvoxamine would be potential therapeutic drugs for the treatment of the cognitive deficits of schizophrenia.	Fluvoxamine	45-56	sigma non-opioid intracellular receptor 1	Mus musculus	11-27
16814933-4	2006	Subchronic treatment of naive rats with imipramine or fluvoxamine significantly decreased the expression of synapsin I.	Fluvoxamine	54-65	synapsin I	Rattus norvegicus	108-118
17166674-6	2007	The fact that fluvoxamine, a potent cytochrome P450 (CYP) 1A2 inhibitor, reduced tacrine toxicity and the expression of the CYP 1A2 gene was maintained in gel entrapped hepatocytes, but not in hepatocyte monolayers, could illustrate a close association between CYP 1A2 expression levels and tacrine toxicity.	Fluvoxamine	14-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	36-61
17166674-6	2007	The fact that fluvoxamine, a potent cytochrome P450 (CYP) 1A2 inhibitor, reduced tacrine toxicity and the expression of the CYP 1A2 gene was maintained in gel entrapped hepatocytes, but not in hepatocyte monolayers, could illustrate a close association between CYP 1A2 expression levels and tacrine toxicity.	Fluvoxamine	14-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	124-131
17166674-6	2007	The fact that fluvoxamine, a potent cytochrome P450 (CYP) 1A2 inhibitor, reduced tacrine toxicity and the expression of the CYP 1A2 gene was maintained in gel entrapped hepatocytes, but not in hepatocyte monolayers, could illustrate a close association between CYP 1A2 expression levels and tacrine toxicity.	Fluvoxamine	14-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	261-268
17596106-1	2007	OBJECTIVE: To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its pharmacodynamically active metabolite roflumilast N-oxide.	Fluvoxamine	64-75	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	93-118
17596106-1	2007	OBJECTIVE: To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its pharmacodynamically active metabolite roflumilast N-oxide.	Fluvoxamine	64-75	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	123-130
17596106-1	2007	OBJECTIVE: To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its pharmacodynamically active metabolite roflumilast N-oxide.	Fluvoxamine	64-75	phosphodiesterase 4A	Homo sapiens	213-217
17596106-8	2007	The combined effect of fluvoxamine co-administration on roflumilast and roflumilast N-oxide exposures resulted in a moderate (i.e. 59%) increase in total PDE4 inhibitory activity.	Fluvoxamine	23-34	phosphodiesterase 4A	Homo sapiens	154-158
17596106-9	2007	CONCLUSION: Co-administration of roflumilast and fluvoxamine affects the disposition of roflumilast and its active metabolite roflumilast N-oxide most likely via a potent dual pathway inhibition of CYP1A2 and CYP2C19 by fluvoxamine.	Fluvoxamine	49-60	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	198-204
17596106-9	2007	CONCLUSION: Co-administration of roflumilast and fluvoxamine affects the disposition of roflumilast and its active metabolite roflumilast N-oxide most likely via a potent dual pathway inhibition of CYP1A2 and CYP2C19 by fluvoxamine.	Fluvoxamine	49-60	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	209-216
17045169-5	2006	Dynamic PET studies using were performed on three controls and two patients, one treated with the antidepressant and inhibitor of cytochrome CYP1A2 fluvoxamine, the other suffering from liver cirrhosis.	Fluvoxamine	148-159	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	141-147
17484519-0	2007	Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine.	Fluvoxamine	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	24-39
17484519-4	2007	The formation of fluvoxamino alcohol from fluvoxamine in pooled human liver microsomes was significantly inhibited by quinidine, a relatively specific CYP2D6 inhibitor, with a Ki value of 2.2 microM, whereas other several relatively specific CYP inhibitors did not inhibit the formation of fluvoxamino alcohol.	Fluvoxamine	42-53	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	151-157
17484519-4	2007	The formation of fluvoxamino alcohol from fluvoxamine in pooled human liver microsomes was significantly inhibited by quinidine, a relatively specific CYP2D6 inhibitor, with a Ki value of 2.2 microM, whereas other several relatively specific CYP inhibitors did not inhibit the formation of fluvoxamino alcohol.	Fluvoxamine	42-53	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	151-154
17484519-7	2007	These data suggest that CYP2D6 is the only enzyme predominantly responsible for the first-step oxidation of fluvoxamine to fluvoxamino alcohol, and alcohol dehydrogenase is involved in the second-step oxidation of fluvoxamino alcohol to the corresponding carbolic acid.	Fluvoxamine	108-119	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
17484519-7	2007	These data suggest that CYP2D6 is the only enzyme predominantly responsible for the first-step oxidation of fluvoxamine to fluvoxamino alcohol, and alcohol dehydrogenase is involved in the second-step oxidation of fluvoxamino alcohol to the corresponding carbolic acid.	Fluvoxamine	108-119	aldo-keto reductase family 1 member A1	Homo sapiens	148-169
17214606-12	2007	Of a particular clinical significance is the interaction between fluvoxamine, a potent CYP1A2 inhibitor, and clozapine.	Fluvoxamine	65-76	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	87-93
17596106-9	2007	CONCLUSION: Co-administration of roflumilast and fluvoxamine affects the disposition of roflumilast and its active metabolite roflumilast N-oxide most likely via a potent dual pathway inhibition of CYP1A2 and CYP2C19 by fluvoxamine.	Fluvoxamine	220-231	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	198-204
17596106-10	2007	The exposure increases observed for roflumilast N-oxide are suggested to be attributable to CYP2C19 co-inhibition by fluvoxamine and thus, are not to be expected to occur when roflumilast is co-administered with more selective CYP1A2 inhibitors.	Fluvoxamine	117-128	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	92-99
16856883-11	2006	Fluvoxamine increased the AUC(0-infinity) and t(1/2) of rosiglitazone moderately and hence may be a weak inhibitor of CYP2C8.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	118-124
16985100-8	2006	Fluvoxamine decreased the rofecoxib-caused inactivation of CYP1A2 in a concentration-dependent manner.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	59-65
17240844-3	2006	We recently reported that chronic treatment with fluvoxamine or paroxetine desensitized 5-HT2C receptor function.	Fluvoxamine	49-60	5-hydroxytryptamine receptor 2C	Homo sapiens	88-94
16846619-0	2006	Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors.	Fluvoxamine	0-11	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	120-126
16846619-6	2006	The antiallodynic effects of systemic fluvoxamine were also reduced by both systemic and intrathecal administration of ketanserin, a 5-HT2A/2C receptor antagonist.	Fluvoxamine	38-49	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	133-139
16846619-8	2006	These results indicate that fluvoxamine exerts its antiallodynic effects on neuropathic pain via descending 5-HT fibers and spinal 5-HT2A or 5-HT2C receptors, and the antinociception on acute mechanical pain via 5-HT3 receptors.	Fluvoxamine	28-39	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	131-137
16846619-8	2006	These results indicate that fluvoxamine exerts its antiallodynic effects on neuropathic pain via descending 5-HT fibers and spinal 5-HT2A or 5-HT2C receptors, and the antinociception on acute mechanical pain via 5-HT3 receptors.	Fluvoxamine	28-39	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	141-147
16814933-6	2006	Subchronic treatment of naive rats with fluvoxamine but not imipramine showed a tendency to decrease the expression of synapsin I.	Fluvoxamine	40-51	synapsin I	Rattus norvegicus	119-129
16874005-0	2006	Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.	Fluvoxamine	107-118	solute carrier family 6 member 4	Homo sapiens	61-82
16918719-2	2006	We studied the effect of co-administration of fluvoxamine (CYP1A2 inhibitor) and erythromycin (CYP3A4 inhibitor) on the pharmacokinetics of lidocaine in a double-blind, randomized, three-way cross-over study.	Fluvoxamine	46-57	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	59-65
16918719-10	2006	We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces the presystemic metabolism of oral lidocaine and may increase the risk of lidocaine toxicity if lidocaine is ingested.	Fluvoxamine	41-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	31-37
16522641-12	2006	We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+]i) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release.	Fluvoxamine	163-174	brain derived neurotrophic factor	Homo sapiens	18-22
16522641-12	2006	We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+]i) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release.	Fluvoxamine	163-174	brain derived neurotrophic factor	Homo sapiens	187-191
16678550-0	2006	Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.	Fluvoxamine	111-122	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	55-74
16678550-1	2006	BACKGROUND AND OBJECTIVES: In vivo inhibition of cytochrome P450 (CYP) 1A2 by fluvoxamine causes a reduction in the clearance of the high-extraction drug lidocaine, which decreases in proportion to the degree of liver dysfunction.	Fluvoxamine	78-89	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	49-74
16678550-12	2006	Two mechanisms, as follows in order of importance, are responsible for the effect of liver dysfunction: (1) decreased sensitivity to fluvoxamine of CYP1A2-mediated biotransformations in the cirrhotic liver, probably resulting from reduced uptake of the inhibitory drug, and (2) reduced hepatic expression of CYP1A2, which makes its contribution to overall drug elimination less important.	Fluvoxamine	133-144	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	148-154
16678550-12	2006	Two mechanisms, as follows in order of importance, are responsible for the effect of liver dysfunction: (1) decreased sensitivity to fluvoxamine of CYP1A2-mediated biotransformations in the cirrhotic liver, probably resulting from reduced uptake of the inhibitory drug, and (2) reduced hepatic expression of CYP1A2, which makes its contribution to overall drug elimination less important.	Fluvoxamine	133-144	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	308-314
16487224-0	2006	Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.	Fluvoxamine	21-32	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	80-87
16487224-8	2006	There was a significant difference in fluvoxamine-mediated percentage increase in AUC(0,infinity) of rabeprazole and rabeprazole thioether between CYP2C19 genotypes.	Fluvoxamine	38-49	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	147-154
16487224-9	2006	CONCLUSIONS: The present study indicates that there are significant drug interactions between rabeprazole and fluvoxamine in EMs of CYP2C19.	Fluvoxamine	110-121	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	132-139
16488409-3	2006	Administration of the non-selective MAO inhibitor, pargyline, and the selective MAO-A inhibitor, clorgyline, resulted in 5-HT syndrome in 5-HTP-treated rats, and subchronic co-administration of fluvoxamine intensified the syndrome.	Fluvoxamine	194-205	monoamine oxidase A	Rattus norvegicus	80-85
16360124-6	2006	These results suggest that the desensitization of 5-HT2A receptor function occurs in the same way as that of 5-HT2C receptor function through chronic treatment with either fluvoxamine or paroxetine as a consequence of prolonged exposure to elevated levels of serotonin.	Fluvoxamine	172-183	5-hydroxytryptamine receptor 2A	Homo sapiens	50-65
16360124-6	2006	These results suggest that the desensitization of 5-HT2A receptor function occurs in the same way as that of 5-HT2C receptor function through chronic treatment with either fluvoxamine or paroxetine as a consequence of prolonged exposure to elevated levels of serotonin.	Fluvoxamine	172-183	5-hydroxytryptamine receptor 2C	Rattus norvegicus	109-115
16546220-4	2006	We examined the effects of chronic administration of imipramine, fluvoxamine, maprotiline and, as a negative control, cocaine on the level of G(olf) protein in the rat striatum.	Fluvoxamine	65-76	G protein subunit alpha L	Rattus norvegicus	142-148
16546220-8	2006	Chronic fluvoxamine and maprotiline treatment (20 mg/kg for 2 weeks) also significantly increased the level of G(olf) (by 9% and 25%, respectively), but cocaine did not alter it significantly.	Fluvoxamine	8-19	G protein subunit alpha L	Rattus norvegicus	111-117
16633150-0	2006	Time course of in vivo 5-HTT transporter occupancy by fluvoxamine.	Fluvoxamine	54-65	huntingtin	Homo sapiens	25-28
16633150-2	2006	In this study, we measured the time course of the selective serotonin reuptake inhibitor fluvoxamine in the human brain based on serotonin transporter (5-HTT) occupancy by positron emission tomography.	Fluvoxamine	89-100	huntingtin	Homo sapiens	154-157
16633150-6	2006	The relationship between the plasma concentration of fluvoxamine and 5-HTT occupancy at these different time points was fitted to the law of mass action.	Fluvoxamine	53-64	huntingtin	Homo sapiens	71-74
16205777-0	2006	Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.	Fluvoxamine	105-116	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	57-74
16205777-2	2006	CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism.	Fluvoxamine	81-92	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-24
16205777-2	2006	CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism.	Fluvoxamine	81-92	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	150-156
16205777-2	2006	CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism.	Fluvoxamine	111-122	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-24
16205777-2	2006	CytochromeP450 (CYP) 2D6 may also be associated with the side effects induced by fluvoxamine, since the plasma fluvoxamine concentration depends on a CYP2D6 gene polymorphism.	Fluvoxamine	111-122	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	150-156
16205777-12	2006	5-HT2A receptor and CYP2D6 gene polymorphisms had a synergistic effect for the prediction of fluvoxamine-induced gastrointestinal side effects.	Fluvoxamine	93-104	5-hydroxytryptamine receptor 2A	Homo sapiens	0-15
16205777-12	2006	5-HT2A receptor and CYP2D6 gene polymorphisms had a synergistic effect for the prediction of fluvoxamine-induced gastrointestinal side effects.	Fluvoxamine	93-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	20-26
16893613-0	2006	Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2.	Fluvoxamine	34-45	interleukin 2	Homo sapiens	68-81
16893613-5	2006	It turns out that the medication fluvoxamine approved by the FDA for the treatment of obsessive compulsive disorder is a potent inhibitor of the CYP1A2 enzyme, with the effect that co-administration of ramelton and fluvoxamine increases blood levels of ramelton by 100-200 fold.	Fluvoxamine	33-44	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	145-151
16893613-5	2006	It turns out that the medication fluvoxamine approved by the FDA for the treatment of obsessive compulsive disorder is a potent inhibitor of the CYP1A2 enzyme, with the effect that co-administration of ramelton and fluvoxamine increases blood levels of ramelton by 100-200 fold.	Fluvoxamine	215-226	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	145-151
16893613-7	2006	Thus, here we point out that co-administration of ramelton and modest doses of fluvoxamine may be able to smoothly produce increased levels of Il-2, this may be useful in diseases and conditions such as metastatic cancer and maintenance of suppression of the HIV virus.	Fluvoxamine	79-90	interleukin 2	Homo sapiens	143-147
17356306-0	2006	Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients.	Fluvoxamine	87-98	vesicle associated membrane protein 2	Homo sapiens	26-63
17356306-3	2006	The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine.	Fluvoxamine	136-147	vesicle associated membrane protein 2	Homo sapiens	57-62
16874005-1	2006	In this study, we tested the influence of the serotonin type 2A, 3A and 3B receptor genes (HTR2A, HTR3A, HTR3B) in addition to a polymorphism in the promoter region of the serotonin transporter (SERTPR), and investigated the different characteristics of clinical responses to paroxetine and fluvoxamine.	Fluvoxamine	291-302	solute carrier family 6 member 4	Homo sapiens	172-193
16874005-4	2006	Patients with the l allele of SERTPR showed a better response to SSRIs than s/s genotype carriers (p = 0.015-0.042), more significantly to fluvoxamine.	Fluvoxamine	139-150	solute carrier family 6 member 4	Homo sapiens	30-36
16874005-5	2006	The -1438G/G genotype of HTR2A was associated with a good response to SSRIs (p = 0.010-0.039), especially to fluvoxamine, and significantly with severe nausea in paroxetine-treated patients (p = 0.013).	Fluvoxamine	109-120	5-hydroxytryptamine receptor 2A	Homo sapiens	25-30
16226034-8	2005	However, higher doses of fluvoxamine may elevate plasma risperidone levels, presumably as a result of a dose-dependent inhibitory effect of fluvoxamine on CYP2D6-and/or CYP3A4-mediated 9-hydroxylation of risperidone.	Fluvoxamine	25-36	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	155-161
16282844-2	2005	The antidepressant fluvoxamine is an inhibitor of cytochrome P450 3A4.	Fluvoxamine	19-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-69
16226034-8	2005	However, higher doses of fluvoxamine may elevate plasma risperidone levels, presumably as a result of a dose-dependent inhibitory effect of fluvoxamine on CYP2D6-and/or CYP3A4-mediated 9-hydroxylation of risperidone.	Fluvoxamine	25-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-175
16226034-8	2005	However, higher doses of fluvoxamine may elevate plasma risperidone levels, presumably as a result of a dose-dependent inhibitory effect of fluvoxamine on CYP2D6-and/or CYP3A4-mediated 9-hydroxylation of risperidone.	Fluvoxamine	140-151	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	155-161
16226034-8	2005	However, higher doses of fluvoxamine may elevate plasma risperidone levels, presumably as a result of a dose-dependent inhibitory effect of fluvoxamine on CYP2D6-and/or CYP3A4-mediated 9-hydroxylation of risperidone.	Fluvoxamine	140-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-175
16236038-1	2005	BACKGROUND: Coadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half-life, which is attributable to inhibition of CYP1A2 by fluvoxamine.	Fluvoxamine	32-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	157-163
16359723-6	2005	Furthermore, as with selective serotonin reuptake inhibitors such as fluvoxamine and paroxetine, SIV was also reduced by the serotonin and noradrenaline reuptake inhibitor milnacipran and the metabotropic glutamate receptor 5 antagonist MPEP, while desipramine was without effect.	Fluvoxamine	69-80	glutamate metabotropic receptor 5	Rattus norvegicus	192-225
16236038-1	2005	BACKGROUND: Coadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half-life, which is attributable to inhibition of CYP1A2 by fluvoxamine.	Fluvoxamine	167-178	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	157-163
15963095-0	2005	Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.	Fluvoxamine	97-108	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	60-67
16079297-9	2005	Furthermore, the time-dependent change of SERT mRNA expression and uptake activity in the midbrain is suggested to be the mechanism underlying the 24-h rhythm of anti-immobility effect of fluvoxamine.	Fluvoxamine	188-199	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	42-46
15963095-2	2005	The aim of this study was to examine the effects of fluvoxamine, a CYP2C19 inhibitor, on the pharmacokinetics of each lansoprazole enantiomer among three different CYP2C19 genotype groups.	Fluvoxamine	52-63	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	67-74
15963095-7	2005	The mean fluvoxamine-mediated percent increase in the AUC(0, infinity) of (R)-lansoprazole in the homEMs compared with the PMs was significant (P = 0.0117); however, C(max) did not differ among the three CYP2C19 genotypes.	Fluvoxamine	9-20	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	204-211
16119478-0	2005	Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism.	Fluvoxamine	21-32	solute carrier family 6 member 4	Homo sapiens	66-87
16119478-1	2005	We studied the correlation between response to fluvoxamine and serotonin transporter gene promoter region polymorphism (5-HTTLPR).	Fluvoxamine	47-58	solute carrier family 6 member 4	Homo sapiens	63-84
16119478-1	2005	We studied the correlation between response to fluvoxamine and serotonin transporter gene promoter region polymorphism (5-HTTLPR).	Fluvoxamine	47-58	solute carrier family 6 member 4	Homo sapiens	120-128
16119478-7	2005	5-HTTLPR may influence the individual responses to fluvoxamine administration.	Fluvoxamine	51-62	solute carrier family 6 member 4	Homo sapiens	0-8
15845683-2	2005	We studied the effect of coadministration of the antidepressant fluvoxamine (CYP1A2 inhibitor) and antimicrobial drug erythromycin (CYP3A4 inhibitor) on lidocaine pharmacokinetics in a double-blind, randomized, three-way crossover study.	Fluvoxamine	64-75	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	77-83
15845683-8	2005	We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces elimination of lidocaine and may increase the risk of lidocaine toxicity.	Fluvoxamine	41-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	31-37
15383832-12	2005	These findings suggest that the combination of prefrontal DA-D2/3 receptor blockade and 5-HT1A receptor activation in regions other than the cortex plays an important role in sulpiride and fluvoxamine-induced increase in prefrontal DA release.	Fluvoxamine	189-200	5-hydroxytryptamine receptor 1A	Rattus norvegicus	88-94
15719219-3	2005	OBJECTIVES: This study was conducted to examine the effects of chronic pretreatment with the SSRIs fluvoxamine and paroxetine on the facilitation of ejaculation induced by the 5-HT1A receptor agonist 8-OH-DPAT.	Fluvoxamine	99-110	5-hydroxytryptamine receptor 1A	Rattus norvegicus	176-182
15738749-5	2005	The present prospective study tested the hypothesis that olanzapine steady-state doses can be significantly decreased by coadministration of a low subclinical dose of fluvoxamine, a potent inhibitor of cytochrome P450 1A2.	Fluvoxamine	167-178	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	202-221
15738749-11	2005	4"-N-desmethylolanzapine/olanzapine metabolic ratio decreased from 0.45 +/- 0.20 at baseline to 0.25 +/- 0.11 at week 6, suggesting inhibition of the cytochrome P450 1A2-mediated olanzapine 4"-N-demethylation by fluvoxamine (P < 0.05).	Fluvoxamine	212-223	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	150-169
15678084-3	2005	Oral administration of fluvoxamine, fluoxetine, paroxetine and sertraline at pharmacologically relevant doses exerted dose- and time-dependent binding activity of brain SERT as revealed by significant increases in KD for specific [3H]paroxetine binding, and the in vivo SERT-binding potency was in the order of paroxetine>>fluoxetine, sertraline>fluvoxamine.	Fluvoxamine	23-34	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	169-173
15678084-3	2005	Oral administration of fluvoxamine, fluoxetine, paroxetine and sertraline at pharmacologically relevant doses exerted dose- and time-dependent binding activity of brain SERT as revealed by significant increases in KD for specific [3H]paroxetine binding, and the in vivo SERT-binding potency was in the order of paroxetine>>fluoxetine, sertraline>fluvoxamine.	Fluvoxamine	23-34	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	270-274
15678084-3	2005	Oral administration of fluvoxamine, fluoxetine, paroxetine and sertraline at pharmacologically relevant doses exerted dose- and time-dependent binding activity of brain SERT as revealed by significant increases in KD for specific [3H]paroxetine binding, and the in vivo SERT-binding potency was in the order of paroxetine>>fluoxetine, sertraline>fluvoxamine.	Fluvoxamine	355-366	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	169-173
15678084-11	2005	In conclusion, the present study has provided the first in vivo evidences to support that fluvoxamine, fluoxetine, paroxetine and sertraline orally administered bind to the pharmacologically relevant brain SERT in mice and that their SERT-binding characteristics is closely associated with the pharmacokinetics and inhibition of marble-burying behaviour.	Fluvoxamine	90-101	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	206-210
15678084-11	2005	In conclusion, the present study has provided the first in vivo evidences to support that fluvoxamine, fluoxetine, paroxetine and sertraline orally administered bind to the pharmacologically relevant brain SERT in mice and that their SERT-binding characteristics is closely associated with the pharmacokinetics and inhibition of marble-burying behaviour.	Fluvoxamine	90-101	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	234-238
15458611-3	2004	The aim of this study is to investigate a possible association between this 5-HT1A receptor variant and antidepressant response to fluvoxamine in a sample of 262 mood-disorder subjects (151 major depressed and 111 bipolars) treated with fluvoxamine for 6 wk.	Fluvoxamine	131-142	5-hydroxytryptamine receptor 1A	Homo sapiens	76-91
15458611-3	2004	The aim of this study is to investigate a possible association between this 5-HT1A receptor variant and antidepressant response to fluvoxamine in a sample of 262 mood-disorder subjects (151 major depressed and 111 bipolars) treated with fluvoxamine for 6 wk.	Fluvoxamine	237-248	5-hydroxytryptamine receptor 1A	Homo sapiens	76-91
15458611-6	2004	In bipolars, 5-HT1A*C/C genotype carriers showed a better response to fluvoxamine (p=0.036), independently from clinical variables.	Fluvoxamine	70-81	5-hydroxytryptamine receptor 1A	Homo sapiens	13-19
15545309-2	2004	Administration of a potent CYP1A2 inhibitor (eg, fluvoxamine) may alter the pharmacokinetics of olanzapine.	Fluvoxamine	49-60	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	27-33
15301922-0	2004	Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats.	Fluvoxamine	23-34	5-hydroxytryptamine receptor 2C	Rattus norvegicus	48-54
15496639-2	2004	The aim of this study was to compare the inhibitory effects of fluvoxamine, an inhibitor of CYP2C19, on the metabolism of lansoprazole between CYP2C19 genotypes.	Fluvoxamine	63-74	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	92-99
15496639-2	2004	The aim of this study was to compare the inhibitory effects of fluvoxamine, an inhibitor of CYP2C19, on the metabolism of lansoprazole between CYP2C19 genotypes.	Fluvoxamine	63-74	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	143-150
15496639-7	2004	There was a significant difference in the fluvoxamine-mediated percentage increase in the AUC(0-infinity) of lansoprazole between CYP2C19 genotypes.	Fluvoxamine	42-53	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	130-137
15319333-10	2004	Experiments with thiotepa and ketoconazole suggested inhibition of microsomal CYP2B6 and CYP3A4 activity, whereas studies with fluvoxamine (a substrate of CYP2C19) were inconclusive due to lack of specificity.	Fluvoxamine	127-138	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	155-162
15301922-3	2004	In the present study, we investigated whether chronic administration of fluvoxamine desensitizes 5-HT2C receptors using a putative in vivo rat model of 5-HT2C receptor function.	Fluvoxamine	72-83	5-hydroxytryptamine receptor 2C	Rattus norvegicus	97-103
15301922-3	2004	In the present study, we investigated whether chronic administration of fluvoxamine desensitizes 5-HT2C receptors using a putative in vivo rat model of 5-HT2C receptor function.	Fluvoxamine	72-83	5-hydroxytryptamine receptor 2C	Rattus norvegicus	152-158
15301922-5	2004	This effect of fluvoxamine was reversed by treatment with a selective 5-HT2C receptor antagonist, SB 242084.	Fluvoxamine	15-26	5-hydroxytryptamine receptor 2C	Rattus norvegicus	70-76
15301922-8	2004	These results suggest that 5-HT2C receptors are desensitized by chronic treatment with fluvoxamine, as well as paroxetine.	Fluvoxamine	87-98	5-hydroxytryptamine receptor 2C	Rattus norvegicus	27-33
15301922-9	2004	Thus, the clinical efficacy of fluvoxamine on anxiety disorders might involve the normalization of the 5-HT2C receptor function.	Fluvoxamine	31-42	5-hydroxytryptamine receptor 2C	Rattus norvegicus	103-109
15167270-6	2004	5-HT-induced contraction of normal aorta was potentiated by the 5-HTT inhibitor fluvoxamine.	Fluvoxamine	80-91	solute carrier family 6 member 4	Rattus norvegicus	64-69
15251034-5	2004	METHODS: Fatigued patients were randomised to receive fluvoxamine (75 mg BID) or placebo for a six-week period.	Fluvoxamine	54-65	BH3 interacting domain death agonist	Homo sapiens	73-76
15167270-7	2004	A change in arterial 5-HTT function occurs in deoxycorticosterone (DOCA)-salt hypertension as the potency and threshold of 5-HT in contracting aorta from the DOCA-salt rat was increased by fluoxetine and fluvoxamine (1 micromol/L; DOCA fluvoxamine -log EC50 [mol/L] = 6.85 +/- 0.08, DOCA-control = 6.44 +/- 0.08); expression of transporter was significantly increased in aorta of DOCA salt rats (145% Sham).	Fluvoxamine	204-215	solute carrier family 6 member 4	Rattus norvegicus	21-26
15025747-0	2004	Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.	Fluvoxamine	31-42	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	76-83
15170064-6	2004	The author also examined polymorphisms of the serotonin transporter/biosynthetic or metabolizing enzymes in depressive patients treated with fluvoxamine, a selective serotonin reuptake inhibitor, and the relationship between clinical efficacy and polymorphisms was investigated.	Fluvoxamine	141-152	solute carrier family 6 member 4	Homo sapiens	46-67
15025747-2	2004	The inhibitory effect of fluvoxamine, an inhibitor of CYP2C19 as well as CYP1A2, on the metabolism of omeprazole was compared between different genotypes for CYP2C19.	Fluvoxamine	25-36	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	54-61
15025747-12	2004	These findings confirm a potent inhibitory effect of fluvoxamine on CYP2C19 activity.	Fluvoxamine	53-64	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	68-75
14749694-10	2004	The extent of fluvoxamine-lidocaine interaction decreases as liver function worsens, most likely because of the concomitant decrease in the hepatic level of CYP1A2.	Fluvoxamine	14-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	157-163
15060511-12	2004	Inhibition of tizanidine-metabolizing enzyme(s), mainly CYP1A2, by fluvoxamine seems to explain the observed interaction.	Fluvoxamine	67-78	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	56-62
15164615-0	2004	[Postherpetic neuralgia alleviated by an SSRI fluvoxamine: two cases of PHN accompanied with depression were treated with fluvoxamine].	Fluvoxamine	46-57	carbamoyl-phosphate synthase 1	Homo sapiens	72-75
15164615-0	2004	[Postherpetic neuralgia alleviated by an SSRI fluvoxamine: two cases of PHN accompanied with depression were treated with fluvoxamine].	Fluvoxamine	122-133	carbamoyl-phosphate synthase 1	Homo sapiens	72-75
15164615-8	2004	It would be concluded that fluvoxamine alleviates PHN by restoration of the descending serotonergic inhibition of primary afferent activity that carries pain impulses.	Fluvoxamine	27-38	carbamoyl-phosphate synthase 1	Homo sapiens	50-53
15148501-1	2004	We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study.	Fluvoxamine	118-129	5-hydroxytryptamine receptor 1A	Homo sapiens	33-71
15148501-1	2004	We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study.	Fluvoxamine	131-134	5-hydroxytryptamine receptor 1A	Homo sapiens	33-71
12883230-0	2003	Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.	Fluvoxamine	99-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	15-22
15199661-3	2004	Thus, fluoxetine, fluvoxamine and paroxetine are partially metabolised by CYP2D6, citalopram by CYP2C19 and sertraline by at least five different CYPs.	Fluvoxamine	18-29	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	74-80
15199661-3	2004	Thus, fluoxetine, fluvoxamine and paroxetine are partially metabolised by CYP2D6, citalopram by CYP2C19 and sertraline by at least five different CYPs.	Fluvoxamine	18-29	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	96-103
14642738-7	2003	Fluvoxamine and diphenytriazol inhibited zolmitriptan N-demethylase activity catalyzed by CYP1A2 (K(i)=3.8+/-0.3 and 3.2+/-0.1 microM, respectively).	Fluvoxamine	0-11	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	90-96
14642738-13	2003	This study aso demonstrated that fluvoxamine may be a mechanism-based inactivator of CYP1A2.	Fluvoxamine	33-44	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	85-91
14501158-4	2003	The compound was as effective as SERT inhibitors such as fluoxetine and fluvoxamine in a 5-hydroxytryptophan-enhancing test in mice.	Fluvoxamine	72-83	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	33-37
12721776-0	2003	Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.	Fluvoxamine	141-152	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	22-28
15199661-5	2004	Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-43
15199661-5	2004	Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	48-55
15199661-5	2004	Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	84-90
14703714-4	2003	Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4.	Fluvoxamine	59-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	51-57
14703714-4	2003	Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4.	Fluvoxamine	59-70	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	89-95
14703714-4	2003	Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4.	Fluvoxamine	59-70	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	100-107
12969751-2	2003	Local administration by reversed microdialysis of the selective 5-HT reuptake inhibitor, fluvoxamine (0.1-10 microM), concentration dependently increased 5-HT to the same extent in wildtype and in 5-HT1B knockout (KO) mice.	Fluvoxamine	89-100	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	197-203
12644890-7	2003	In the presence of fluvoxamine, the increased 5-HT release evoked by KCl depolarization was augmented by NAS-181, supporting the idea that blockade of 5-HT transporters is necessary to measure an effect of 5-HT(1B) receptor blockade.	Fluvoxamine	19-30	5-hydroxytryptamine receptor 1B	Rattus norvegicus	206-213
12755054-2	2003	To create better treatment, we studied here clinical adverse effects of fluvoxamine and correlated them with genetic polymorphism of two genes, the promoter region of serotonin transporter gene (5-HTTLPR) and serotonin 2A receptor gene (5-HT2AR).	Fluvoxamine	72-83	solute carrier family 6 member 4	Homo sapiens	167-188
12755054-2	2003	To create better treatment, we studied here clinical adverse effects of fluvoxamine and correlated them with genetic polymorphism of two genes, the promoter region of serotonin transporter gene (5-HTTLPR) and serotonin 2A receptor gene (5-HT2AR).	Fluvoxamine	72-83	solute carrier family 6 member 4	Homo sapiens	195-203
12755054-2	2003	To create better treatment, we studied here clinical adverse effects of fluvoxamine and correlated them with genetic polymorphism of two genes, the promoter region of serotonin transporter gene (5-HTTLPR) and serotonin 2A receptor gene (5-HT2AR).	Fluvoxamine	72-83	5-hydroxytryptamine receptor 2A	Homo sapiens	209-230
12839860-0	2003	Drug binding to HERG channels: evidence for a "non-aromatic" binding site for fluvoxamine.	Fluvoxamine	78-89	potassium voltage-gated channel subfamily H member 2	Homo sapiens	16-20
12839862-0	2003	Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.	Fluvoxamine	39-50	potassium voltage-gated channel subfamily H member 2	Homo sapiens	12-16
12839862-3	2003	The objectives of this study were (i) to identify and characterise any inhibitory action on HERG of the selective-serotonin re-uptake inhibitor fluvoxamine, (ii) to then determine whether fluvoxamine shared the consensus molecular determinants of HERG blockade of those drugs so far tested.	Fluvoxamine	144-155	potassium voltage-gated channel subfamily H member 2	Homo sapiens	92-96
12839862-6	2003	I(HERG) tails, following repolarisation from +20 to -40 mV, were blocked by fluvoxamine with an IC(50) of 3.8 micro M. 3.	Fluvoxamine	76-87	potassium voltage-gated channel subfamily H member 2	Homo sapiens	2-6
12839862-7	2003	Blockade of wild-type HERG was of extremely rapid onset (within 10 ms) and showed voltage dependence, with fluvoxamine also inducing a leftward shift in voltage-dependent activation of I(HERG).	Fluvoxamine	107-118	potassium voltage-gated channel subfamily H member 2	Homo sapiens	22-26
12839862-7	2003	Blockade of wild-type HERG was of extremely rapid onset (within 10 ms) and showed voltage dependence, with fluvoxamine also inducing a leftward shift in voltage-dependent activation of I(HERG).	Fluvoxamine	107-118	potassium voltage-gated channel subfamily H member 2	Homo sapiens	187-191
12839862-11	2003	The S6 mutations, Y652A and F656A, and the pore helix mutant S631A only partially attenuated blockade by fluvoxamine at concentrations causing profound blockade of wild-type HERG.	Fluvoxamine	105-116	potassium voltage-gated channel subfamily H member 2	Homo sapiens	174-178
12828569-10	2003	Inclusion of the CYP1A2 inhibitor fluvoxamine in the incubation mixture with human liver microsomes resulted in potent inhibition of tangeretin and genistein metabolism.	Fluvoxamine	34-45	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	17-23
12695344-0	2003	Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.	Fluvoxamine	59-70	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	78-85
12695344-1	2003	A previous study suggested that fluvoxamine inhibition potency toward CYP1A2 is 10 times greater in vivo than in vitro.	Fluvoxamine	32-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	70-76
12695344-2	2003	The present study was designed to determine whether the same gap exists for CYP2C19, another isozyme inhibited by fluvoxamine.	Fluvoxamine	114-125	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	76-83
12695344-3	2003	In vitro studies examined the effect of nonspecific binding on the determination of inhibition constant (K(i)) values of fluvoxamine toward CYP2C19 in human liver microsomes and in a cDNA-expressed microsomal (Supersomes) system using (S)-mephenytoin as a CYP2C19 probe.	Fluvoxamine	121-132	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	140-147
12695344-3	2003	In vitro studies examined the effect of nonspecific binding on the determination of inhibition constant (K(i)) values of fluvoxamine toward CYP2C19 in human liver microsomes and in a cDNA-expressed microsomal (Supersomes) system using (S)-mephenytoin as a CYP2C19 probe.	Fluvoxamine	121-132	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	256-263
12618595-4	2003	The production of 5-HT from 5-MT catalyzed by CYP2D6 was inhibited by selective serotonin reuptake inhibitors, and their inhibition potency (K(i), micromol/l) decreased in the order of fluoxetine (0.411) > norfluoxetine (1.38) > fluvoxamine (10.1) > citalopram (10.9).	Fluvoxamine	235-246	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
12649369-6	2003	In L-MDR1 cells fluoxetine, norfluoxetine, fluvoxamine, reboxetine, and paroxetine-M revealed intermediate Pgp inhibition and citalopram, desmethylcitalopram, venlafaxine, and N-desmethylvenlafaxine were only weak inhibitors.	Fluvoxamine	43-54	ATP binding cassette subfamily B member 1	Homo sapiens	107-110
12695316-0	2003	High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.	Fluvoxamine	110-121	solute carrier family 6 member 4	Homo sapiens	15-36
12695316-14	2003	CONCLUSIONS: Clinical doses of clomipramine and fluvoxamine occupied approximately 80% of 5-HTT, and dose escalation would have minimal effect on 5-HTT blockade.	Fluvoxamine	48-59	solute carrier family 6 member 4	Homo sapiens	90-95
12640215-8	2003	These results are consistent with two previously published observations, which indicate that the initial affinity of the 5-HTT predicted response to fluvoxamine or fluoxetine in the same way.	Fluvoxamine	149-160	solute carrier family 6 member 4	Homo sapiens	121-126
12886034-2	2003	The authors first investigated whether a functional polymorphism in the monoamine oxidase A (MAOA-VNTR) and a -1438G/A polymorphism in the promoter region of the 5-HT(2A) gene were associated with the incidence of nausea induced by fluvoxamine.	Fluvoxamine	232-243	5-hydroxytryptamine receptor 2A	Homo sapiens	162-169
12610741-1	2003	OBJECTIVE: The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms.	Fluvoxamine	78-89	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	128-134
12496948-4	2003	Both 6- and 12-week fluvoxamine treatments were associated with a significant and robust reduction of the adrenocorticotrophic hormone (ACTH) and cortisol response to the DEX/CRH test.	Fluvoxamine	20-31	corticotropin releasing hormone	Homo sapiens	175-178
12480170-0	2003	Fluvoxamine suppresses the long-term potentiation in the hippocampal CA1 field of anesthetized rats: an effect mediated via 5-HT1A receptors.	Fluvoxamine	0-11	carbonic anhydrase 1	Rattus norvegicus	69-72
12480170-0	2003	Fluvoxamine suppresses the long-term potentiation in the hippocampal CA1 field of anesthetized rats: an effect mediated via 5-HT1A receptors.	Fluvoxamine	0-11	5-hydroxytryptamine receptor 1A	Rattus norvegicus	124-130
12856820-2	2003	It was decided to evaluate the influence of imipramine (IMI), amitriptyline (AMI), fluvoxamine (FLU), mianserin (MIA) and tianeptine (TIA) on PLA2 activity after an acute and long-term (4 weeks) drug administration.	Fluvoxamine	83-94	phospholipase A2 group IB	Rattus norvegicus	142-146
12607287-0	2003	[Serotonin 2A receptor gene polymorphism and clinical efficacy of fluvoxamine in children with autistic disorder].	Fluvoxamine	66-77	5-hydroxytryptamine receptor 2A	Homo sapiens	1-22
12856820-8	2003	It seems that FLU was the only antidepressant, which induced either inhibition or activation of PLA2 depending on time of administration.	Fluvoxamine	14-17	phospholipase A2 group IB	Rattus norvegicus	96-100
12856820-2	2003	It was decided to evaluate the influence of imipramine (IMI), amitriptyline (AMI), fluvoxamine (FLU), mianserin (MIA) and tianeptine (TIA) on PLA2 activity after an acute and long-term (4 weeks) drug administration.	Fluvoxamine	96-99	phospholipase A2 group IB	Rattus norvegicus	142-146
12452751-8	2002	Fluvoxamine has the potential to inhibit CYP1A2, CYP2C9, CYP2C19, and CYP3A4 to a significant degree.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	41-47
12452751-8	2002	Fluvoxamine has the potential to inhibit CYP1A2, CYP2C9, CYP2C19, and CYP3A4 to a significant degree.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	49-55
12452751-8	2002	Fluvoxamine has the potential to inhibit CYP1A2, CYP2C9, CYP2C19, and CYP3A4 to a significant degree.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	57-64
12452751-8	2002	Fluvoxamine has the potential to inhibit CYP1A2, CYP2C9, CYP2C19, and CYP3A4 to a significant degree.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
12502014-5	2002	The present study fails to demonstrate that the genetic polymorphisms of MAOA-VNTR and TPH-A218C affect the antidepressant effect of fluvoxamine in Japanese patients with major depressive disorder.	Fluvoxamine	133-144	monoamine oxidase A	Homo sapiens	73-77
12444499-10	2002	Thus, fluvoxamine-induced facilitatory effects appear to be mediated via 5-HT(1A) and 5-HT(4)/5-HT(7) receptors in an inhibitory and a stimulatory manner, respectively.	Fluvoxamine	6-17	5-hydroxytryptamine receptor 1A	Rattus norvegicus	73-80
12444499-11	2002	In the CA3 field, excitability produced by fluvoxamine was abolished by either NAN 190 or DR 4004, but not by GR 113808, suggesting that 5-HT(1A) and 5-HT(7) receptors contribute to this facilitation.	Fluvoxamine	43-54	carbonic anhydrase 3	Rattus norvegicus	7-10
12444499-11	2002	In the CA3 field, excitability produced by fluvoxamine was abolished by either NAN 190 or DR 4004, but not by GR 113808, suggesting that 5-HT(1A) and 5-HT(7) receptors contribute to this facilitation.	Fluvoxamine	43-54	5-hydroxytryptamine receptor 1A	Rattus norvegicus	137-144
12523495-8	2002	The obtained results suggest a strong inhibitory effect of perazine on human CYP1A2 activity with predicted Ki value similar to those of the known for CYP1A2 inhibitors, such as furafylline and fluvoxamine.	Fluvoxamine	194-205	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	77-83
12419542-5	2002	The selective serotonin reuptake inhibitor, fluvoxamine, prolonged 5-HT clearance in both CA3 and DRN.	Fluvoxamine	44-55	carbonic anhydrase 3	Rattus norvegicus	90-93
12352274-2	2002	In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia.	Fluvoxamine	96-107	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	79-85
12523495-8	2002	The obtained results suggest a strong inhibitory effect of perazine on human CYP1A2 activity with predicted Ki value similar to those of the known for CYP1A2 inhibitors, such as furafylline and fluvoxamine.	Fluvoxamine	194-205	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	151-157
11985826-5	2002	In conclusion, like fluvoxamine and clomipramine, selective, non-peptidergic NK(1) receptor antagonists block marble-burying in mice.	Fluvoxamine	20-31	tachykinin receptor 1	Mus musculus	77-91
11955666-3	2002	Microsomal flavonoid metabolism was potently inhibited by the CYP1A2 inhibitors, fluvoxamine and -naphthoflavone.	Fluvoxamine	81-92	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	62-68
11907488-0	2002	Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).	Fluvoxamine	35-46	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	88-106
11937097-10	2002	Local administration of 0.3 microM fluvoxamine resulted in comparable increases in extracellular 5-HT in both genotypes, whereas 1.0 microM fluvoxamine produced a twofold greater increase in 5-HT levels in 5-HT(1B) knockout as compared to wildtype mice.	Fluvoxamine	140-151	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	206-213
11937097-12	2002	In addition, the different dose-response to fluvoxamine suggests that 5-HT(1B) knockout mice have possible adaptations of 5-HT transporters in order to compensate for the loss of the terminal 5-HT(1B) autoreceptor.	Fluvoxamine	44-55	5-hydroxytryptamine (serotonin) receptor 1B	Mus musculus	70-77
11907488-11	2002	At steady state, the 25 mg x 1 or x 2 fluvoxamine dose caused a pronounced inhibition of about 75% to 80% for both CYP1A2 and CYP2C19, whereas the inhibition after the lower 10 mg x 1 or x 2 dose was about 40% to 50%.	Fluvoxamine	38-49	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	115-121
11907488-1	2002	OBJECTIVES: Fluvoxamine is metabolized by the polymorphic cytochrome P450 (CYP) 2D6 and the smoking-inducible CYP1A2.	Fluvoxamine	12-23	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-83
11907488-11	2002	At steady state, the 25 mg x 1 or x 2 fluvoxamine dose caused a pronounced inhibition of about 75% to 80% for both CYP1A2 and CYP2C19, whereas the inhibition after the lower 10 mg x 1 or x 2 dose was about 40% to 50%.	Fluvoxamine	38-49	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	126-133
11907488-1	2002	OBJECTIVES: Fluvoxamine is metabolized by the polymorphic cytochrome P450 (CYP) 2D6 and the smoking-inducible CYP1A2.	Fluvoxamine	12-23	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	110-116
11907488-18	2002	A nontherapeutic oral daily dose of fluvoxamine is sufficient to provide a marked inhibition of both caffeine (CYP1A2) and omeprazole (CYP2C19) metabolism.	Fluvoxamine	36-47	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	111-117
11907488-18	2002	A nontherapeutic oral daily dose of fluvoxamine is sufficient to provide a marked inhibition of both caffeine (CYP1A2) and omeprazole (CYP2C19) metabolism.	Fluvoxamine	36-47	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	135-142
11907488-2	2002	Therapeutic doses of fluvoxamine inhibit both CYP1A2 and CYP2C19.	Fluvoxamine	21-32	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	46-52
11907488-2	2002	Therapeutic doses of fluvoxamine inhibit both CYP1A2 and CYP2C19.	Fluvoxamine	21-32	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	57-64
11803239-6	2002	These findings are compatible with those in earlier reports that cytochrome P450 1A2 plays a major role in fluvoxamine metabolism.	Fluvoxamine	107-118	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	65-84
12057029-1	2002	The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n = 248) and bipolar (n = 195) depressives, with or without psychotic features.	Fluvoxamine	177-188	monoamine oxidase A	Homo sapiens	66-85
12057029-1	2002	The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n = 248) and bipolar (n = 195) depressives, with or without psychotic features.	Fluvoxamine	177-188	monoamine oxidase A	Homo sapiens	87-91
12057029-1	2002	The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n = 248) and bipolar (n = 195) depressives, with or without psychotic features.	Fluvoxamine	177-188	5-hydroxytryptamine receptor 2A	Homo sapiens	120-127
11817517-0	2002	Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.	Fluvoxamine	104-115	solute carrier family 6 member 4	Homo sapiens	17-38
12222750-0	2002	Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.	Fluvoxamine	20-31	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	47-54
12222750-1	2002	OBJECTIVE: To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19.	Fluvoxamine	47-58	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	131-156
12222750-1	2002	OBJECTIVE: To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19.	Fluvoxamine	60-63	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	131-156
11876575-6	2002	Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	24-30
11876575-6	2002	Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	35-42
11876575-6	2002	Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	69-75
11876575-6	2002	Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	77-83
11876575-6	2002	Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
12038880-11	2002	Within the group of SSRIs, fluoxetine and paroxetine are potent inhibitors of CYP2D6, while fluvoxamine predominantly affects CYP1A2 and CYP2C19 activity.	Fluvoxamine	92-103	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	126-132
12038880-11	2002	Within the group of SSRIs, fluoxetine and paroxetine are potent inhibitors of CYP2D6, while fluvoxamine predominantly affects CYP1A2 and CYP2C19 activity.	Fluvoxamine	92-103	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	137-144
12422060-0	2002	Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.	Fluvoxamine	85-96	5-hydroxytryptamine receptor 2A	Homo sapiens	58-75
11728615-3	2001	Plasma 5-hydroxyindoleacetic acid (p5-HIAA) levels after fluvoxamine administration were significantly higher in patients with nausea (6.6+/-3.4 ng/ml) than in those without nausea (3.5+/-2.7 ng/ml).	Fluvoxamine	57-68	solute carrier family 10 member 5	Homo sapiens	35-42
11673783-0	2001	The effects of the selective serotonin reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated by corticotropin-releasing hormone.	Fluvoxamine	58-69	corticotropin releasing hormone	Rattus norvegicus	116-147
11719727-1	2001	OBJECTIVE: Several reports indicate that fluvoxamine decreases the clearance of cytochrome P4501A2 (CYP1A2) substrates.	Fluvoxamine	41-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	80-98
11719727-1	2001	OBJECTIVE: Several reports indicate that fluvoxamine decreases the clearance of cytochrome P4501A2 (CYP1A2) substrates.	Fluvoxamine	41-52	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	100-106
11719727-2	2001	This study compared in vitro and in vivo inhibition potencies of fluvoxamine toward CYP1A2 with an approach based on inhibition constants (K(i)) determined in vitro and in vivo.	Fluvoxamine	65-76	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	84-90
11719727-4	2001	Fluvoxamine in vivo inhibition constants (K(i)iv) for CYP1A2 were obtained from an investigation of single-dose theophylline (250 mg) disposition in 9 healthy volunteers receiving steady-state (9 days) fluvoxamine at 3 doses (0, 25, or 75 mg/d) in a randomized crossover design.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	54-60
11704898-7	2001	Inhibition of CYP1A2 by fluvoxamine yields increased concentrations; however, clinically relevant CYP2D6 inhibition was observed only in combination with additional disposition factors, such as female gender or old age.	Fluvoxamine	24-35	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	14-20
11791895-0	2001	The major fluvoxamine metabolite in urine is formed by CYP2D6.	Fluvoxamine	10-21	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
11791895-1	2001	OBJECTIVE: Previous studies have shown that fluvoxamine is metabolized by CYP1A2 and CYP2D6, but there is no information on the impact the various CYP enzymes have on the different metabolic pathways of fluvoxamine biotransformation.	Fluvoxamine	44-55	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	74-80
11791895-1	2001	OBJECTIVE: Previous studies have shown that fluvoxamine is metabolized by CYP1A2 and CYP2D6, but there is no information on the impact the various CYP enzymes have on the different metabolic pathways of fluvoxamine biotransformation.	Fluvoxamine	44-55	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	85-91
11791895-3	2001	METHODS: The major fluvoxamine metabolite, the 5-demethoxylated carboxylic acid metabolite, was analyzed in urine from 50 healthy volunteers after intake of a single oral dose of 50 mg fluvoxamine, and the formation clearance for the metabolite (CLm) was calculated.	Fluvoxamine	19-30	laminin subunit beta 1	Homo sapiens	246-249
11791895-7	2001	RESULTS: Oral clearance of fluvoxamine was significantly higher in smokers, and significantly lower in CYP2D6 PMs than in non-smoking EMs.	Fluvoxamine	27-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	103-109
11791895-11	2001	CLm decreased with increasing fluvoxamine dosage, but the decrease in oral clearance was even higher.	Fluvoxamine	30-41	laminin subunit beta 1	Homo sapiens	0-3
11791895-12	2001	CONCLUSION: These results indicate that CYP2D6 catalyzes the major metabolic pathway of fluvoxamine, whereas CYP1A2 seems to catalyze other less important pathways.	Fluvoxamine	88-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-46
11791895-12	2001	CONCLUSION: These results indicate that CYP2D6 catalyzes the major metabolic pathway of fluvoxamine, whereas CYP1A2 seems to catalyze other less important pathways.	Fluvoxamine	88-99	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	109-115
11791895-13	2001	Both the CYP2D6 and the CYP1A2 pathways seem to be saturated in parallel with increasing fluvoxamine dosage.	Fluvoxamine	89-100	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	9-15
11791895-13	2001	Both the CYP2D6 and the CYP1A2 pathways seem to be saturated in parallel with increasing fluvoxamine dosage.	Fluvoxamine	89-100	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	24-30
11434513-5	2001	The first six phenotyping measures were used to estimate baseline CYP3A activity, then subjects received the moderate CYP3A inhibitor fluvoxamine 150 mg/day for the last 4 weeks (two phenotyping visits) of the study.	Fluvoxamine	134-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-123
11599655-0	2001	Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.	Fluvoxamine	164-175	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	66-72
11599655-1	2001	OBJECTIVE: To characterize the distribution of mathematically derived human hepatic CYP1A1 activity using differential inhibition of ethoxyresorufin O-deethylation (EROD) by fluvoxamine.	Fluvoxamine	174-185	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	84-90
11599655-2	2001	METHODS: Quantitative CYP1A1- and CYP1A2-mediated EROD activities were determined in 42 human livers using differential inhibition of EROD by fluvoxamine.	Fluvoxamine	142-153	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	22-28
11599655-2	2001	METHODS: Quantitative CYP1A1- and CYP1A2-mediated EROD activities were determined in 42 human livers using differential inhibition of EROD by fluvoxamine.	Fluvoxamine	142-153	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	34-40
11477325-5	2001	This indicated that fluvoxamine inhibits the metabolism of olanzapine, probably because of inhibition of cytochrome P450 (CYP) 1A2, whereas sertraline is unlikely to interfere with the metabolism of olanzapine.	Fluvoxamine	20-31	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	105-130
11526473-0	2001	Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.	Fluvoxamine	71-82	solute carrier family 6 member 4	Homo sapiens	40-61
11519155-5	2001	Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	49-55
11519155-5	2001	Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	60-67
11519155-5	2001	Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
11519155-5	2001	Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-109
11270913-3	2001	Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes.	Fluvoxamine	8-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	47-62
11304754-0	2001	Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys.	Fluvoxamine	75-86	solute carrier family 6 member 4	Homo sapiens	20-41
11304754-5	2001	When the SERT blocker fluvoxamine (1 mg/kg) was administered intravenously 30 min after tracer injection, specific binding of SERT was displaced in both age groups.	Fluvoxamine	22-33	solute carrier family 6 member 4	Homo sapiens	9-13
11304754-5	2001	When the SERT blocker fluvoxamine (1 mg/kg) was administered intravenously 30 min after tracer injection, specific binding of SERT was displaced in both age groups.	Fluvoxamine	22-33	solute carrier family 6 member 4	Homo sapiens	126-130
11304754-9	2001	In addition, these observations suggest that the age-related impairment of SERT sensitivity for fluvoxamine might be related to the reduced efficacy of antidepressant therapy in elderly patients with depression.	Fluvoxamine	96-107	solute carrier family 6 member 4	Homo sapiens	75-79
11270913-3	2001	Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) enzymes, the authors studied the biotransformation of melatonin and the effects of fluvoxamine on the metabolism of melatonin in vitro using human liver microsomes and recombinant human CYP isoenzymes.	Fluvoxamine	8-19	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-67
11317475-7	2001	CONCLUSIONS: Our results strongly suggest that 6-hydroxylation, the main metabolic pathway of melatonin, is mediated mainly, but not exclusively, by CYP1A2, the high-affinity enzyme involved in melatonin metabolism, confirming the observation that a single oral dose of fluvoxamine increases nocturnal serum melatonin levels in healthy subjects.	Fluvoxamine	270-281	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	149-155
11240973-1	2001	BACKGROUND AND OBJECTIVES: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to inhibit several hepatic cytochrome P450 (CYP) isozymes, in particular CYP1A2.	Fluvoxamine	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	118-133
11240973-1	2001	BACKGROUND AND OBJECTIVES: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to inhibit several hepatic cytochrome P450 (CYP) isozymes, in particular CYP1A2.	Fluvoxamine	27-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	135-138
11240973-1	2001	BACKGROUND AND OBJECTIVES: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to inhibit several hepatic cytochrome P450 (CYP) isozymes, in particular CYP1A2.	Fluvoxamine	27-38	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	164-170
11166521-5	2001	The hyperactivity elicited by fluvoxamine (20 mg/kg) plus mazindol (1 mg/kg) was significantly attenuated by the 5-HT(2A) receptor antagonist M100907 (2 mg/kg) and potentiated by the 5-HT(2B/2C) receptor antagonist SB 206553 (2 mg/kg).	Fluvoxamine	30-41	5-hydroxytryptamine receptor 2A	Rattus norvegicus	113-120
11166521-7	2001	The hyperactivity evoked by the combination of fluvoxamine and mazindol seems to be mediated in part by 5-HT(2A) receptors; whereas, 5-HT(2B/2C) receptors may serve to limit this effect.	Fluvoxamine	47-58	5-hydroxytryptamine receptor 2A	Rattus norvegicus	104-111
11206048-5	2001	The interaction may be a result of inhibition of both CYP2C9 and 2C19 by fluvoxamine.	Fluvoxamine	73-84	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	54-60
11038165-8	2000	Fluvoxamine and anti-CYP2C antibody inhibited 3",4"-diHPPH formation from 10 microM 4"-HPPH in a human liver sample that contained relatively high levels of CYP2C, whereas ketoconazole and anti-CYP3A antibody showed inhibitory effects on the activities in liver microsomal samples in which CYP3A4 levels were relatively high.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	290-296
11791889-12	2001	These results indicate that CYP 3A4 inhibition may not be clinically significant compared to CYP 1A2, as previous studies show a dramatic increase in CLZ plasma concentrations with fluvoxamine (CYP 1A2 inhibitor).	Fluvoxamine	181-192	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	194-201
11038165-8	2000	Fluvoxamine and anti-CYP2C antibody inhibited 3",4"-diHPPH formation from 10 microM 4"-HPPH in a human liver sample that contained relatively high levels of CYP2C, whereas ketoconazole and anti-CYP3A antibody showed inhibitory effects on the activities in liver microsomal samples in which CYP3A4 levels were relatively high.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	157-162
11180037-0	2001	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	25-31
11180037-1	2001	OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9.	Fluvoxamine	108-119	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	129-135
11180037-13	2001	CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.	Fluvoxamine	12-23	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	51-57
24921690-9	2001	Potent inhibitors of CYP 1A2 such as fluvoxamine can precipitate caffeine toxicity.	Fluvoxamine	37-48	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	21-28
11074049-6	2000	Golgi analysis showed that a single injection of fluvoxamine produced a significant increase in dendritic spine density in stratum radiatum of CA1 and in the dentate gyrus.	Fluvoxamine	49-60	carbonic anhydrase 1	Rattus norvegicus	143-146
11038165-8	2000	Fluvoxamine and anti-CYP2C antibody inhibited 3",4"-diHPPH formation from 10 microM 4"-HPPH in a human liver sample that contained relatively high levels of CYP2C, whereas ketoconazole and anti-CYP3A antibody showed inhibitory effects on the activities in liver microsomal samples in which CYP3A4 levels were relatively high.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	194-199
11098879-5	2000	One controlled study of the selective SRI fluvoxamine found it to be significantly better than placebo for reducing repetitive phenomena and aggression in adults with autistic disorder.	Fluvoxamine	42-53	sorcin	Homo sapiens	38-41
11085201-3	2000	Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2.	Fluvoxamine	25-36	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	60-85
11085201-3	2000	Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2.	Fluvoxamine	25-36	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	111-118
11085201-3	2000	Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2.	Fluvoxamine	25-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
11085201-3	2000	Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2.	Fluvoxamine	25-36	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	156-162
11062862-9	2000	This indicates that (+/-)-pindolol has the ability to block the somatodendritic 5-HT1A autoreceptors, thereby weakening the fluvoxamine-induced indirect action of the autoreceptors in the raphe.	Fluvoxamine	124-135	5-hydroxytryptamine receptor 1A	Rattus norvegicus	80-86
10917404-16	2000	An interaction with fluvoxamine may be of importance in poor metabolizers for CYP2D6.	Fluvoxamine	20-31	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	78-84
10982203-2	2000	Previous reports have shown that fluvoxamine can increase plasma clozapine concentrations by inhibition of cytochrome P450 (CYP) 1A2.	Fluvoxamine	33-44	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	107-132
10954064-1	2000	The cytochrome enzyme P450 2D6 (CYP2D6) is thought to play a role in the human metabolism of fluvoxamine.	Fluvoxamine	93-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-30
10954064-1	2000	The cytochrome enzyme P450 2D6 (CYP2D6) is thought to play a role in the human metabolism of fluvoxamine.	Fluvoxamine	93-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
10877005-0	2000	Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-113
10877005-0	2000	Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	114-120
10877005-0	2000	Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	125-132
10877005-6	2000	FLU inhibits CYP1A2 potently, and to some extent also CYP2C19, whereas CIT is without such an effect.	Fluvoxamine	0-3	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	13-19
10877005-6	2000	FLU inhibits CYP1A2 potently, and to some extent also CYP2C19, whereas CIT is without such an effect.	Fluvoxamine	0-3	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	54-61
10805611-4	2000	RESULTS: On the basis of comparable plasma levels of clozapine and N-desmethylclozapine, the coadministration of fluvoxamine 1) attenuated and delayed the clozapine-induced increase in TNF-alpha plasma levels, 2) enhanced and accelerated the clozapine-induced increase in leptin plasma levels without significant effect on clozapine-induced weight gain, and 3) decreased granulocyte counts.	Fluvoxamine	113-124	tumor necrosis factor	Homo sapiens	185-194
10706994-1	2000	In the course of investigating the mechanisms underlying the beneficial effect of fluvoxamine augmentation on negative symptoms of schizophrenia, the authors found a reduction in human platelet monoamine oxidase-B activity after 5 weeks of treatment.	Fluvoxamine	82-93	monoamine oxidase B	Homo sapiens	194-213
10774624-6	2000	Fluvoxamine is metabolized to inactive metabolites by CYP1A2 and CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	54-60
10774624-6	2000	Fluvoxamine is metabolized to inactive metabolites by CYP1A2 and CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	65-71
10706994-3	2000	The current study examined the effect of long-term administration, up to 6 weeks, of fluvoxamine, desipramine or saline on MAO-A and MAO-B activities in rat striatum, frontal cortex and liver.	Fluvoxamine	85-96	monoamine oxidase A	Rattus norvegicus	123-128
10706994-3	2000	The current study examined the effect of long-term administration, up to 6 weeks, of fluvoxamine, desipramine or saline on MAO-A and MAO-B activities in rat striatum, frontal cortex and liver.	Fluvoxamine	85-96	monoamine oxidase B	Rattus norvegicus	133-138
10653206-0	2000	Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-83
11249525-5	2000	Differences in the metabolic balance between hepatic P450 (especially CYP 1A2) and MAO-A inactivation lead to potential drug interactions for all TELs with the oral contraceptive pill (OCP), fluvoxamine and the quinilone antibiotics (with increased triptan levels).	Fluvoxamine	191-202	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	70-77
11249525-5	2000	Differences in the metabolic balance between hepatic P450 (especially CYP 1A2) and MAO-A inactivation lead to potential drug interactions for all TELs with the oral contraceptive pill (OCP), fluvoxamine and the quinilone antibiotics (with increased triptan levels).	Fluvoxamine	191-202	monoamine oxidase A	Homo sapiens	83-88
10653206-5	2000	Fluvoxamine also inhibited in a concentration-dependent manner the activity of all five cytochrome P450 (CYP) isoforms previously determined to be capable of catalyzing the demethylation of clozapine.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	88-103
10653206-5	2000	Fluvoxamine also inhibited in a concentration-dependent manner the activity of all five cytochrome P450 (CYP) isoforms previously determined to be capable of catalyzing the demethylation of clozapine.	Fluvoxamine	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	105-108
10653206-6	2000	Fluvoxamine inhibited CYP1A2 and 2C19 with the highest affinities (Ki values of 0.041 and 0.087 microM, respectively).	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	22-28
11015030-8	2000	Chronic treatment with fluvoxamine, desipramine and lithium carbonate is apparently associated with a modulation in PBR expression in the testes, adrenals, kidneys, liver and brain, and in CBR expression in brain.	Fluvoxamine	23-34	translocator protein	Rattus norvegicus	116-119
10627170-0	1999	CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.	Fluvoxamine	60-71	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
11015030-3	2000	We investigated the effect of 21 days administration, followed by 7 days withdrawal, of fluvoxamine (10 mg/kg), desipramine (10 mg/kg) and lithium carbonate (25 mg/kg) on PBR and CBR binding characteristics in male Sprague-Dawley rats.	Fluvoxamine	88-99	translocator protein	Rattus norvegicus	171-174
10674711-9	2000	Paroxetine and, to a lesser degree, fluoxetine and norfluoxetine are potent inhibitors of CYP2D6 and fluvoxamine of CYP1A2 and CYP2C19.	Fluvoxamine	101-112	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	116-122
10674711-9	2000	Paroxetine and, to a lesser degree, fluoxetine and norfluoxetine are potent inhibitors of CYP2D6 and fluvoxamine of CYP1A2 and CYP2C19.	Fluvoxamine	101-112	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	127-134
10456487-3	1999	The aim of this study was to establish whether the potent CYP1A2 inhibitor fluvoxamine in clinically relevant doses could inhibit tacrine metabolism.	Fluvoxamine	75-86	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	58-64
10550852-5	1999	Of the SSRIs, fluvoxamine is one of the most potent inhibitors of the isoenzyme CYP 1A2.	Fluvoxamine	14-25	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	80-87
10587283-6	1999	In conclusion, fluvoxamine markedly interferes with the metabolism of THD, probably at the CYP2C19 and/or CYP1A2 enzyme level.	Fluvoxamine	15-26	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	91-98
10587283-6	1999	In conclusion, fluvoxamine markedly interferes with the metabolism of THD, probably at the CYP2C19 and/or CYP1A2 enzyme level.	Fluvoxamine	15-26	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	106-112
10023505-7	1999	In fact, prolactin response to d-fenfluramine was significantly diminished after treatment with fluvoxamine but not fluoxetine.	Fluvoxamine	96-107	prolactin	Homo sapiens	9-18
10371024-0	1999	Serum beta-endorphin level in patients with depression on fluvoxamine.	Fluvoxamine	58-69	proopiomelanocortin	Homo sapiens	6-20
10371024-1	1999	The main interest of the present study was to determine possible alternations in beta-endorphin serum levels in healthy volunteers and in patients with depression, as well as changes in beta-endorphin serum levels caused by fluvoxamine treatment.	Fluvoxamine	224-235	proopiomelanocortin	Homo sapiens	186-200
10371024-5	1999	A 4-week treatment of fluvoxamine (200 mg/day) caused a statistically significant increase in beta-endorphin serum levels in all patients (nonendogenous depression 132.10 +/- 2.38 pg/ml and endogenous depression 50.09 +/- 2.45 pg/ml) in comparison to values found before the onset of the therapy.	Fluvoxamine	22-33	proopiomelanocortin	Homo sapiens	94-108
10340631-11	1999	Inhibition of fluvoxamine induced potentiation of 5-HT signal in the presence of MK-801 suggests that MK-801 and fluvoxamine may interact at the level of the 5-HT transporter.	Fluvoxamine	14-25	solute carrier family 6 member 4	Homo sapiens	158-174
10340631-11	1999	Inhibition of fluvoxamine induced potentiation of 5-HT signal in the presence of MK-801 suggests that MK-801 and fluvoxamine may interact at the level of the 5-HT transporter.	Fluvoxamine	113-124	solute carrier family 6 member 4	Homo sapiens	158-174
10471171-8	1999	Fluvoxamine is a potent inhibitor of CYP1A2, a moderate inhibitor of CYP3A and a mild inhibitor of CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-43
10471171-8	1999	Fluvoxamine is a potent inhibitor of CYP1A2, a moderate inhibitor of CYP3A and a mild inhibitor of CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-74
10471171-8	1999	Fluvoxamine is a potent inhibitor of CYP1A2, a moderate inhibitor of CYP3A and a mild inhibitor of CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	99-105
10192828-15	1999	Fluvoxamine (FX), at a concentration of 20 microM, decreased NDV production by 46% consistent with the capacity of FX to inhibit CYP3A, 2C9, and 2C19.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-139
10192828-15	1999	Fluvoxamine (FX), at a concentration of 20 microM, decreased NDV production by 46% consistent with the capacity of FX to inhibit CYP3A, 2C9, and 2C19.	Fluvoxamine	13-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-139
10211917-0	1999	CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.	Fluvoxamine	72-83	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
10051063-7	1999	Serotonin-specific reuptake inhibitor (SSRI) comedication (fluoxetine, two patients; citalopram, two patients; paroxetine, one patient; fluvoxamine, one patient) was significantly associated with 4.6-fold higher concentrations of parent compound, in keeping with an inhibitory action on CYP2D6 enzyme.	Fluvoxamine	136-147	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	287-293
10192755-1	1999	OBJECTIVE: Evidence exists to suggest that fluvoxamine is metabolized by CYP1A2.	Fluvoxamine	43-54	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	73-79
10192755-2	1999	The present study was undertaken in order to further elucidate the role of CYPIA2 in fluvoxamine disposition.	Fluvoxamine	85-96	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	75-81
10192756-10	1999	This is consistent with in vivo data indicating that amongst the SSRIs, fluvoxamine has the greatest potential for inhibiting CYP2C9-mediated drug metabolism.	Fluvoxamine	72-83	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	126-132
9871099-3	1998	While binding of [123I]nor-beta-CIT in the hypothalamus was blocked significantly by fluvoxamine (a selective serotonin transporter blocker) but not by GBR12,909 (a selective dopamine transporter blocker), the opposite was observed in the striatum.	Fluvoxamine	85-96	citron rho-interacting serine/threonine kinase	Rattus norvegicus	32-35
9871099-3	1998	While binding of [123I]nor-beta-CIT in the hypothalamus was blocked significantly by fluvoxamine (a selective serotonin transporter blocker) but not by GBR12,909 (a selective dopamine transporter blocker), the opposite was observed in the striatum.	Fluvoxamine	85-96	solute carrier family 6 member 4	Rattus norvegicus	110-131
9888626-4	1998	Pre-exposure with the 5-HT2C receptor agonist MK 212 [6-chloro-2(1-piperazinyl)pyrazine] partially prevented the fluvoxamine-induced CTA, pre-exposure with the 5-HT2A/2C receptor agonist DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl] did not prevent the CTA induced by fluvoxamine.	Fluvoxamine	113-124	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	22-37
9868741-7	1998	The formation of 1,7-dimethylxanthine was virtually abolished by 10 microM of fluvoxamine, indicating that the N3-demethylation of caffeine is almost exclusively catalysed by CYP1A2.	Fluvoxamine	78-89	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	175-181
9868741-1	1998	The selective serotonin re-uptake inhibitor, fluvoxamine, is a very potent inhibitor of CYP1A2, and accordingly causes pharmacokinetic interactions with drugs metabolised by CYP1A2, such as caffeine, theophylline, imipramine, tacrine and clozapine.	Fluvoxamine	45-56	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	88-94
9868741-1	1998	The selective serotonin re-uptake inhibitor, fluvoxamine, is a very potent inhibitor of CYP1A2, and accordingly causes pharmacokinetic interactions with drugs metabolised by CYP1A2, such as caffeine, theophylline, imipramine, tacrine and clozapine.	Fluvoxamine	45-56	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	174-180
9888626-4	1998	Pre-exposure with the 5-HT2C receptor agonist MK 212 [6-chloro-2(1-piperazinyl)pyrazine] partially prevented the fluvoxamine-induced CTA, pre-exposure with the 5-HT2A/2C receptor agonist DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl] did not prevent the CTA induced by fluvoxamine.	Fluvoxamine	278-289	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	22-37
9888626-9	1998	We conclude that 5-HT1A receptors are involved in the stimulus properties of both fluvoxamine and fluoxetine, that 5-HT2C receptors are involved in fluvoxamine and especially fluoxetine, and, based primarily on the cross-comparison tests, that the two SSRIs have somewhat different stimulus properties.	Fluvoxamine	82-93	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	17-23
9888626-9	1998	We conclude that 5-HT1A receptors are involved in the stimulus properties of both fluvoxamine and fluoxetine, that 5-HT2C receptors are involved in fluvoxamine and especially fluoxetine, and, based primarily on the cross-comparison tests, that the two SSRIs have somewhat different stimulus properties.	Fluvoxamine	148-159	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	115-121
9923581-9	1998	The mechanism of this interaction is probably inhibition of the CYP3A4-mediated first-pass metabolism of buspirone by fluvoxamine.	Fluvoxamine	118-129	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
9757149-0	1998	Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.	Fluvoxamine	10-21	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	51-57
9923577-0	1998	Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	25-32
9923577-1	1998	OBJECTIVE: The potent CYP1A2 inhibitor fluvoxamine has recently been shown also to be an effective inhibitor of the CYP2C19-mediated metabolism of the antimalarial drug proguanil in vivo.	Fluvoxamine	39-50	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	22-28
9923577-1	1998	OBJECTIVE: The potent CYP1A2 inhibitor fluvoxamine has recently been shown also to be an effective inhibitor of the CYP2C19-mediated metabolism of the antimalarial drug proguanil in vivo.	Fluvoxamine	39-50	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	116-123
9923577-11	1998	CONCLUSIONS: Fluvoxamine is a fairly potent inhibitor of CYP2C19 and it has the potential for causing drug-drug interactions with substrates for CYP2C19 such as imipramine, clomipramine, amitriptyline and diazepam.	Fluvoxamine	13-24	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	57-64
9923577-11	1998	CONCLUSIONS: Fluvoxamine is a fairly potent inhibitor of CYP2C19 and it has the potential for causing drug-drug interactions with substrates for CYP2C19 such as imipramine, clomipramine, amitriptyline and diazepam.	Fluvoxamine	13-24	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	145-152
9857976-0	1998	Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.	Fluvoxamine	98-109	solute carrier family 6 member 4	Homo sapiens	40-61
9857976-4	1998	We tested the hypothesis that allelic variation of the 5-HTT promoter could be related to the antidepressant response to fluvoxamine and/or augmentation with pindolol (a serotonin autoreceptors antagonist) which has been suggested as an augmentation therapy for nonresponders.	Fluvoxamine	121-132	solute carrier family 6 member 4	Homo sapiens	55-60
9857976-9	1998	Both homozygotes for the long variant (l/l) of the 5-HTT promoter and heterozygotes (l/s) showed a better response to fluvoxamine than homozygotes for the short variant (s/s).	Fluvoxamine	118-129	solute carrier family 6 member 4	Homo sapiens	51-56
9857976-11	1998	Fluvoxamine efficacy in delusional depression seems to be related to allelic variation within the promoter of the 5-HTT gene.	Fluvoxamine	0-11	solute carrier family 6 member 4	Homo sapiens	114-119
9757149-0	1998	Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.	Fluvoxamine	10-21	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	59-65
9757149-0	1998	Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.	Fluvoxamine	10-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-76
9757149-1	1998	OBJECTIVE: To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam.	Fluvoxamine	49-60	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	82-88
9757149-1	1998	OBJECTIVE: To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam.	Fluvoxamine	49-60	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	90-96
9757149-1	1998	OBJECTIVE: To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam.	Fluvoxamine	49-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-103
9757149-1	1998	OBJECTIVE: To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam.	Fluvoxamine	49-60	N-acetyltransferase 2	Homo sapiens	105-126
9757149-1	1998	OBJECTIVE: To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam.	Fluvoxamine	49-60	N-acetyltransferase 2	Homo sapiens	128-132
9757149-8	1998	For CYP1A2, CYP2D6, and CYP3A phenotypes, significant differences existed between baseline and fluvoxamine therapy.	Fluvoxamine	95-106	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	4-10
9757149-8	1998	For CYP1A2, CYP2D6, and CYP3A phenotypes, significant differences existed between baseline and fluvoxamine therapy.	Fluvoxamine	95-106	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	12-18
9757149-8	1998	For CYP1A2, CYP2D6, and CYP3A phenotypes, significant differences existed between baseline and fluvoxamine therapy.	Fluvoxamine	95-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
9757149-9	1998	For CYP1A2, the mean urinary metabolite ratio (+/-SD) was 7.53 +/- 7.44 at baseline and 4.30 +/- 2.82 with fluvoxamine ( P = .012).	Fluvoxamine	107-118	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	4-10
9757149-12	1998	For CYP1A2, CYP2D6, and CYP3A, fluvoxamine therapy changed the phenotyping measures by a median of -44.4%, 123.5%, and -34.4%, respectively.	Fluvoxamine	31-42	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	4-10
9757149-12	1998	For CYP1A2, CYP2D6, and CYP3A, fluvoxamine therapy changed the phenotyping measures by a median of -44.4%, 123.5%, and -34.4%, respectively.	Fluvoxamine	31-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-29
9757149-13	1998	CONCLUSIONS: We concluded that fluvoxamine may cause significant inhibition of CYP1A2, CYP2D6, and CYP3A activity.	Fluvoxamine	31-42	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	79-85
9757149-13	1998	CONCLUSIONS: We concluded that fluvoxamine may cause significant inhibition of CYP1A2, CYP2D6, and CYP3A activity.	Fluvoxamine	31-42	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
9757149-13	1998	CONCLUSIONS: We concluded that fluvoxamine may cause significant inhibition of CYP1A2, CYP2D6, and CYP3A activity.	Fluvoxamine	31-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-104
9469504-8	1998	Interestingly, both nefazodone and fluvoxamine are known to potently inhibit the CYP3A3/4 isoenzymes.	Fluvoxamine	35-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
9817620-4	1998	Accordingly fluvoxamine has interactions with other drugs eliminated by CYP1A2 including caffeine, clozapine, olanzapine, theophylline, propranolol and tacrine.	Fluvoxamine	12-23	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	72-78
9817620-10	1998	CYP2D6 only makes up about 2-5% of the total P450 in the human liver, but anyway is the major enzyme catalyzing more than 30 clinically used drugs including all of the tricyclic antidepressants, several neuroleptics, opiates, betablockers, antiarrhythmics and among the SSRIs N-desmethylcitalopram, fluvoxamine, fluoxetine and paroxetine but not sertraline.	Fluvoxamine	299-310	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
9617978-0	1998	Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.	Fluvoxamine	105-116	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	58-64
9617978-0	1998	Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.	Fluvoxamine	105-116	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	69-75
9617978-3	1998	The antidepressants paroxetine and fluvoxamine are potent in vitro inhibitors of CYP2D6 and CYP1A2 isozymes, respectively.	Fluvoxamine	35-46	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
9617978-3	1998	The antidepressants paroxetine and fluvoxamine are potent in vitro inhibitors of CYP2D6 and CYP1A2 isozymes, respectively.	Fluvoxamine	35-46	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	92-98
9617978-6	1998	The aim of this study was to assess the determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition during paroxetine and fluvoxamine treatment.	Fluvoxamine	149-160	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	98-104
9617978-6	1998	The aim of this study was to assess the determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition during paroxetine and fluvoxamine treatment.	Fluvoxamine	149-160	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	109-115
9617978-16	1998	The extent of inhibition of CYP2D6 and CYP1A2 by paroxetine and fluvoxamine, respectively, displayed a positive correlation with baseline enzyme activity (p < 0.05).	Fluvoxamine	64-75	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
9617978-16	1998	The extent of inhibition of CYP2D6 and CYP1A2 by paroxetine and fluvoxamine, respectively, displayed a positive correlation with baseline enzyme activity (p < 0.05).	Fluvoxamine	64-75	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	39-45
9617978-18	1998	These data indicate that paroxetine and fluvoxamine treatment with minimum clinically effective doses significantly inhibit CYP2D6 and CYP1A2, respectively.	Fluvoxamine	40-51	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	124-130
9617978-18	1998	These data indicate that paroxetine and fluvoxamine treatment with minimum clinically effective doses significantly inhibit CYP2D6 and CYP1A2, respectively.	Fluvoxamine	40-51	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	135-141
9617978-19	1998	The extent of inhibition of CYP2D6 by paroxetine and of CYP1A2 by fluvoxamine is dependent in part on the baseline enzyme activity.	Fluvoxamine	66-77	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	28-34
9617978-19	1998	The extent of inhibition of CYP2D6 by paroxetine and of CYP1A2 by fluvoxamine is dependent in part on the baseline enzyme activity.	Fluvoxamine	66-77	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	56-62
9617978-21	1998	Most patients treated with fluvoxamine (50-100 mg/day) will reach population minimums for CYP1A2 activity.	Fluvoxamine	27-38	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	90-96
9669506-2	1998	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.	Fluvoxamine	65-76	solute carrier family 6 member 4	Rattus norvegicus	111-127
9669506-2	1998	The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.	Fluvoxamine	65-76	solute carrier family 6 member 2	Rattus norvegicus	215-241
9817620-3	1998	Thus fluvoxamine, but not citalopram, fluoxetine, paroxetine and sertraline is a potent inhbitor of CYP1A2.	Fluvoxamine	5-16	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	100-106
9832352-10	1998	The results of this pilot study should be regarded as a hint at the possible therapeutic benefits of lower fluvoxamine serum concentrations by means of lower fluvoxamine dosages.	Fluvoxamine	107-118	histidine triad nucleotide binding protein 1	Homo sapiens	56-60
9832352-10	1998	The results of this pilot study should be regarded as a hint at the possible therapeutic benefits of lower fluvoxamine serum concentrations by means of lower fluvoxamine dosages.	Fluvoxamine	158-169	histidine triad nucleotide binding protein 1	Homo sapiens	56-60
9716316-0	1998	Patterns of c-fos expression induced by fluvoxamine are different after acute vs. chronic oral administration.	Fluvoxamine	40-51	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	12-17
9716316-2	1998	We used the expression of c-fos, after both acute and chronic oral administration of fluvoxamine in the rat, to study its immediate and long-term effects, in relation to the distribution of Galanin (GAL) and Vasoactive Intestinal Polypeptide (VIP).	Fluvoxamine	85-96	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	26-31
9716316-5	1998	It is concluded that activation of 5-HT3-receptors in the caudal brainstem or gastro-intestinal afferents of the vagal nerve may play a role in the observed pattern of Fos-IR after fluvoxamine administration.	Fluvoxamine	181-192	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	168-171
10022747-0	1998	Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man.	Fluvoxamine	77-88	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	38-57
10022747-6	1998	The Ki of fluvoxamine on 1-hydroxytacrine formation rate observed with rH-CYP1A2 was similar to that observed with human liver microsome (0.35+/-0.05 versus 0.20+/-0.20 microM, respectively).	Fluvoxamine	10-21	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	74-80
10022747-7	1998	Using the Km, Vmax and Ki determined with rH-CYP1A2, we calculated that fluvoxamine produced an inhibition of 1-, 2- and 4-hydroxytacrine formation rate of 91, 87 and 88%, respectively, in the range of tacrine and fluvoxamine concentrations observed in man.	Fluvoxamine	72-83	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	45-51
9435993-14	1997	Fluvoxamine, as a potent inhibitor of CYP1A2, can inhibit the metabolism of clozapine, resulting in higher plasma concentrations.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	38-44
9384467-6	1997	Thus, assuming comparable molar concentrations at the site of inhibition, fluvoxamine can be expected to have the highest probability of interfering with the metabolism of CYP2C9 substrates.	Fluvoxamine	74-85	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	172-178
9418315-8	1997	The positive response to buspirone (5-HT1A) augmentation of fluvoxamine (SSRI) suggested that disturbed central serotonergic neurotransmission might play an important role in the pathogenesis of kleptomania.	Fluvoxamine	60-71	5-hydroxytryptamine receptor 1A	Homo sapiens	36-42
9442550-5	1997	With regard to interactions of SSRIs and clozapine, fluvoxamine, a potent inhibitor of cytochrome P450 1A2, gives rise to higher clozapine levels at an earlier time, compared to other SSRIs (paroxetine, fluoxetine and sertraline), which are potent cytochrome P450 2D6 inhibitors.	Fluvoxamine	52-63	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	87-106
9353355-5	1997	Omeprazole 5-hydroxylation by liver microsomes of a human sample that contained relatively high levels of CYP3A4 and low levels of CYP2C19 were inhibited very significantly by ketoconazole and anti-CYP3A4 antibodies, although a human sample having high in CYP2C19 and low in CYP3A4 was found to be sensitive toward fluvoxamine and anti-CYP2C9 antibodies.	Fluvoxamine	315-326	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
9353355-5	1997	Omeprazole 5-hydroxylation by liver microsomes of a human sample that contained relatively high levels of CYP3A4 and low levels of CYP2C19 were inhibited very significantly by ketoconazole and anti-CYP3A4 antibodies, although a human sample having high in CYP2C19 and low in CYP3A4 was found to be sensitive toward fluvoxamine and anti-CYP2C9 antibodies.	Fluvoxamine	315-326	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	131-138
9353355-5	1997	Omeprazole 5-hydroxylation by liver microsomes of a human sample that contained relatively high levels of CYP3A4 and low levels of CYP2C19 were inhibited very significantly by ketoconazole and anti-CYP3A4 antibodies, although a human sample having high in CYP2C19 and low in CYP3A4 was found to be sensitive toward fluvoxamine and anti-CYP2C9 antibodies.	Fluvoxamine	315-326	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	198-204
9353355-5	1997	Omeprazole 5-hydroxylation by liver microsomes of a human sample that contained relatively high levels of CYP3A4 and low levels of CYP2C19 were inhibited very significantly by ketoconazole and anti-CYP3A4 antibodies, although a human sample having high in CYP2C19 and low in CYP3A4 was found to be sensitive toward fluvoxamine and anti-CYP2C9 antibodies.	Fluvoxamine	315-326	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	198-204
9442550-5	1997	With regard to interactions of SSRIs and clozapine, fluvoxamine, a potent inhibitor of cytochrome P450 1A2, gives rise to higher clozapine levels at an earlier time, compared to other SSRIs (paroxetine, fluoxetine and sertraline), which are potent cytochrome P450 2D6 inhibitors.	Fluvoxamine	52-63	cytochrome P450 2D6	Homo sapiens	248-267
9333103-0	1997	Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	25-32
9333103-1	1997	OBJECTIVE: To investigate the interaction between fluvoxamine and chloroguanide (INN, proguanil) to confirm that fluvoxamine inhibits CYP2C19.	Fluvoxamine	113-124	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	134-141
9333103-13	1997	CONCLUSION: Fluvoxamine is an effective inhibitor of CYP2C19.	Fluvoxamine	12-23	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	53-60
9335078-0	1997	Effect of fluvoxamine on platelet 5-HT2A receptors as studied by [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy volunteers.	Fluvoxamine	10-21	5-hydroxytryptamine receptor 2A	Homo sapiens	34-40
9335078-6	1997	The study demonstrates that fluvoxamine affects platelet 5-HT2A receptor status irrespective of underlying psychiatric disease, and that this effect is evident already after 1 week at a subtherapeutic fluvoxamine dose.	Fluvoxamine	28-39	5-hydroxytryptamine receptor 2A	Homo sapiens	57-72
9232209-0	1997	Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment.	Fluvoxamine	94-105	prolactin	Homo sapiens	7-16
9232209-5	1997	After 10-week fluvoxamine treatment, the PRL response to the serotonergic agent normalized.	Fluvoxamine	14-25	prolactin	Homo sapiens	41-44
9223030-2	1997	The present study was designed to investigate whether ACTH 4-9 interferes with the effects of antidepressants: fluoxetine (FLU), fluvoxamine (FOX), selegiline (SEL) or dopamine agonists: piribedil (PRB) or quinpirol (QPR) in forced swimming test and in open field in rats.	Fluvoxamine	129-140	proopiomelanocortin	Homo sapiens	54-58
9241009-0	1997	The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status.	Fluvoxamine	14-25	prolactin	Homo sapiens	35-44
9241009-6	1997	Two subjects had substantial increases in serum prolactin levels (up to 35 microg/L) during fluvoxamine treatment, and these two subjects had higher Bmax for platelet [3H]LSD binding before fluvoxamine treatment than the six other subjects (32.7 vs. 23.1 fmol/mg protein).	Fluvoxamine	92-103	prolactin	Homo sapiens	48-57
9241009-9	1997	The results indicate that fluvoxamine affects serum prolactin as well as serum sodium concentrations and lend indirect support to the suggestion that 5-HT2A receptors might be involved in the mediation of these effects.	Fluvoxamine	26-37	prolactin	Homo sapiens	52-61
9241009-9	1997	The results indicate that fluvoxamine affects serum prolactin as well as serum sodium concentrations and lend indirect support to the suggestion that 5-HT2A receptors might be involved in the mediation of these effects.	Fluvoxamine	26-37	5-hydroxytryptamine receptor 2A	Homo sapiens	150-156
9209244-2	1997	Fluvoxamine, a potent CYP1A2 inhibitor, may be coadministered with tacrine.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	22-28
9330023-5	1997	RESULTS: PRL response in OCD patients was blunted under the drug-free condition; correlated inversely with pretreatment ratings of obsessive-compulsive and depressive symptomatology; and correlated inversely with the improvement in obsessive-compulsive score observed after fluvoxamine treatment.	Fluvoxamine	274-285	prolactin	Homo sapiens	9-12
9147017-2	1997	Fluoxetine and fluvoxamine reinforced the response to norepinephrine of isolated rat vas deferens incubated in Krebs-Henseleit solution.	Fluvoxamine	15-26	arginine vasopressin	Rattus norvegicus	85-88
9090339-1	1997	OBJECTIVE: The purpose of this study was to investigate the pharmacokinetics of fluvoxamine in the human brain by using fluorine-19 magnetic resonance spectroscopy (19F MRS) and to assess the relationships among fluvoxamine brain levels, fluvoxamine plasma levels, and clinical efficacy.	Fluvoxamine	80-91	MROS	Homo sapiens	169-172
10950475-3	1997	This suggests that cytochrome P450IID6 (CYP2D6), an enzyme that is strongly inhibited by FLX, preferentially metabolizes (R)-MTD, whereas CYP1A2, which is strongly inhibited by FLV, metabolizes both enantiomers.	Fluvoxamine	177-180	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	40-46
10950475-3	1997	This suggests that cytochrome P450IID6 (CYP2D6), an enzyme that is strongly inhibited by FLX, preferentially metabolizes (R)-MTD, whereas CYP1A2, which is strongly inhibited by FLV, metabolizes both enantiomers.	Fluvoxamine	177-180	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	138-144
9085405-0	1997	Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.	Fluvoxamine	53-64	protein tyrosine kinase 7 (inactive)	Homo sapiens	68-73
9105404-0	1997	Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole.	Fluvoxamine	72-83	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	15-21
9105404-0	1997	Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole.	Fluvoxamine	72-83	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	26-32
9105404-5	1997	Isosafrole and fluvoxamine were found to inhibit CYP1A2 selectively, with Ki values of 14 and 800 times, respectively, lower than those for CY1A1.	Fluvoxamine	15-26	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	49-55
9184622-12	1997	Fluvoxamine has prominent affinity for the CYP12 isozyme, lesser affinity for the CYP3A4 and CYP2C isozymes, and minimal affinity for CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 8 subfamily B member 1	Homo sapiens	43-48
9029748-7	1997	Fluvoxamine is a potent inhibitor of CYP1A2, and period B was included as a positive control.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-43
9174682-0	1997	Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.	Fluvoxamine	21-32	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
9174682-0	1997	Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.	Fluvoxamine	21-32	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	61-68
9174682-1	1997	OBJECTIVE: The purpose of this study was to investigate whether the disposition of fluvoxamine is associated with the CYP2D6 and CYP2C19 phenotype polymorphisms.	Fluvoxamine	83-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	118-124
9174682-1	1997	OBJECTIVE: The purpose of this study was to investigate whether the disposition of fluvoxamine is associated with the CYP2D6 and CYP2C19 phenotype polymorphisms.	Fluvoxamine	83-94	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	129-136
9174682-5	1997	CONCLUSION: The results are consistent with a possible minor to moderate role of CYP2D6, but not CYP2C19, in fluvoxamine metabolism.	Fluvoxamine	109-120	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
9184622-12	1997	Fluvoxamine has prominent affinity for the CYP12 isozyme, lesser affinity for the CYP3A4 and CYP2C isozymes, and minimal affinity for CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
9184622-12	1997	Fluvoxamine has prominent affinity for the CYP12 isozyme, lesser affinity for the CYP3A4 and CYP2C isozymes, and minimal affinity for CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	93-98
9184622-12	1997	Fluvoxamine has prominent affinity for the CYP12 isozyme, lesser affinity for the CYP3A4 and CYP2C isozymes, and minimal affinity for CYP2D6.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	134-140
8968657-11	1996	CYP2D6 is inhibited by SSRIs, in order of decreasing potency paroxetine, norfluoxetine, fluoxetine, sertraline, citalopram and fluvoxamine.	Fluvoxamine	127-138	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
8968657-19	1996	Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19, CYP2D6 and CYP1A1, but it is also an inhibitor of CYP3A.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	46-52
8968657-19	1996	Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19, CYP2D6 and CYP1A1, but it is also an inhibitor of CYP3A.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	54-61
8968657-19	1996	Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19, CYP2D6 and CYP1A1, but it is also an inhibitor of CYP3A.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	63-69
8968657-19	1996	Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19, CYP2D6 and CYP1A1, but it is also an inhibitor of CYP3A.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	74-80
8968657-19	1996	Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19, CYP2D6 and CYP1A1, but it is also an inhibitor of CYP3A.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-118
9032002-8	1996	Fluvoxamine is a substantial inhibitor of CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A3/4.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	42-48
9032002-8	1996	Fluvoxamine is a substantial inhibitor of CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A3/4.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	53-60
9032002-8	1996	Fluvoxamine is a substantial inhibitor of CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A3/4.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
8986010-6	1996	Among six selective serotonin reuptake inhibitor (SSRI) antidepressants, fluvoxamine was a potent inhibitor of 1A2 (mean Ki1 = 0.24 microM).	Fluvoxamine	73-84	TNF receptor superfamily member 8	Homo sapiens	121-124
8986013-5	1996	According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine.	Fluvoxamine	258-269	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134
8986013-5	1996	According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine.	Fluvoxamine	258-269	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	96-103
8986013-5	1996	According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine.	Fluvoxamine	258-269	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	117-123
8838442-6	1996	The average apparent Ki values determined using CYP2D6-dependent dextromethorphan O-demethylation were: 33, 52 and 22 microM for rac-venlafaxine, R(+)-venlafaxine and S(-)-venlafaxine, respectively, vs 0.065 to 1.8 microM for paroxetine, fluoxetine, norfluoxetine, fluvoxamine and sertraline.	Fluvoxamine	265-276	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
8885123-1	1996	All available antidepressants with the exception of fluvoxamine and nefazodone either are metabolized by cytochrome P450 2D6 (CYP2D6) and/or inhibit this isozyme.	Fluvoxamine	52-63	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	105-124
8885123-1	1996	All available antidepressants with the exception of fluvoxamine and nefazodone either are metabolized by cytochrome P450 2D6 (CYP2D6) and/or inhibit this isozyme.	Fluvoxamine	52-63	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	126-132
8823236-0	1996	Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.	Fluvoxamine	15-26	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	70-76
8823236-0	1996	Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.	Fluvoxamine	15-26	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	93-99
8823236-2	1996	This study investigated the relationship between fluvoxamine disposition and the polymorphic CYP2D6 and the polycyclic aromatic hydrocarbon (as contained in cigarette smoke) inducible CYP1A2.	Fluvoxamine	49-60	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	93-99
8823236-2	1996	This study investigated the relationship between fluvoxamine disposition and the polymorphic CYP2D6 and the polycyclic aromatic hydrocarbon (as contained in cigarette smoke) inducible CYP1A2.	Fluvoxamine	49-60	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	184-190
8823236-7	1996	The oral clearance of fluvoxamine correlated to the CYP1A2 index in the 14 subjects (rs = 0.58; p < 0.05; Spearman rank correlation).	Fluvoxamine	22-33	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	52-58
8823236-8	1996	CONCLUSION: The disposition of fluvoxamine in humans is associated with the polymorphic CYP2D6 activity, but CYP1A2 also seems to be involved.	Fluvoxamine	31-42	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-94
8823236-8	1996	CONCLUSION: The disposition of fluvoxamine in humans is associated with the polymorphic CYP2D6 activity, but CYP1A2 also seems to be involved.	Fluvoxamine	31-42	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	109-115
8944409-8	1996	The increased buspirone concentrations are likely to be due to inhibition of first pass liver metabolism by fluvoxamine acting on the cytochrome P-450 system.	Fluvoxamine	108-119	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	134-150
8944409-10	1996	The blunting of GH and psychological responses suggest that 5-HT1A receptor function is reduced by chronic fluvoxamine treatment.	Fluvoxamine	107-118	5-hydroxytryptamine receptor 1A	Homo sapiens	60-75
8904628-1	1996	Studies were performed in eight healthy extensive metabolizers of mephenytoin and debrisoquine to determine the effect of fluvoxamine on the activities of S-mephenytoin 4"-hydroxylase (CYP2C19) and metoprolol alpha-hydroxylase (CYP2D6).	Fluvoxamine	122-133	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	155-183
8904628-1	1996	Studies were performed in eight healthy extensive metabolizers of mephenytoin and debrisoquine to determine the effect of fluvoxamine on the activities of S-mephenytoin 4"-hydroxylase (CYP2C19) and metoprolol alpha-hydroxylase (CYP2D6).	Fluvoxamine	122-133	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	185-192
8904628-6	1996	These results indicated fluvoxamine has a modest inhibitory effect on the activity of CYP2C19, but no effect on that of CYP2D6 in vivo.	Fluvoxamine	24-35	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	86-93
8610817-5	1996	Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophylline, clozapine, and others.	Fluvoxamine	36-47	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	0-19
8732441-3	1996	Thus, among the SSRIs, fluvoxamine is the only very potent inhibitor of cytochrome P4501A2 (CYP1A2).	Fluvoxamine	23-34	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	72-90
8732441-3	1996	Thus, among the SSRIs, fluvoxamine is the only very potent inhibitor of cytochrome P4501A2 (CYP1A2).	Fluvoxamine	23-34	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	92-98
8587855-3	1995	This review summarizes information to date regarding the inhibitory potency of fluoxetine, fluvoxamine, paroxetine, sertraline, nefazodone, and venlafaxine on five isoenzyme systems: CYP2D6, CYP3A3/4, CYP1A2, CYP2C9, and CYP2C19.	Fluvoxamine	91-102	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	183-189
8880055-13	1996	CONCLUSION: This investigation confirms that paroxetine and fluoxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxetine are moderate inhibitors of CYP2C19 and that fluvoxamine is a potent inhibitor of CYP1A2 in humans in vivo.	Fluvoxamine	109-120	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	163-170
8880055-13	1996	CONCLUSION: This investigation confirms that paroxetine and fluoxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxetine are moderate inhibitors of CYP2C19 and that fluvoxamine is a potent inhibitor of CYP1A2 in humans in vivo.	Fluvoxamine	180-191	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	96-102
8880055-13	1996	CONCLUSION: This investigation confirms that paroxetine and fluoxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxetine are moderate inhibitors of CYP2C19 and that fluvoxamine is a potent inhibitor of CYP1A2 in humans in vivo.	Fluvoxamine	180-191	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	217-223
8771220-8	1995	Baseline beta-EP values were normal in the bulimic patients but had declined by month 4 of fluvoxamine therapy.	Fluvoxamine	91-102	proopiomelanocortin	Homo sapiens	9-16
8880055-0	1996	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.	Fluvoxamine	83-94	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	29-35
8880055-0	1996	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.	Fluvoxamine	83-94	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	37-44
8880055-0	1996	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.	Fluvoxamine	83-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	49-55
8880055-1	1996	OBJECTIVE: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine.	Fluvoxamine	243-254	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	126-132
8880055-1	1996	OBJECTIVE: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine.	Fluvoxamine	243-254	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	134-141
8880055-1	1996	OBJECTIVE: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine.	Fluvoxamine	243-254	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	146-152
7770611-1	1995	This study investigated the alterations of the 5-HT1A and 5-HT1B autoreceptor function following chronic treatment with fluvoxamine using osmotic minipumps.	Fluvoxamine	120-131	5-hydroxytryptamine receptor 1A	Rattus norvegicus	47-64
7586931-1	1995	OBJECTIVES: Although fluvoxamine inhibits the biotransformation of drugs known to be metabolized by CYP1A2, there are no data available with regard to the importance of CYP1A2 for the metabolism of fluvoxamine itself.	Fluvoxamine	21-32	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	100-106
7586931-2	1995	Because smoking induces the metabolism of drugs catalyzed by CYP1A2, this study investigated the pharmacokinetics of fluvoxamine in smokers and nonsmokers.	Fluvoxamine	117-128	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	61-67
7586931-8	1995	This finding is consistent with a possible role of CYP1A2 in fluvoxamine metabolism.	Fluvoxamine	61-72	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	51-57
7479582-7	1995	Propylene glycol inhibited the activity of CYP2E1 as indicated by 84% reduction in the clearance of 3 mg/kg dose of chlorzoxazone, whereas fluvoxamine inhibited the activity of CYP1A2 as indicated by 40% reduction in the clearance of a 10 mg/kg dose of caffeine.	Fluvoxamine	139-150	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	177-183
7494384-0	1995	5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice.	Fluvoxamine	47-58	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	0-15
7494384-10	1995	However, the 5-HT1A antagonist NAN-190 (1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine) inhibited the suppressive effect of fluvoxamine on the marble-burying.	Fluvoxamine	135-146	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	13-19
7494384-11	1995	From these results, the 5-HT1A-receptor subtype may be involved in the suppressive effect of fluvoxamine on the marble-burying, but the 5-HT2-receptor subtype is not involved in this effect.	Fluvoxamine	93-104	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	24-39
7494385-7	1995	On the other hand, the 5-HT1A antagonist NAN-190 (1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine) potentiated the effect of fluvoxamine on forced-swimming.	Fluvoxamine	135-146	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	23-29
7494385-8	1995	It is expected, however, that a 5-HT1A antagonist should antagonize the effect of fluvoxamine when 5-HT1A mediates the suppressive effect of fluvoxamine on the immobility time in forced-swimming.	Fluvoxamine	82-93	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-38
7494385-8	1995	It is expected, however, that a 5-HT1A antagonist should antagonize the effect of fluvoxamine when 5-HT1A mediates the suppressive effect of fluvoxamine on the immobility time in forced-swimming.	Fluvoxamine	141-152	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	32-38
7494385-8	1995	It is expected, however, that a 5-HT1A antagonist should antagonize the effect of fluvoxamine when 5-HT1A mediates the suppressive effect of fluvoxamine on the immobility time in forced-swimming.	Fluvoxamine	141-152	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	99-105
7617560-0	1995	Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2.	Fluvoxamine	27-38	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	98-104
7622807-2	1995	From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme.	Fluvoxamine	194-205	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	102-108
7622807-3	1995	Fluvoxamine interacts with these drugs by a mechanism involving inhibition of CYP1A2, CYP3A4, and CYP2C19.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	78-84
7622807-3	1995	Fluvoxamine interacts with these drugs by a mechanism involving inhibition of CYP1A2, CYP3A4, and CYP2C19.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-92
7622807-3	1995	Fluvoxamine interacts with these drugs by a mechanism involving inhibition of CYP1A2, CYP3A4, and CYP2C19.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	98-105
8685072-12	1995	This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450.	Fluvoxamine	41-52	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	170-176
8685072-12	1995	This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450.	Fluvoxamine	41-52	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	221-237
7742153-6	1995	Norfluoxetine, sertraline and fluvoxamine inhibited CYP1A1 (7-ethoxyresorufin O-deethylase) in microsomes from human placenta (IC50 values 29 microM, 35 microM and 80 microM, respectively).	Fluvoxamine	30-41	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	52-58
7742153-7	1995	Fluvoxamine was a potent inhibitor of CYP1A2-mediated 7-ethoxyresorufin O-deethylase activity (IC50 = 0.3 microM) in human liver.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	38-44
7742153-13	1995	Ethanol and fluvoxamine both inhibited 8-hydroxylation by about 45% and, in combination, the compounds decreased the formation of 1,3-dimethyluric acid by 90%, indicating that CYP1A2 and CYP2E1 are equally important isoforms for the 8-hydroxylation of theophylline.	Fluvoxamine	12-23	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	176-182
7742153-13	1995	Ethanol and fluvoxamine both inhibited 8-hydroxylation by about 45% and, in combination, the compounds decreased the formation of 1,3-dimethyluric acid by 90%, indicating that CYP1A2 and CYP2E1 are equally important isoforms for the 8-hydroxylation of theophylline.	Fluvoxamine	12-23	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	187-193
7742153-15	1995	It is concluded that pharmacokinetic interaction between fluvoxamine and theophylline is due to potent inhibition of CYP1A2.	Fluvoxamine	57-68	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	117-123
8775761-2	1995	Fluvoxamine administered for 5 days significantly enhanced the 32P incorporation stimulated by cAMP into MAP2, while it failed to produce this effect after 12 and 21 days.	Fluvoxamine	0-11	cathelicidin antimicrobial peptide	Rattus norvegicus	95-99
8846617-10	1995	The specific cytochrome P450 (CYP) isoenzymes involved in the metabolism of fluvoxamine are unknown.	Fluvoxamine	76-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	13-28
8846617-10	1995	The specific cytochrome P450 (CYP) isoenzymes involved in the metabolism of fluvoxamine are unknown.	Fluvoxamine	76-87	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	30-33
8846617-11	1995	CYP2D6, which is crucially involved in the metabolism of paroxetine and fluoxetine, appears to play a clinically insignificant role in the metabolism of fluvoxamine.	Fluvoxamine	153-164	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
8846617-17	1995	Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	71-77
8846617-17	1995	Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions.	Fluvoxamine	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
8846617-17	1995	Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine > fluoxetine identical to norfluoxetine > or = sertraline > or = fluvoxamine > venlafaxine.	Fluvoxamine	335-346	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	133-148
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine > fluoxetine identical to norfluoxetine > or = sertraline > or = fluvoxamine > venlafaxine.	Fluvoxamine	335-346	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-153
8846618-2	1995	The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine display the following rank order of in vitro potency against the cytochrome P450 (CYP) isoenzyme CYP2D6 as measured by their inhibition sparteine and/or dextromethorphan metabolism: paroxetine > fluoxetine identical to norfluoxetine > or = sertraline > or = fluvoxamine > venlafaxine.	Fluvoxamine	335-346	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	165-171
8846618-11	1995	Consistent with its minimal in vitro effect on CYP2D6, fluvoxamine shows minimal in vivo pharmacokinetic interaction with desipramine, but does interact with imipramine (approximately 3- to 4-fold increase in AUC) through inhibition of CYP3A3/4, CYP1A2, and CYP2C19.	Fluvoxamine	55-66	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	246-252
8846618-11	1995	Consistent with its minimal in vitro effect on CYP2D6, fluvoxamine shows minimal in vivo pharmacokinetic interaction with desipramine, but does interact with imipramine (approximately 3- to 4-fold increase in AUC) through inhibition of CYP3A3/4, CYP1A2, and CYP2C19.	Fluvoxamine	55-66	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	258-265
8846619-4	1995	Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-43
8846619-5	1995	This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation.	Fluvoxamine	17-28	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	98-104
8846619-5	1995	This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation.	Fluvoxamine	17-28	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	173-179
8846620-11	1995	Those agents metabolised by cytochrome P450 1A2 isoenzyme appear most likely to be involved in drug-drug interactions with fluvoxamine.	Fluvoxamine	123-134	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	28-47
8846622-8	1995	A number of drugs have been shown to inhibit CYP2C19 in vivo, including fluvoxamine and fluoxetine.	Fluvoxamine	72-83	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	45-52
8775761-2	1995	Fluvoxamine administered for 5 days significantly enhanced the 32P incorporation stimulated by cAMP into MAP2, while it failed to produce this effect after 12 and 21 days.	Fluvoxamine	0-11	microtubule-associated protein 2	Rattus norvegicus	105-109
8466541-0	1993	Fluvoxamine is a potent inhibitor of cytochrome P4501A2.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-55
8567194-5	1995	As shown in another simple table, the author compared the hepatic enzymatic inhibitions of four selective serotonin reuptake inhibitors and pointed out the inhibition potentials of fluvoxamine at CYP1A2, fluoxetine and paroxetine at CYP2D6, and fluoxetine and fluvoxamine at CYP3A4 if these two SSRIs have higher serum concentrations.	Fluvoxamine	181-192	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	196-202
8567194-5	1995	As shown in another simple table, the author compared the hepatic enzymatic inhibitions of four selective serotonin reuptake inhibitors and pointed out the inhibition potentials of fluvoxamine at CYP1A2, fluoxetine and paroxetine at CYP2D6, and fluoxetine and fluvoxamine at CYP3A4 if these two SSRIs have higher serum concentrations.	Fluvoxamine	181-192	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	233-239
8567194-5	1995	As shown in another simple table, the author compared the hepatic enzymatic inhibitions of four selective serotonin reuptake inhibitors and pointed out the inhibition potentials of fluvoxamine at CYP1A2, fluoxetine and paroxetine at CYP2D6, and fluoxetine and fluvoxamine at CYP3A4 if these two SSRIs have higher serum concentrations.	Fluvoxamine	181-192	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	275-281
7974626-12	1994	The pathways are not known with certainty, but CYP1A2 may be of major importance for the metabolism of clozapine, since fluvoxamine is a potent inhibitor of this enzyme.	Fluvoxamine	120-131	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	47-53
7928004-4	1994	The uptake of [3H]5-HT was temperature, sodium and chloride dependent and was potently inhibited by the antidepressants clomipramine, imipramine, fluoxetine and fluvoxamine, which are specific for the 5-HT transporter.	Fluvoxamine	161-172	solute carrier family 6 member 4	Homo sapiens	201-217
7938563-6	1994	At endpoint both the decrease in HAMD-scores and the percentage responders (CGI 1-2) differed significantly comparing fluvoxamine with placebo and tended to differ significantly comparing with imipramine in the severely depressed patients.	Fluvoxamine	118-129	mitochondrial transcription termination factor 3	Homo sapiens	76-83
8466541-2	1993	The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers.	Fluvoxamine	36-47	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	148-166
8466541-2	1993	The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers.	Fluvoxamine	36-47	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	168-174
8466541-5	1993	Our findings explain the mechanism of the pharmacokinetic interactions between fluvoxamine and drugs that are metabolized by CYP1A2, e.g. theophylline and imipramine.	Fluvoxamine	79-90	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	125-131
33806634-6	2021	DDI model performance was evaluated by prediction of clinical studies with rifampicin (CYP2B6 and CYP2C19 inducer), fluvoxamine (CYP2C19 inhibitor) and voriconazole (CYP2B6 and CYP2C19 inhibitor).	Fluvoxamine	116-127	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	129-136
33806634-6	2021	DDI model performance was evaluated by prediction of clinical studies with rifampicin (CYP2B6 and CYP2C19 inducer), fluvoxamine (CYP2C19 inhibitor) and voriconazole (CYP2B6 and CYP2C19 inhibitor).	Fluvoxamine	116-127	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	129-136
1389950-10	1992	Three other SSRIs, citalopram, desmethylcitalopram and fluvoxamine, were less potent inhibitors of CYP2D6, with apparent Ki-values of 19, 1.3 and 3.9 microM, respectively.	Fluvoxamine	55-66	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	99-105
1389951-4	1992	Fluvoxamine (8.2 microM) and citalopram (5.1 microM) also inhibited CYP2D6 activity.	Fluvoxamine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	68-74
1933139-22	1991	Blockers of neuronal 5-HT uptake (citalopram 0.1 or 1 microM, fluvoxamine 1 microM) usually reduced the MSR and, to a lesser extent, the PSR.	Fluvoxamine	62-73	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Rattus norvegicus	104-107
34975483-3	2021	Here, I investigated the effect of an antidepressant drug fluvoxamine on membrane trafficking of the SARS-CoV-2 spike protein and its cell host receptor ACE2 in HEK293T cells.	Fluvoxamine	58-69	angiotensin converting enzyme 2	Homo sapiens	153-157
34555857-0	2022	Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase.	Fluvoxamine	26-37	nitric oxide synthase 3	Homo sapiens	57-90
34975483-0	2021	Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants.	Fluvoxamine	9-20	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	67-72
34975483-4	2021	A sub-therapeutic concentration (80 nM) of fluvoxamine rapidly upregulated fluid-phase endocytosis, resulting in enhanced accumulation of the spike-ACE2 complex in enlarged early endosomes.	Fluvoxamine	43-54	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	142-147
34975483-3	2021	Here, I investigated the effect of an antidepressant drug fluvoxamine on membrane trafficking of the SARS-CoV-2 spike protein and its cell host receptor ACE2 in HEK293T cells.	Fluvoxamine	58-69	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	112-117
34975483-4	2021	A sub-therapeutic concentration (80 nM) of fluvoxamine rapidly upregulated fluid-phase endocytosis, resulting in enhanced accumulation of the spike-ACE2 complex in enlarged early endosomes.	Fluvoxamine	43-54	angiotensin converting enzyme 2	Homo sapiens	148-152
34564289-7	2021	Fluvoxamine is one of the most potent inhibitors of CYP1A2 and can lead to an increase in clozapine levels.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	52-58
34605737-4	2021	For CYP2D6.39, the kcat values for fluvoxamine, fluoxetine, and milnacipran, but not for paroxetine and fluphenazine, gradually increased with increasing concentrations, indicating activation of the catalyzed reaction.3.	Fluvoxamine	35-46	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	4-10
34881402-8	2022	Meanwhile, preadministration of fluvoxamine significantly extended the time needed for the elimination of phenacetin, possibly due to the inhibition of CYP1A2.	Fluvoxamine	32-43	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	152-158
34881402-9	2022	This suggests that the intake of an excess amount of atemoya juice is necessary to cause a change in the pharmacokinetics of phenacetin when the IC50 values for CYP1A2 inhibition by atemoya and fluvoxamine are taken into account.	Fluvoxamine	194-205	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	161-167
34630662-6	2021	MI rats were administered different treatments, including normal saline, YQHX and fluvoxamine, an agonist of the Sigma-1 receptor.	Fluvoxamine	82-93	sigma non-opioid intracellular receptor 1	Rattus norvegicus	113-129
34697991-3	2021	Fluvoxamine can bind to S1R and reduce the serotonin uptake of neurons and platelets.	Fluvoxamine	0-11	sigma non-opioid intracellular receptor 1	Rattus norvegicus	24-27
34392133-7	2021	Not the selective norepinephrine reuptake inhibitor reboxetine but the selective serotonin reuptake inhibitors fluvoxamine and sertraline upregulated the PGD2-induced osteoprotegerin release, which was further amplified by morphine.	Fluvoxamine	111-122	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	167-182
34117140-0	2021	Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder.	Fluvoxamine	80-91	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	38-44
34234701-0	2021	Interest of Fluvoxamine as an Add-On to Clozapine in Children With Severe Psychiatric Disorder According to CYP Polymorphisms: Experience From a Case Series.	Fluvoxamine	12-23	peptidylprolyl isomerase G	Homo sapiens	108-111
34234701-5	2021	Clozapine plasma levels may be increased with CYP inhibitors such as fluvoxamine.	Fluvoxamine	69-80	peptidylprolyl isomerase G	Homo sapiens	46-49
34117140-13	2021	CONCLUSIONS: The effect of genetic polymorphism of the CYP2D6 gene on the efficacy and safety profiles of fluvoxamine was demonstrated in a group of 96 patients with depressive disorders comorbid with alcohol use disorder.	Fluvoxamine	106-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	55-61
34117140-1	2021	BACKGROUND: Previous studies have shown that cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of fluvoxamine, the activity of which is highly dependent, inter alia, on the polymorphism of the gene encoding it.	Fluvoxamine	107-118	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	45-64
34117140-1	2021	BACKGROUND: Previous studies have shown that cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of fluvoxamine, the activity of which is highly dependent, inter alia, on the polymorphism of the gene encoding it.	Fluvoxamine	107-118	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	66-72
34117140-2	2021	The objective of our study was to investigate the effect of 1846G>A polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine, using findings on CYP2D6 enzymatic activity and on CYP2D6 expression level in patients with depressive disorders comorbid with alcohol use disorder.	Fluvoxamine	130-141	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	88-94
34117140-2	2021	The objective of our study was to investigate the effect of 1846G>A polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine, using findings on CYP2D6 enzymatic activity and on CYP2D6 expression level in patients with depressive disorders comorbid with alcohol use disorder.	Fluvoxamine	130-141	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	161-167
34117140-2	2021	The objective of our study was to investigate the effect of 1846G>A polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine, using findings on CYP2D6 enzymatic activity and on CYP2D6 expression level in patients with depressive disorders comorbid with alcohol use disorder.	Fluvoxamine	130-141	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	194-200
34117140-3	2021	STUDY QUESTION: Efficacy and safety of fluvoxamine depend on the polymorphism of CYP2D6 gene in patients with major depressive disorder.	Fluvoxamine	39-50	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	81-87
35611779-6	2022	The pharmacokinetics of many antiseizure medications is not influenced by antipsychotics and anxiolytics while some newer antidepressants namely fluoxetine, fluvoxamine and viloxazine, may inhibit CYP enzymes leading to increased serum concentrations of some antiseizure medications including phenytoin and carbamazepine.	Fluvoxamine	157-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	197-200
34130375-3	2021	Thus, in this current computational study we carried out molecular docking experiments to assess the bridging potentials of some commercial drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, camostat, famotidine, umifenovir, nitazoxanide, ivermectin, and fluvoxamine at the interface between human ACE2 and the coronavirus spike glycoprotein complex.	Fluvoxamine	285-296	angiotensin converting enzyme 2	Homo sapiens	328-332
35258103-6	2022	Finally, pharmacoepidemiological-pharmacodynamic analysis revealed a significant correlation between the decrease in serum sodium levels and binding affinity for serotonin transporter (SERT; r=-0.84, P=0.02), suggesting that lower binding affinity of mirtazapine, fluvoxamine, and milnacipran against SERT is responsible for the above difference.	Fluvoxamine	264-275	solute carrier family 6 member 4	Homo sapiens	162-183
35258103-6	2022	Finally, pharmacoepidemiological-pharmacodynamic analysis revealed a significant correlation between the decrease in serum sodium levels and binding affinity for serotonin transporter (SERT; r=-0.84, P=0.02), suggesting that lower binding affinity of mirtazapine, fluvoxamine, and milnacipran against SERT is responsible for the above difference.	Fluvoxamine	264-275	solute carrier family 6 member 4	Homo sapiens	185-189
35362343-0	2022	Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug-drug interaction.	Fluvoxamine	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	75-82
35383578-1	2022	BACKGROUND: Recent clinical trials have investigated the use of fluvoxamine in preventing clinical deterioration in nonhospitalized patients with acute COVID-19 infection via stimulation of sigma-1 receptors, which regulates cytokine production and functional inhibition of acid sphingomyelinase activity, which may prevent infection of epithelial cells with SARS-CoV-2.	Fluvoxamine	64-75	sphingomyelin phosphodiesterase 1	Homo sapiens	274-295
35599943-6	2022	Results: Fluvoxamine and mirtazapine significantly protected against WIRS and pyloric ligation-induced gastric lesions, as evidenced by a dose-dependent decrease in ulcer index, myeloperoxidase (MPO) activity, lipid peroxidation, and an increase in prostaglandin E2, nitric oxide (NO), and reduced glutathione levels, as well as increased antioxidant enzyme activity.	Fluvoxamine	9-20	myeloperoxidase	Rattus norvegicus	178-193
35599943-6	2022	Results: Fluvoxamine and mirtazapine significantly protected against WIRS and pyloric ligation-induced gastric lesions, as evidenced by a dose-dependent decrease in ulcer index, myeloperoxidase (MPO) activity, lipid peroxidation, and an increase in prostaglandin E2, nitric oxide (NO), and reduced glutathione levels, as well as increased antioxidant enzyme activity.	Fluvoxamine	9-20	myeloperoxidase	Rattus norvegicus	195-198
35473584-2	2022	Monocrotaline (60 mg/kg) was administered to induce pulmonary arterial hypertension, and fluvoxamine was given for 21 consecutive days to activate S1R after one week of monocrotaline administration.	Fluvoxamine	89-100	sigma non-opioid intracellular receptor 1	Rattus norvegicus	147-150
34997196-5	2022	In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19.	Fluvoxamine	130-141	solute carrier family 6 member 4	Homo sapiens	59-80
34997196-5	2022	In this article, we review the mechanisms of action (i.e., serotonin transporter, sigma-1 receptor, and acid sphingomyelinase) of fluvoxamine for COVID-19.	Fluvoxamine	130-141	sphingomyelin phosphodiesterase 1	Homo sapiens	104-125
35327555-11	2022	Clinical trials demonstrated that several Sig-1R agonists (pridopidine, ANAVEX3-71, fluvoxamine, dextrometorphan) and their combinations have a neuroprotective effect and slow down the progression of distinct NDDs.	Fluvoxamine	84-95	sigma non-opioid intracellular receptor 1	Homo sapiens	42-48